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Lung fibrosis is characterised by increased deposition of fibrotic extracellular matrix 
(ECM) in the lung interstitium causing lung dysfunction. Idiopathic pulmonary fibrosis 
(IPF) is the most common form of fibrotic interstitial lung diseases. It is believed that 
the disruption of alveolar homoeostasis and abnormal wound healing drives the lung 
fibrosis process and leads to a dysregulated chronic fibrotic condition. The macrophage 
is a key effector cell in normal wound healing and fibrosis. 
Autophagy is an important mechanism for the maintenance of cellular homoeostasis, 
however, its role in macrophages and lung fibrosis is largely unknown. ECM has been 
proposed as an active functional component that regulates cell biology and it can 
modulate the autophagy process. Modulation of autophagy affects the secretion of 
exosomes which are mediators of cell-cell communication. Thus, it is hypothesised in 
this thesis that fibrotic ECM modulates the autophagy pathway in alveolar macrophages 
(AM) and subsequently affects exosome secretion in the fibrotic lung.  
In this thesis, I investigated the effect of ECM on macrophage autophagy and the 
subsequent effect on exosome biology using in vitro models and clinical samples. It was 
shown that collagen-I, the most common type of increased ECM in IPF, upregulated the 
basal autophagy pathway in macrophages in that it increased the formation and 
facilitated the degradation of autophagosomes. It was also shown that there is a 
blockage of the autophagy pathway and lysosomal dysfunction in AM from the fibrotic 
lungs (fibrotic AM). ECM derived from IPF lung fibroblasts did not block the 
autophagy pathway, but it increased both the basal and rapamycin-induced autophagy 
in macrophages. Modulation of the autophagy pathway in macrophages affected 
exosome secretion in vitro and fibrotic AM released fewer exosomes ex vivo. BAL fluid 
exosome levels were significantly lower in fibrotic ILD and low baseline exosome 
levels in BAL fluid may be associated with progressed IPF. BAL fluid exosomes 
expressed classic exosome markers but their origin remained unclear because they did 
not express the typical surface markers of specific cell types. 
To summarise, this study suggests the normal homeostatic process of autophagy and 
exosome biosynthesis in AM is subverted in the fibrotic lungs. Fibrotic ECM may 
Abstract X 
exacerbate the impairment of autophagy in the setting of dysfunctional lysosomes which 
affects exosome secretion and compromises cellular communication and signalling. 
Thus, normalising the autophagy pathway and restoring the cellular communication via 
alveolar exosomes may have a role in normal lung healing and gain therapeutic benefit 
for patients with lung fibrosis.
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Lay abstract 
Lung fibrosis is scarring in the lungs and idiopathic pulmonary fibrosis (IPF) is the most 
common form of serious lung fibrosis. The cause of IPF is unknown. Scar tissue, called 
extra-cellular matrix (ECM) affects normal lung function and may affect the behaviour 
of the surrounding cells. The macrophage is an important type of immune cell. The 
specific macrophages that live in the lung air sacs are named alveolar macrophages 
(AMs). Functional macrophages are essential for the normal tissue repair and 
maintaining cell fitness. 
Autophagy (“self-eating”) is an important process that removes cell waste and keeps 
cells functional and healthy. ECM has biological roles and it regulates many processes 
including autophagy. Autophagy affects the production of exosomes which are small 
vesicles produced by cells. Exosomes contain biological information which can be 
passed on to other cells. Thus, it is hypothesised that ECM can change the exosome 
production in AMs by affecting “self-eating”, thereby affecting the normal reparative 
mechanisms and worsens fibrosis. 
During this PhD study, the interplay among ECM, “self-eating” and exosome 
production in different macrophages was investigated. It was shown that collagen-I, the 
most common ECM in IPF, increased basal “self-eating” in macrophages. In AMs that 
were obtained from patients with lung fibrosis, “self-eating” was blocked and 
dysfunctional. In these fibrotic AMs, the waste degradation units of “self-eating”, called 
lysosomes, were also dysfunctional. ECM is mainly produced by cells termed as 
fibroblasts. ECM was generated from cultured fibroblasts obtained from patients with 
fibrotic or non-fibrotic lung diseases. The fibrotic ECM increased basal and stimulated 
“self-eating” response in macrophages when compared to the non-fibrotic ECM, but 
neither ECM blocked “self-eating” in macrophages. Changes in “self-eating” affected 
the exosome production in macrophages. Exosome levels in the lung fluid acquired 
from patients with lung fibrosis were lower than those without fibrosis. It was shown 
that exosomes in the lung fluid contain specific proteins, but the precise source of the 
exosomes is uncertain. 
Lay abstract XII 
To summarise, these studies showed that both “self-eating” and exosome production 
are impaired in macrophages in fibrotic lungs. When lysosomes are not functional, 
fibrotic ECM may worsen the damage to macrophages by stimulating basal “self-
eating”. Damage to “self-eating” may reduce exosome production and impairs 
communication between macrophages. Thus, normalising “self-eating” process and 
restoring lung exosome signals may help the repair of the lung and may be beneficial 
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Chapter 1 Introduction 
 
1.1 Idiopathic pulmonary fibrosis (IPF): scarring in 
the lung 
Idiopathic pulmonary fibrosis (IPF) is a type of chronic and progressive interstitial lung 
disease (ILD) that is characterised by irreversible fibrosis and an unknown aetiology 
[1]. ILD is an umbrella medical term that covers more than 200 parenchymal lung 
conditions [1]. Lung fibrosis is associated with excessive deposition of collagen-I rich 
extracellular matrix proteins within the interstitial space and the alveolar space of the 
lung [2-4]. 
1.1.1 Function and structure of the lung 
The primary function of the lung is gas exchange which occurs at the functional unit 
called alveolar sacs. These functional units are the terminal parts of the respiratory tree. 
Gas exchange in the lungs includes the elimination of waste gases, mainly carbon 
dioxide (CO2), and in exchange, the diffusion of oxygen (O2) from the air to the 
bloodstream which is transported to the whole body.  
For this simple but fundamental purpose, the lung has a delicate structure that comprises 
a range of unique and specialised cell types: 1) pulmonary epithelial cells are the major 
cells that form the respiratory airways; 2) under the alveolar epithelial lining lies the 
basement membrane; 3) next to the basement membrane, there is the pulmonary blood 
vessel which consists of endothelial cells, smooth muscle cells, and adventitial 
fibroblast components, which again is also surrounded by the basement membrane; 4) 
in the lung interstitium, there are supportive extracellular matrix structures which are 
mainly produced by lung fibroblasts, and are separated from the alveolar sacs and blood 
vessels by the basement membrane; 5) in the alveolar space, there are residential 
alveolar macrophages. In the case of inflammation, other leucocytes such as 
lymphocytes, neutrophils, eosinophils, and monocytes will migrate into the alveolar 
space. The lung and its constituent cells are responsive to the injury and stimuli that are 
caused by the inhalation of foreign material and pathogens [5-7].  
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1.1.2 Clinical feature of idiopathic pulmonary fibrosis: 
rapid decline  
Idiopathic pulmonary fibrosis makes up more than half of the ILD cases in clinical 
practice, making it the most common type of ILD [8].The prevalence of ILD is 
approximately 23 in 100,000 in Europe [9] and 43 in 100,000 in the United States [10]. 
The estimated incidence of IPF is dependent on geographical regions, ranging from 3 
to 9 cases each year worldwide [11]. In the UK, the incidence of IPF is about 7 in 
100,000 and the incidence continues to rise  [12]. IPF is more common in men than 
women and it is more often found in people over 60 years of age [13]. The median 
survival time of IPF patients is 3 years which is a much worse prognosis compared with 
many malignancies [14].  
1.1.3 Risk factors and demographics of IPF  
Lung fibrosis is a dysregulated wound healing process that results in scarring of the 
lungs [15, 16]. There are many risk factors that contribute to the fibrotic lung injury and 
healing process which include inhaled exposures (e.g. air pollution and smoking), viral 
infections, gastrointestinal comorbidities (e.g. gastroesophageal reflux disease/ GERD), 
ageing, and genetic factors [17]. 
Smoking has been a recognised risk factor in both sporadic and familial IPF [18, 19]. 
Tobacco history is strongly linked with IPF and may be associated with disease 
progression [20, 21].  
Several lines of evidence have suggested a link between environmental and 
occupational exposures with IPF [13]. A variety of dust and particles have been strongly 
related to the diagnosis of IPF [18, 22], which include metal dust [18, 22-24], wood dust 
[18, 25], silica [18], livestock and farming [18, 22, 26]. 
The chronic exposure and inhalation of viruses have been linked with IPF but the role 
of infection in IPF is still unclear [13]. Different types of viruses have been studied in 
IPF which include cytomegalovirus [27], Epstein-Barr virus [27], hepatitis C virus [28], 
human herpes viruses (HHV)-7 and HHV-8 [27].  
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A strong association of GERD with IPF has been demonstrated in a few studies, and the 
microaspiration of gastric contents has been proposed as the mechanism [10, 29, 30]. 
GERD is a very common comorbidity with IPF patients. Several studies have shown 
that 67 - 88% of IPF patients may have distal oesophageal reflux and 33 - 71% may 
have proximal oesophageal reflux [31]. Chronic microaspiration occurs when the 
weakened lower oesophageal sphincter allows the gastric fluid, includes gastric acid 
and bile, to travel up into the oesophagus and then enter the airways. Repeated lung 
epithelium injury via the chronic microaspiration of gastric fluid may lead to 
granulomatous pneumonitis, dysregulated wound healing, and eventually lung fibrosis 
[31].  
Familial IPF was previously thought to be account for less than 5% of total IPF [32, 33], 
but recent studies suggest it may be underestimated [34, 35]. The potential mutations 
that are associated with familial IPF include surfactant proteins C (SPC) [36, 37], SP2A 
[38], and telomerase-related genes [39-41]. These were not commonly found in sporadic 
IPF.  
The identification of a common polymorphism in the promoter of mucin 5B gene 
(MUC5B) in both familial and sporadic IPF in 2011 led to the discovery of other single 
nucleotide polymorphisms in sporadic IPF [42, 43]. Since then, more than 10 other loci 
have been found in association with IPF, and taking all the cases together they may 
represent more than 1/3 of the genetic risk for IPF [44]. More importantly, some gene 
polymorphisms have been associated with specific outcomes in IPF patients. For 
example, MUC5B polymorphism is not associated with interstitial pneumonia in 
systemic sclerosis [45], but TOLLIP and TLR3 polymorphism are associated with 
disease progression and early mortality [46, 47]. Even though it is not recommended to 
carry out genetic testing routinely with either familial or sporadic IPF, it is clearly 
suggested the outcome of IPF is associated with genetic factors and might affect the 
management of IPF patients in the future. 
1.1.4 Diagnosis of idiopathic pulmonary fibrosis: 
multidisciplinary teamwork  
IPF can be diagnosed based on the symptoms, physical examination and high-resolution 
computed tomography (HRCT) [13, 48, 49]. BAL fluid assessment offers 
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complimentary data for the exclusion of other similar conditions [50]. A multi-
disciplinary team meeting is advised to categorise them into different stages of the 
disease [13].  
By definition, IPF means interstitial lung diseases (ILD) with an unknown cause. Thus 
to be diagnosed with IPF, one has to rule out other possible causes of lung fibrosis, such 
as occupational or environmental exposures, toxic drugs, radiation and underlying 
connective tissue disease. [13, 51].  
A detailed history and physical examination are necessary for the diagnosis of IPF. 
Dyspnoea is the main complaint when patients come to the clinic. Developing from 
breathless to dyspnoea could take more than a year and chronic dyspnoea has recently 
been associated with poor prognosis [52]. Smoking history, family history, use of 
certain medications and exposure to risk factors should also be included. Patient age 
may also be helpful in making the diagnosis as IPF most commonly presents in patients 
aged over 60 [13]. Patients with other ILD are often present at a younger age, most 
commonly in their 50s, and the majority of sarcoidosis present even younger, aged 
between 25 to 40 years [53]. Pulmonary examination often observes the classic bilateral 
fine-end inspiratory crepitations. In addition, extrapulmonary findings such as finger 
clubbing (occurs in more than 50% IPF), pulmonary hypertension (e.g., loud second 
heart sound), and peripheral oedema [53] may be apparent. 
Chest radiography (CXR) and HRCT are important radiological tools to diagnose IPF 
and monitor the disease [53, 54]. The typical CXR features of IPF are reticulations and 
reduced lung volumes. It is a simple but important method to help distinguish IPF from 
other lung conditions, such as lung malignancy, pulmonary oedema and infection. 
HRCT is a powerful tool and now used routinely to diagnose IPF. The main feature of 
IPF on HRCT is honeycombing, which is the cystic dilation of distal bronchioles 
secondary to the fibrotic destruction of adjacent airspaces. When honeycombing is 
present with a basal predominance together with septal thickening, this is indicative of 
the underlying pathology being usual interstitial pneumonia (UIP). However, there are 
UIP-similar patterns which can occur with drug exposure, environmental factors and in 
association with collagen vascular diseases [55]. UIP-similar patterns on HRCT can be 
very difficult to be distinguished from the UIP-IPF pattern. Therefore, other evidence, 
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such as clinical presentation, physical examination, and lung function testing are 
necessary to secure the diagnosis. In some cases, bronchoscopy or even surgical biopsy 
(for the histology evidence of UIP) may be required to confirm the diagnosis [13, 51]. 
Instillation of saline solution into the alveolar space was first performed by Stitt in 1927 
[56]. Later, it was used as a tool for the treatment of septic lung disease and pulmonary 
alveolar proteinosis by lavage of the distal airways [57, 58]. Bronchial lavage with a 
flexible bronchoscope for research purposes was first introduced by Reynolds and 
Newball in 1974 [59]. The technique of saline lavage of a defined portion of the lung 
became known as bronchoalveolar lavage (BAL) [60-62].  
BAL is a well-tolerated and useful tool for the diagnosis of ILD and IPF when used in 
conjunction with clinical observations and HRCT imaging [13, 50]. The gross 
appearance of the BAL fluid can be informative of certain lung conditions, such as 
pulmonary haemorrhage (pink coloured fluid) or pulmonary alveolar proteinosis (PAP, 
cloudy and milky fluid). BAL cell differential count provides helpful information. 
Normally the differential cell count of healthy human adults consists of macrophages 
as the main cells (>85%), variable lymphocytes (<15%) and small numbers of 
granulocytes with neutrophils (<3%) and eosinophils (<1%) [48, 60, 62]. Increased red 
blood cells (RBCs) in cytocentrifuge preparations also suggests pulmonary 
haemorrhage. An increase in neutrophils indicates infection and inflammation. Greater 
than 10% of eosinophils is uncommon in ILD and more than 25% of eosinophils 
indicates eosinophilic pneumonia (EP) or other eosinophilic lung disorders [63, 64]. For 
IPF diagnosis, BAL is useful in excluding other causes of ILD. Furthermore, it may 
offer information that relates to the disease severity and progression. In Dr. Hirani’s 
group, we have shown that CD74+ macrophages may be associated with disease 
progression in IPF [65]. Others have also shown that increased number of lymphocytes 
may indicate a better prognosis [66-68], whereas increased eosinophils may be linked 
to a severe condition with a worse outcome [68, 69]. In addition to the cell population 
and phenotypes, the levels of cytokines, growth factors and mediators in the BAL fluid 
can also be relevant to the disease and are candidates for research, drug development 
and potential treatments [70] [71].  
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Disease progression is critical in the management of patients and can be life-threatening. 
Lung function is important in monitoring disease progression and it should be regularly 
measured once IPF is diagnosed. There is robust evidence that a 10% or greater 
reduction in forced vital capacity (FVC) within 6 – 12 month is associated with an 
increased risk of death and therefore accepted as a marker of progression [13]. A decline 
in FVC is the FDA approved primary end-point for Phase 3 clinical trial in IPF and this 
reiterates the importance of FVC decline as a measure of disease progression [72]. CXR 
and HRCT can confirm the severity of the lung fibrosis and also contribute to 
monitoring the disease during its natural course after diagnosis [13]. 
Following the clinical examinations and investigations, a dedicated multidisciplinary 
team should discuss, confirm and categorise the case. This team should include 
respiratory physicians (lung fibrosis specialist), thoracic radiologists, pathologists, and 
specialist nurses [13]. The aims of the meeting are 1) to confirm the diagnosis and the 
stage of the disease, and 2) to establish a future management plan for the patient. 
Management options may include available clinical trials. Some cases, however, may 
be too complex to reach a management plan or sometimes even a defined diagnosis. 
1.1.5 Current strategy of working with lung fibrosis and ILD  
Lung fibrosis was first known as the Hamman-Rich Syndrome following the 
presentation of four cases of pulmonary diseases at John’s Hopkins Hospital in the 
1940s [73]. Hamman-Rich syndrome is now classified as acute interstitial pneumonia 
(AIP) rather than the IPF type usual interstitial pneumonia (UIP). The classification of 
ILD only began in the 1960s, when Dr. Liebow and his group proposed five 
histopathologic subgroups of chronic idiopathic interstitial pneumonia (IIP) which 
included UIP [74]. In 1964, Dr. Scadding in the United Kingdom proposed the term 
“fibrosing alveolitis”, to which “cryptogenic” was added to describe what is now termed 
IPF [75]. More than three decades after the Liebow classification, in 1998 Drs 
Katzenstein and Myers suggested an update to the classification of IIPs and four other 
histologically distinct forms of IIP were presented with UIP, which were: desquamative 
interstitial pneumonia (DIP), respiratory bronchiolitis interstitial lung disease (RBILD), 
acute interstitial pneumonia (AIP, Hamman–Rich disease) and nonspecific interstitial 
pneumonia (NSIP) [76]. By 2002, the American Thoracic Society and European 
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Respiratory Society (ATS/ ERS) published a consensus classification of IIPs which 
added clinical and radiographic features to the Katzenstein/ Myers classification [77]. 
The ATS/ERS 2002 guideline, which was revised in 2011, and later in 2013 and 2015, 




The classification of ILD is currently achieved by a multidisciplinary approach which 
is recommended by the ATS/ERS. The classification of ILD is largely based on the 
aetiology of fibrosis and the histopathological findings. In fact, the majority of ILD 
conditions can be characterised by the different level of inflammation and the degrees 
of fibrosis [79]. For example, sarcoidosis is primarily inflammatory, however, IPF in 
nature is predominating fibrotic with a lack of inflammation [79-81]. On the other hand, 
a few conditions are characterised by the filling of certain cells or materials in the 
alveolar airspace such as desquamative interstitial pneumonitis (with macrophages) and 
alveolar proteinosis (with granular proteinaceous material). There are also some cases 
that remain unclassifiable in ILD even following the multidisciplinary discussion. 
Figure 1-1 Survival in idiopathic interstitial pneumonia.  
Idiopathic interstitial pneumonia (IIP) with fibrosis (which includes IPF) has lower survival rate than 
IIP without fibrosis (graphed by Dr. Nik Hirani, University of Edinburgh). Survival rate of Edinburgh 
cohort (2007-2016) stratified according to HRCT on the presence of lung parenchymal fibrosis. 
Patients with fibrosis (n=565) had a median survival of 4.8 years compared to 8 years for those 
without fibrosis (n=77), hazard ratio (HR) 3.9, 95% confidence interval (CI) 2.9-5.3, p=0.0001, 
unadjusted for baseline variables. 
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However, these unclassifiable diseases appear to have a better prognosis when 
compared to IPF but may be worse than non-IPF ILD [82]. It has been shown that IPF 
has a much poorer prognosis than non-IPF ILD [82, 83]. Even without a definite 
diagnosis of a specific ILD, the clinician can identify ‘fibrotic’ versus ‘non-fibrotic’ 
disease based on HRCT and/or biopsy, thus can monitor the lung function to identify 
‘progressive’ cases from ‘non-progressive’ cases. In patients that die of interstitial 
pneumonia, most die of progressive lung fibrosis. The presence of fibrosis on HRCT at 
presentation has been shown to be associated with a poor prognosis in the Edinburgh 
cohort (Fig 1.1). Thus, a simple method is to group patients based on the presence of 
fibrosis on HRCT scan which is more relevant to prognosis.  
1.1.6 Limited treatments for ILD and IPF 
Currently, there are limited treatments for many ILD conditions [53]. In IPF, the aim is 
to stabilise the condition and slow down disease progression [13, 54]. Other ILD are 
self-limiting and potentially reversible, such as sarcoidosis and respiratory bronchiolitis 
associated interstitial lung disease. In patients with chronic hypersensitivity 
pneumonitis or non-specific interstitial pneumonia, regardless of the strategy of 
immunosuppression treatment, some of the cases can progress to severe fibrosis. In 
unclassifiable ILD, a working diagnosis should be reached for the treatment and 
management of the disease [82, 84]. Treatment plans should also include supportive 
therapies which include pulmonary rehabilitation, symptomatic relief (for example, 
cough and anxiety), and supplementary oxygen [13, 54]. 
Pirfenidone is the first licensed treatment for IPF and has been currently approved by 
the National Institute for Health and Care Excellence in the UK in 2013 [85]. Later in 
2016, the use of Nintedanib was also approved [86]. NICE recommends the use of both 
drugs in patients with a forced vital capacity of 50-80% predicted. Randomised 
controlled trials have shown that neither drugs reverse the established fibrosis but both 
can slow the decline in lung function and modestly reduce mortality [54]. They have 
similar side effects mainly gastrointestinal (diarrhoea, nausea, and dyspepsia) together 
with fatigue and in the case of pirfenidone, photosensitivity [87]. According to NICE 
guidelines, the treatment should be discontinued if lung function declines by 10% or 
more from baseline in a year. There are other drugs that are currently in phase 2a trials 
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(TD139) and phase 2b trials (simtuzimab and lebrikizumab) [88]. Certain patients may 
benefit from enrolment into drug trials for emerging new treatment options, which may 
slow down the inexorable declining rate of lung function. The future of clinical 
treatment for IPF is more promising. 
Previous treatments for IPF patients have been shown to be ineffective or even harmful. 
These include corticosteroids, cyclophosphamide, triple therapy (prednisolone, 
azathioprine and N-acetylcysteine), or N-acetylcysteine alone [89, 90].  Interestingly, a 
recent study was suggested that some patients may be more responsive to treatment with 
N-acetylcysteine when associated with certain genetic polymorphisms [91].  
The availability of lung transplantation is limited in IPF patients but remains the only 
treatment with proven benefit for carefully selected subjects [92]. In total, IPF 
represents about 23% of total lung transplants worldwide [93].  There are many factors 
to be considered for lung transplantation, the predominant factor being the rapid decline 
in lung function which shortens the life expectancy of the patient [94]. Age of the patient 
is a challenge for the success of lung transplantation, and 65 years of age is suggested 
as the upper age limit although successful cases have been performed on patients over 
this limit [95]. About half of patients with IPF receive bilateral lung transplants and one 
in six patients dies before the donor organ is available [53]. In IPF patients, the 
unadjusted three-month mortality after lung transplantation is 15%. The five-year 
survival is 60% for patients who survive one year post-surgery [93]. In successful cases, 
the mobility and general physical activity of the patients are greatly improved.  
1.1.7 IPF: challenges and opportunities  
The rapid decline in lung function and unpredictable clinical course are the major 
challenges of IPF management [14]. Lack of the biomarkers has prevented researchers 
from understanding the disease and the development of new therapies [14, 96].  
To date, early diagnosis of IPF has not been possible due to the lack of diagnostic tools 
[96]. However, early diagnosis is essential for the accurate diagnosis and appropriate 
management which may affect prognosis. Early diagnosis may also help monitor 
disease progression and create opportunities for new therapies. For nearly half of 
patients, the mean time to referral to a specialist from the onset of dyspnoea is more 
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than 18 months [97]. It is suggested that half of the patients have already got the late 
stage of disease at the time of diagnosis [97]. A late diagnosis is related to a poorer 
prognosis and these patients may have limited treatment options and be ineligible for 
clinical trials with newly developed medications [97, 98].  
The natural course of IPF can be very rapid and disease progression is a poor prognostic 
marker [14]. Besides the very limited and effective treatments, there is currently no 
marker that can accurately predict the prognosis of IPF [13]. A few candidates markers 
of disease progression, such as cytokines and inflammatory factors have been elevated, 
and more recently, genetic and epigenetic significance, transcriptional and post-
transcriptional mechanisms, and metabolic factors have also been studied [96]. 
However, there is no evidence that the any of these have a better correlation to disease 
progression. It is now believed that in IPF there are different subgroups with a specific 
signature that are associated with the vulnerability, development, progression, 
treatment, and prognosis of the disease. It is the aim of clinicians and researchers to 
identify such groups of patients and develop personalised care strategies to further 
develop the management of IPF. The breakthrough will be the identification of disease-
relevant biomarkers and early diagnosis of IPF. 
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1.2 IPF pathogenesis and extracellular matrix 
(ECM) biology 
In the last few decades, there has been progress in the definition and diagnosis of IPF, 
[13, 51, 54, 77, 78]. However, there has been limited progress towards understanding 
the fundamental pathogenic mechanisms in usual interstitial pneumonia (UIP) which is 
the pathological feature of IPF. Current understanding of UIP has been focused on 
recurrent epithelial injury and aberrant epithelial/ fibroblastic communication. 
Inflammation, which was hypothesised as the initiating event in lung fibrosis, is now 
not regarded as the primary driver of UIP, although the evidence for the absence of 
inflammation is limited. Nevertheless, inflammation is an essential component of the 
wound healing process with important roles in the regulation of tissue fibrosis and its 
resolution [99-102]. 
1.2.1 Epithelial injury and abnormal wound healing in IPF  
Normal wound healing can be divided into three steps that include: initial injury, 
initiation and resolution of inflammation, and finally tissue repair. In lung fibrosis, 
especially UIP, the normal wound healing is disrupted. The aberrant wound healing and 
on-going injury result in excessive deposition of ECM in the lungs [16, 80, 103]. 
 The “fibroblastic focus” is a well-recognised morphological lesion of UIP that is the 
subepithelial accumulation of (myo)fibroblasts [104-106]. Fibroblastic foci are 
prominent in UIP but can be seen in other fibrotic lung diseases such as chronic 
hypersensitivity pneumonitis (HP), non-specific interstitial pneumonia (NSIP) and 
rheumatic interstitial lung disease (RILD) [107-109]. Fibroblast foci represent the 
classic alveolar epithelial cell injury response that leads to fibrosis [110] and they are 
identified as the areas of active fibrosis [111, 112]. Fibroblastic foci are observed in the 
interstitium and are lined by alveolar epithelium [3, 113]. In advanced fibrosis, 
fibroblasts can migrate through the damaged epithelial barriers into the alveolar space 
and continue to proliferate and produce ECM in the alveolar space [80]. 
It is proposed that there are at least three potential origins of the fibroblast foci 1) 
activation of interstitial lung fibroblasts by pro-fibrotic growth factors; 2) type-II 
epithelial cells undergoing epithelial-mesenchymal transition (EMT); and 3) fibrocytes, 
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circulating bone marrow-derived progenitor cells [114]. ECM components are 
dominant in the fibroblastic foci, including pro-collagen type I, tenascin-C and the 
glycosaminoglycan (GAG) versican [105, 115-118]. In relation to the development of 
fibrosis, fibroblastic foci have been categorised into three stages based on the expression 
of GAGs and collagen [119-121]. Fibroblastic foci also have been correlated with poor 
prognosis in IPF, however, there is conflicting evidence for this initial finding and the 
relationship needs to be further investigated [102, 122-124].  
There are a number of cell types and pathways implicated in this complicated process 
of lung fibrosis. Cells present different roles during the three stages of fibrosis: initiation 
(early stage), development (inflammation stage), and repair or fibrosis (later stage).  
In the early stage, the initial injury causes damage and dysfunction in the lung 
epithelium cells which leads to apoptosis or EMT. It is documented that type II alveolar 
epithelial cell injury is an important early feature in the pathogenesis of pulmonary 
fibrosis [80]. Important events in this early stage include activation and increase of 
transforming growth factor β (TGF-β), the release of different chemokines, the increase 
of oxidative stress and the accumulation of endoplasmic reticulum (ER) stress [100, 
125, 126]. It has been reported that TGF- β promoted the EMT of normal peripheral 
lung epithelial cells in vitro [127].  
The initiation of inflammation is triggered by epithelial cell death. Epithelial injury 
leads to the recruitment of local lung macrophages and the infiltration of inflammatory 
cells such as neutrophils, lymphocytes, and monocytes from the blood vessels. The 
presence of inflammatory cells on the site of injury triggers a cascade of inflammatory 
events and creates a profibrotic microenvironment by releasing cytokines and 
chemokine in response to the injury.  
In the later stage, the important events in the remodelling of lung fibrosis include the 
activation of fibroblasts, myofibroblast differentiation, EMT and fibrocyte recruitment 
[128, 129]. The pathological changes in fibrocyte in the lungs may promote 
mesenchymal cell activation and leads to progressive fibrosis [130, 131]. Excessive 
deposition of ECM is initiated in the lungs if the normal tissue repair was disturbed and 
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an abnormal amount of matrix was produced or the nature of matrix changed to a 
fibrillar type with increased stiffness [132].  
In summary, currently, the dysregulated fibrosis process is thought to be triggered by 
the epithelial injury, continued with or without inflammation and resulting in the 
activation of (myo)fibroblasts. The excessive deposition of ECM resulted in the 
structural changes and eventually leads to respiratory failure.  
1.2.2 Role of inflammation in IPF 
As described above, currently, it is thought that epithelium injury and aberrant wound 
healing are the primary driving forces of UIP. The role of inflammation in UIP is not 
fully established. In fact, there is no study in serial lung biopsies of human IPF or good 
animal models of UIP that can address the question. It is clear that inflammation plays 
a critical role in other forms of lung fibrosis such as chronic HP and NSIP. The evidence 
for inflammation in UIP includes the observation of increased inflammatory cells, such 
as neutrophils and eosinophils, in the alveolar lavage fluids in IPF patients [133]. Some 
studies show a correlation with BAL inflammatory cells and prognosis [134]. However, 
in stable IPF, histologic findings in tissue showed very mild inflammation and 
disproportionate fibrosis. This pathologic pattern is not much changed from the early 
phase of the disease (i.e. mild disease) to the late stage (i.e. severe disease), which is 
against the on-going chronic inflammation theory. More importantly in clinical trials, 
subjects were not responsive to immunosuppressive treatments and this may even be 
harmful in IPF [89]. It may be that inflammation in UIP is an outcome of the injury and 
tissue repair rather than the driving force of the progressive fibrosis process [101, 102].  
Regardless, inflammation is inevitably present within the epithelial injury/remodelling 
theory. Epithelial injury recruits inflammatory cells and exaggerates the inflammation 
response which is an essential part of the normal wound healing process. The 
inflammatory cells, especially macrophages, are responsible for the clear up of the 
apoptotic cells and debris to limit the spread of inflammation. In the repair stage, 
inflammatory cells release pro-fibrotic mediators, such as cytokines and growth factors, 
to enhance the tissue repair and wound healing [135]. These mediators enhance the 
activation, proliferation, and differentiation of fibroblasts to myofibroblasts thus 
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promoting the deposition and accumulation of ECM. Dysregulation of the normal tissue 
repair leads to the disturbance of cellular homoeostasis which favours chronic abnormal 
tissue repair, scarring in the lungs, alveolar destruction, and respiratory failure.  
In all, epithelial injury and cell death are regarded as the major events in UIP, the on-
going inflammation response in chronic wound healing process may be secondary to 
this process but the pro-fibrotic inflammatory mediators released by immune cells are 
likely to be important for the regulation and modification of normal wound healing. 
1.2.3 Macrophages are essential for tissue repair 
Macrophages are found in almost all tissues and organs and they are essential for the 
normal wound healing [15, 136]. Macrophages are key regulators of the recruitment, 
proliferation, and activation of fibroblast which are the key steps of tissue fibrosis [137]. 
Macrophages are found in sites of wound healing and they regulate the normal wound 
healing process by the synthesis and secretion of chemokines and cytokines [135].  
Animal studies have shown that the depletion of macrophages results in retarded tissue 
repair and failure of wound healing [138-140]. The depletion of macrophages in a lung-
specific TGF-β1 transgenic mouse model led to the attenuation of fibrosis. These studies 
suggested the importance of the monocyte/ macrophage lineage cells in the TGF-β 
driven lung fibrosis [141].  
Studies have demonstrated that macrophages have complex and specific functions in 
wound healing. It has been shown that some macrophages clearly promote the fibrosis 
process, while other macrophages may facilitate the resolution and/or reversal of tissue 
fibrosis [137, 142]. More interestingly, macrophages have shown different functions at 
different stages of the wound healing process. A study in a mouse model of liver fibrosis 
demonstrated different roles of macrophages in different phases of the fibrosis process 
[143]. It was reported that if macrophages were depleted during the early inflammatory 
phase of a fibrotic response, the fibrosis was reduced and the differentiation to 
myofibroblasts was also decreased. However, if macrophages were depleted during the 
late remodelling phase, the fibrosis persisted. This study confirmed that macrophages 
could play distinct roles in different phases of the fibrosis process. Later, in a skin model 
Chapter 1 Introduction. 15 
of tissue repair, macrophages were also shown to have different roles at different stages 
of the normal wound healing process [144].  
1.2.4 Macrophages and lung fibrosis 
The macrophage is a key regulatory cell of the normal wound healing process and is at 
the centre of inflammation regulation in the lung and in the alveolar space. In general, 
there are two types of macrophages in the lungs: alveolar macrophages (AM) that live 
in the airways and the interstitial macrophages (IM) that are resident in the parenchymal 
tissues [145, 146].  
The number of AM increases in the terminal airways and they are the most common 
cell type in the BAL fluid from the healthy human lungs [147]. In normal lungs, AM 
reside in surfactant rich alveolar lining fluid at the interface of air and the alveolar 
epithelial barrier [148, 149]. AM are in contact with alveolar epithelial cells via small 
pseudopodia [148]. They interact with each other by releasing many mediators, 
cytokines and growth factors in biological and pathological conditions.  
Upon the epithelium injury, AM are amongst the first group of cells to respond to the 
damage, by producing pro-inflammatory cytokines and trigger a cascade of 
inflammation response. Studies have shown that cytokines and chemokines that are 
related to activated macrophages may have a pro-fibrotic role in the pathogenesis of 
lung fibrosis [150-152].  Upon activation, AM can release mediators that regulate the 
growth and the phenotype of epithelial cells [153]. When the epithelial cells are injured 
or the epithelial barrier is compromised, the AM are exposed to the cells and structures 
that lie underneath the epithelial lining [153]. In lung fibrosis, the on-going injury and 
repair of lung epithelial cells increase the exposure of AM to the excessive ECM and 
ECM components in the alveolar space repeatedly. ECM and its components are 
regarded as biologically functional mediators that regulate many processes which affect 
cell proliferation, migration, activation and cytokine production [154]. They also 
influence the fibrosis process by affecting the cellular behaviour of the effector cells 
such as fibroblasts and macrophages in the lungs [155, 156].  
In IPF, the number of AM is greatly increased, and they also exhibited a distinct 
“wound-healing” phenotype (alternative activated) [151, 157]. Alternatively activated 
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macrophages produce pro-fibrotic mediators, such as TGF-β and platelet-derived 
growth factor (PDGF), that promote the proliferation and activation of collagen-
secreting human fibroblasts [158]. AM isolated from human fibrotic lung tissues can 
produce pro-fibrotic cytokines such as IL-13 [159], interleukin-1β and TNF-α [160]. 
On the other hand, macrophages can also inhibit tissue fibrosis by promoting 
(myo)fibroblast apoptosis and promoting inflammation resolution [137]. Macrophages 
also showed the ability to digest and engulf ECM components [161]. They can also 
induce the production of matrix metalloproteases (MMPs) in different cell types for the 
degradation of collagens [137].  
Macrophages are a heterogeneous population of cells that are derived from peripheral 
blood monocytes. However, studies also suggested that the original AM may have 
different origins and have distinct roles than the newly differentiated macrophages from 
blood [162]. In general, once AM are activated they can adopt a spectrum of activation 
states, but can be broadly dived to two populations: pro-inflammatory (classically 
activated, M1) macrophages and pro-resolution (alternatively activated, M2) 
macrophages [163-165]. It has been well-established that the dominant phenotype of 
AM in lung fibrosis is broadly towards the M2 spectrum of macrophages. More 
importantly, it is believed that M2 macrophages are important regulators of the 
development and progression of the fibrosis process [166-168]. Macrophages are 
polarised to M1 or M2 phenotypes in response to cytokines in the microenvironment. It 
has been well-recognised that IFN-γ and LPS trigger the classic activation (M1) 
whereas IL-4 and IL-13 lead to the alternative activation (M2).  IL-4 and IL-13 mediated 
alternative activation has been shown both in vitro and in vivo [169, 170]. Arginase 1 
(Arg 1) and macrophage mannose receptor 1 (CD206) are commonly used markers for 
M2 activation [171, 172]. 
1.2.5 ECM production and degradation  
In normal lungs, ECM is a constitutive compartment of the human body and it is a 
highly organised network of proteins where other lung cells are resident. ECM not only 
provides structural support but more recently has been shown to be a bio-active material 
that is involved in cell adhesion, differentiation, migration and proliferation [114, 173, 
174]. The quantity of ECM is highly dynamic and it is dependent on its production and 
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degradation, and the dysregulation of either process can lead to fibrotic pathologies [175, 
176].  
ECM is mainly produced by (myo)fibroblasts, but other cells such as epithelial cells can 
also contribute to ECM production [177]. Once stimulated, collagen mRNA transcripts 
will first be increased and then the collagen propeptides will be synthesised [178]. Post-
translational modification is an important step before the formation of the triple helix 
collagen structure in the endoplasmic reticulum. The modifications include 
hydroxylation and glycosylation of collagen residues and the formation of disulfide 
bond. The triple helix structure will be processed in the Golgi apparatus and then 
secreted out of the cells [178]. Mature monomeric collagen molecules are produced 
after further modification by other peptidases. The monomeric collagen molecules are 
used to compose microfibril which interdigitates with other microfibrils to form a 
collagen fibril [179]. The collagen fibrils then formed collagen fibre by extensive cross-
linking and right-handed supertwist [180]. The recognition and binding of ECM with 
its ligands is depended on the structure and orientation of the collagen fibril. Integrins 
are the primary binding sites of collagen [181] other binding sites include 
metalloproteinases [182], fibronectin [183], proteoglycans [184], and von Willebrand 
factor [185]. Some of these sites are not accessible for the ligand recognition as they are 
buried within the microfibrillar structure [186, 187]. 
Collagen degradation is mainly through the production and activation of extracellular 
matrix metalloproteinases (MMPs). However, collagen can be recognised and 
internalised by macrophages and fibroblasts for intracellular degradation through 
lysosomes. Impaired matrix degradation at least is recognised as part of mechanisms 
leading to persistent lung fibrosis together with the activation of (myo)fibroblasts with 
increased matrix production [178]. Of note, the intact fibrillar collagen can only be 
degraded by certain MMPs including MMP-1, MMP-8, MMP-13, MMP-14, MMP-16, 
and MMP-18 [182]. Fragments of cleaved collagen can be further degraded by 
gelatinases (MMP-2 and MMP-9) or cathepsin K or lose their triple-helical structure 
spontaneously [114, 188].   
MMPs are a family of zinc enzymes that perform matrix-degrading functions. In the 
lungs, MMPs are secreted by many cells including AM, neutrophils, and lung epithelial 
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cells [189]. They are released in an inactivated latent form which is then activated 
extracellularly by the proteolytic process. There are at least 24 well-defined MMPs and 
they are divided into subgroups according to the specific ECM proteins they degrade 
[190]. The changes of MMPs and the tissue inhibitors of metalloproteinase (TIMPs) are 
the co-factors that modulate the local ECM microenvironment in biological and 
pathological conditions [191]. 
The internalised collagen in macrophages and fibroblasts was first observed by electron 
microscope [192, 193]. Four different mechanisms have been reported as independent 
means of internalisation of collagens [114]. Collagen can be recognised by specific 
receptors, especially through α2β1 integrin, before internalisation [194]. Collagen can 
also be internalised by endocytosis which is mediated by the transmembrane mannose 
receptors uPARAP/Endo180 on fibroblast [195] and mannose receptor/CD206 on 
macrophages [196]. Mfge8, an extracellular glycoprotein can also mediate the 
internalisation of collagens as a bridging molecule in macrophages [161]. And lastly, 
collagen can be taken up non-selectively through a form of endocytosis termed 
macropinocytosis [197]. Interestingly, collagen internalisation can be modulated by 
cytokines, for example, TGF-β can promote collagen uptake [198] whereas TNF-α and 
IL-1α inhibit this process [199]. The engulfed collagen has been shown to be directed 
to lysosomes for degradation [192].  
1.2.6 ECM in the fibrotic tissue  
The composition of ECM in fibrotic tissue is different from normal tissue. The 
excessive deposition of collagen in UIP [200] has been characterised as the continuous 
deposition of type-I collagen rich matrix in the lung interstitium [2, 3]. However, the 
composition of ECM changes at different stages of the disease [201, 202]. Collagen 
type-I, III and IV may be associated with early stage of lung fibrosis [203]. At the later 
stage of UIP, type-I collagen was found increased and type-IV collagen was found 
decreased [204]. In the areas of established (end-stage) fibrosis, there was almost 
exclusively type I collagen [205]. The increased stiffness of the alveolar spaces prevents 
normal gas exchange and destroys the alveolar structure which leads to respiratory 
failure and consequently cardiac compromise [206, 207].  
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Besides the composition of fibrotic ECM, many other properties should be considered, 
including the stiffness [208], the organisation and orientation (e.g. cross-linking) [175] 
and the post-translational modifications of ECM [175, 209]. Together with other 
physical/mechanical changes, they all contribute to the functional properties of ECM. 
The elasticity/ stiffness of ECM is important for cell biology which is largely depended 
on the ratio of elastin and collagens [210, 211]. With increased ECM stiffness, 
fibroblasts increased proliferation, became resistant to apoptosis and enhanced collagen 
production [208].  
In addition, the orientation of the ECM components may also affect the efficiency of 
their degradation through collagenases. The orientation of collagen in the skin scar 
tissue is more parallel orientated relative to the epithelial surface than normal skin [212]. 
Excessive activation of cross-linking enzymes such as lysyl oxidase (LOX) promotes 
the interaction between hydroxylysine and collagen that can enhance the matrix 
stabilisation and prevent it from degradation [213].  
1.2.7 ECM is bioactive matter in the body 
ECM modulates cell behaviour through biomechanical and biochemical signals [173]. 
The changes ECM components during fibrosis are now regarded as a pathogenic factor 
that contributes to the establishment of fibrosis. Fibrotic ECM causes the perpetuation 
of tissue inflammation, promotes fibroproliferation, and triggers aberrant differentiation 
of cells which all lead to continuous fibrosis [154].    
ECM in fibrotic tissue interacts with major effector cells of fibrosis. Fibrotic ECM with 
increased stiffness enhances the proliferation and differentiation of fibroblast. The 
phenotype of normal fibroblasts is altered to pro-fibrotic in matrices with increased 
stiffness [202]. The modification and the re-organisation of ECM can also change the 
nature of ECM to be resistant to degradation enzymes thus enhances ECM accumulation 
[178]. In vitro, IPF fibroblast-derived ECM can change the gene expression profile of 
the fibroblast and forms a positive feedback loop of fibrosis that maintains the pro-
fibrotic environment [155]. ECM also plays an important role in determining innate cell 
function in inflammation [156]. The interaction between macrophages and ECM affects 
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the inflammation effector functions of macrophages [214]. ECM may also have 
instructive roles on fundamental cellular homeostatic processes. Recently, it was found 
modulating the autophagy pathway [215]. ECM increases basal autophagy in epithelial 
cells through adhesion molecules [216] and the detachment from ECM also induces 
autophagy as a surviving signal [217]. Many of the ECM components have been shown 
to modulate the autophagy pathway [215]. ECM may also affect many signalling 
pathways that are associated with autophagy such as the redox signalling and reactive 
oxygen species (ROS) production [154]. 
ECM also interacts with growth factors thus modulating lung fibrosis. ECM proteins 
can activate the latent form of TGF-β which is a key mediator in lung fibrosis and 
promote ECM production and deposition in the lungs [218]. Connective tissue growth 
factor (CTGF) is another important mediator of lung fibrosis which can be induced by 
TGF-β and is highly expressed on activated fibroblasts [219, 220]. CTGF interacts with 
ECM components and enhances the expression of TIMPs, thus inhibiting the matrix 
degradation and promotes tissue fibrosis [221]. 
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1.3 Autophagy: key mechanism for cellular 
homoeostasis 
Cellular homoeostasis provides cells with the critical conditions to survive and to 
perform their functions. The disruption and loss of homoeostasis have pathological 
consequences [175, 222]. Autophagy is one of the important, fundamental and 
constitutive mechanisms that control and regulate cellular homoeostasis [223, 224]. 
1.3.1 A brief history of autophagy: a cellular constitutive 
mechanism for homoeostasis 
The discovery of the lysosome by C de Duve in the 1950s led to the observation of 
autophagy in 1963. Autophagy is described as a “self-eating” (derived from Greek) 
process as the cell captures part of its own cytoplasmic material to form 
autophagosomes (termed as macroautophagy) and then deliver it to lysosomes for 
degradation [225].  
The formation of an autophagosome starts with a structure named as “isolation 
membrane” which is formed around the cellular waste. The isolation membrane 
elongates, encloses the waste and seals up as a double-membrane autophagosome which 
is then directed to a lysosome for degradation. The understanding of this process 
progressed in the 1990s when starvation-induced autophagy was observed in yeast, 
which consequently led to the discovery of autophagy-related genes (ATG) and their 
products [226]. The ATG homologues have since been identified and extensively 
studied by other researchers in many organisms, and remarkable progress has been 
made in its role in human health and diseases [226].  The highlight of autophagy 
research was when Yoshinori Ohsumi was awarded the Nobel Prize of 2016 (in 
Physiology or Medicine) for his contribution to understanding the fundamental 
mechanisms of the autophagy process [227, 228].  
In the last two decades, research in autophagy rapidly progressed towards the 
understanding of its molecular mechanisms and broader role in its involvement in 
human health and disease [223, 229]. 
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1.3.2 The regulation of autophagy: step by step 
Macroautophagy (autophagy) can be divided into five steps: initiation of the isolation 
membrane/ phagophore; membrane elongation; formation of autophagosomes 
(maturation); fusion with lysosomes; and lastly the degradation and release of the 
products back to the cytoplasm [230]. The discovery of autophagy-related genes and 
proteins had promoted the research and understanding of the autophagy process [226].  
 
Figure 1-2 The autophagy-lysosome pathway step by step.  
Macroautophagy (autophagy) includes five steps: initiation of the isolation membrane; membrane 
elongation; formation of autophagosomes (maturation); fusing with lysosomes; and the degradation 
and release of the products back to the cytoplasm. 
 
The first step of autophagy is the initiation of the isolation membrane. The endoplasmic 
reticulum (ER) is proposed as the major resource of the autophagosome membrane, but 
there is evidence that mitochondrial membranes, Golgi apparatus, recycling endosomes, 
and the plasma membrane may also contribute to this structure [231]. The 
autophagosome formation process involves many proteins, among which double FYVE 
domain containing protein 1 (DFDP-1), Atg-14L, uncoordinated 51-like kinase-1 
(ULK1) complex, Atg5, and Atg9/Atg16L are key regulators [231].  
Once the cup-shaped isolation membrane is closed up to form an autophagosome, it is 
directed to a lysosome. The outer membrane of a matured autophagosomes eventually 
fuses with a lysosome to form a single membrane structure (autolysosomes). The exact 
mechanisms for autophagosome-lysosome fusion are under investigation, but it is 
known that small GTPases, especially Rab7, and lysosome-associated membrane 
proteins (e.g., LAMP-1 and LAMP-2) are heavily involved and functionally relevant 
[232-234]. With the lysosomal enzymes such as hydrolases, the autophagosome cargo 
will be degraded which begins once the lysosomal enzymes are activated by 
acidification of the cytosol pH values through the proton pump on the lysosome surface 
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[235]. Autophagy is completed by releasing the degraded products back to the 
cytoplasm and the free amino acid, nucleotide, glucose, and fatty acid are then recycled 
through anabolic pathways [236].  
In mammalian cells, microtubule-associated protein light chain 3 (LC3), the 
mammalian homologue of yeast ATG8, is recognised as the primary autophagy marker 
[237]. After synthesis, nascent LC3 is cleaved by ATG-4 to produce the cytosolic form 
(LC3-I). LC3-I is converted to LC3-II after conjugation with phosphatidylethanolamine 
(PE) by ATG-7 and ATG-3 [238, 239]. LC3-II is the only protein found to be present 
on both the inner and outer membrane of autophagosomes in mammalian cells [237, 
240]. LC3-II on inner autophagosomes membrane is degraded with the cargo and LC3-
II on the outer autophagosome membrane is recycled by ATG4B [241].  
The upper stream of the autophagy pathway is controlled by two distinct signalling 
complexes: Tor-Atg13-Atg1 [242, 243] and Beclin 1 (Atg6)-Atg14-hVPS34 [244-247]. 
The deprivation of amino acid, inhibition of the mammalian target of rapamycin 
(mTOR), hypoxia, ER stress, immune mediators [248], and cellular receptors such as 
pattern recognition receptors [249, 250] and Fc receptor [251] can trigger the autophagy 
process through these two mechanisms. 
1.3.3 Autophagy pathway: the experimental 
measurements  
It is estimated that in every hour around 1%–1.5% of cellular proteins are recycled 
through basal autophagy in the liver [252]. Autophagy is a rapid process and an 
autophagy cycle takes about 7-9 minutes in yeast [253]. The formation of 
autophagosomes takes approximately 4-5 minutes in yeast and 5-10 minutes in 
mammals [252-254].  
Autophagy occurs under resting conditions (basal autophagy) and in response to cellular 
stress (induced autophagy). Basal autophagy is regarded as an important ‘quality 
control’ mechanism for cellular homoeostasis [255]. Induction of autophagy occurs 
through mTOR-dependent and -independent pathways. The most frequently used 
methods of autophagy induction in vitro are starvation and rapamycin treatment, both 
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of which act by inhibiting the mTOR [256]. In vitro, activated functional autophagy 
returns to basal status rapidly if the autophagy stimulus is removed [257-260]. 
Autophagy can be non-selective and selective processes depending on the involvement 
of specific adaptor proteins [255, 261]. Selective autophagy targets specific 
dysfunctional protein aggregates (aggrephagy), damaged cellular organelles 
(mitochondria and mitophagy), foreign pathogens (xenophagy) and excessive lipids 
(lipophagy). The most extensively studied adaptor for selective autophagy is p62. 
However, other adaptor proteins (e.g., NDP52 and NBR1) have also been proposed as 
adaptor proteins for selective autophagy [261, 262].  
The experimental measurement of the autophagy pathway is largely dependent on 
measuring the expression of the autophagy-related proteins of which LC3-II is the only 
specific autophagy marker in mammals [263]. The measurement and interpretation of 
LC3 expression, usually by western blotting, can be complicated and needs to be 
interpreted in the context of data from other assays (e.g., bafilomycin A1 treatment and 
the expression of p62) [230, 264]. The relative expression of autophagy-related proteins 
in the presence of autophagy stimulation and inhibition is, therefore, an important 
surrogate to assay functional autophagy dynamics [230]. A common method to visualise 
the autophagy pathway is GFP-labelled LC3 proteins under fluorescent microscopy, 
however, it has its disadvantages [230]. Monodansylcadaverine (MDC) has been used 
as a dye for the study of autophagic vacuoles [265], but it has been found later to be a 
non-specific marker of autolysosomes with off-target staining of lysosomes and it does 
not stain autophagosomes [263, 266]. Thus, MDC staining may fail to reflect 
autophagosome maturation or degradation [267]. The development of efficient and 
specific autophagy-related dyes such as Cyto-ID have facilitated the study of autophagy 
with live staining of the autophagic compartment in a more specific and efficient 
manner [268]. Nevertheless, the identification of the archetype structure of double-layer 
membrane autophagosomes with transmission electron microscope (TEM) is still the 
gold-standard method to determine the presence of autophagy although it is not 
quantitative [230, 263].  
The autophagy substrate protein p62 is also known as sequestosome 1/SQSTM1. It is a 
ubiquitin protein and only expressed in animals and humans. It binds directly to LC3-II 
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and is incorporated into the autophagosome [269]. Accumulation of p62 is observed 
when autophagy is impaired, and one of the consequences of this is the formation of 
large cellular aggregates in the cells [270]. The p62-positive aggregate is found in 
diseases such as various neurodegenerative disorders, liver disorders and cancers [271-
273]. Genetically modified ATG animal studies have shown that p62 is required for the 
formation of the cellular aggregates [274]. In vitro, p62 is necessary for the clearance 
of M. tuberculosis infection through autophagy and without p62, the organism is not 
efficiently eliminated [275]. In homeostatic condition, p62 is found in the regulation of 
inclusion body formation and elimination of p62 can nullify damage caused by 
autophagy deficiency in mice [270]. 
To study basal autophagy or the functional dynamic of activated autophagy, late-phase 
autophagy blockers are normally used (e.g. bafilomycin A1). Bafilomycin A1 is an 
inhibitor of the v-type ATPase that blocks the fusion of the autophagosome and 
lysosome by inhibiting lysosomal acidification [276]. By blocking the autophagosome 
degradation, neither LC3-II nor p62 proteins will be degraded through the autophagy-
lysosome pathway. Therefore, the accumulation of the autophagy marker (LC3-II) by 
bafilomycin A1 represents the “autophagy activity” in cells or the autophagic flux 
(calculated by the changes of LC3-II and p62 expression) [230].   
1.3.4 Common mechanisms for autophagy in lung 
diseases  
Many lung diseases manifest processes including ER stress, oxidative stress, hypoxia 
and inflammation that in turn are implicated in the autophagy pathway [17]. 
ER stress has been demonstrated as a modulator of the autophagy response [277]. 
Cigarette smoke [278], hypoxia [279] and LPS  [280] have all been shown to induce 
ER stress. In the lung fibroblast cell line WI-38, ER stress increased LC3-II expression 
[281].  
The lungs are particularly susceptible to the oxidative stress as they are exposed to both 
a relatively high oxygen environment and inhaled toxins [282]. The elevated oxidative 
stress has been shown to be associated with the activation of autophagy [283] and it is 
thought that autophagy in smoking-related lung conditions, such as COPD, are related 
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to oxidative stress [7, 284]. Cigarette smoke extract has been shown to increase 
oxidative stress in human bronchial epithelial cells that increased LC3-II expression 
[285]. In starvation-induced autophagy, Atg-4 has been identified as the potential target 
for oxidative stress [286] and the regulation of intracellular superoxide has been 
proposed as a mechanism of starvation-induced autophagy [287].  
Hypoxia is associated with autophagy activation in many contexts, especially in 
tumours, and HIF-1 has been presented as a regulator in hypoxia conditions [279]. 
Protein-kinase-C (PKC) δ has been implicated in the autophagy induction under 
hypoxic conditions [288]. 
Inflammation regulates the autophagy pathway through the activation of Toll-like 
receptors (TLR)[289]. In RAW264.7 mouse macrophages and human alveolar 
macrophages, it has been shown that the induction of autophagy was related to the 
activation of TLR-4 [250]. Other TLRs, such as TLR-7 and TLR-3, have also been 
involved in autophagy in RAW264.7 macrophages [290].   
1.3.5 Autophagy, wound healing and fibrosis 
The association of autophagy with fibrosis is complex. It is generally believed that the 
disruption of homoeostasis is the initiation of a dysregulated wound healing process 
which leads to the failure of normal wound healing and results in tissue fibrosis [175, 
222]. Autophagy, a fundamental process of maintaining cellular homoeostasis, is likely 
implicated in the regulation of the fibrotic process and there is some evidence that ECM 
may instruct cells through the autophagy pathway [215, 291, 292]. 
Induction of autophagy by trifluoperazine (TFP), an autophagy inducer, in primary 
mesangial cells from mice decreased collagen-I protein levels induced by TGF-β in 
vitro [293]. More recently, the newly approved drug for IPF, nintedanib was shown to 
have an anti-fibrotic effect on lung fibroblasts from IPF patients in vitro through three 
independent mechanisms which included the induction of non-canonical autophagy 
[294]. Animal studies provide more evidence to suggest that a functional autophagy 
pathway is critical for the normal wound healing process. In a genetically manipulated 
kidney experimental model, lack of autophagy resulted in excessive collagen in mouse 
kidneys in vivo and the activation of mTOR was accompanied with autophagy 
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resolution and renal repair [295]. In lung fibrosis, IL-17A antagonism improved both 
bleomycin- and silica-induced pulmonary inflammation and fibrosis in mice, which was 
abolished by inhibiting the activation of the autophagy pathway [296]. Researchers also 
showed that, in the bleomycin-treated mouse model of lung fibrosis, rapamycin-induced 
autophagy decreased the level of hydroxyproline and alpha-smooth muscle actin (alpha-
SMA) and increased survival in treated mice [297, 298]. These data all suggest 
autophagy induction is associated with the resolution of lung fibrosis. There is evidence 
however, that autophagy may be a “double-edged sword” in organ fibrosis. In liver 
fibrosis, enhanced autophagy can attenuate liver fibrosis by inhibiting tissue 
inflammation, but can also activate hepatic stellate cells (HSCs) and increase collagen 
synthesis [299]. It has also been suggested that autophagy has a dual role in the lung 
epithelial injury which is proposed as one of the important mechanisms of lung fibrosis 
[300].  
In patients with IPF, previous studies suggested that autophagy is depressed even with 
the known autophagy-regulating mechanism being upregulated [297, 298, 301]. Whole 
lung homogenate or tissue section from IPF patients have decreased levels of LC3 and 
p62 as determined by western blotting and fluorescent microscopy [297]. 
Immunohistochemistry staining showed that the accumulation of p62 was specifically 
increased in type-II epithelial cells within the fibroblastic foci (FF) and with no 
expression of autophagy markers in (myo)fibroblasts or type-I epithelial cells [301]. An 
mTOR downstream effector protein, p-S6, was weakly expressed in healthy lungs but 
was found strongly expressed in IPF lung myofibroblasts suggesting that autophagy 
induction was suppressed in IPF lungs which might be the result of activation of mTOR 
signalling that inhibits the activation of the autophagy pathway. [298]. In these three 
studies, AM were not specifically described. However, there are AM found in the 
alveolar space in these images and the immunohistochemistry (IHC) showed similar 
staining of p62, ubiquitin and beclin in AM as in type-II epithelial cells [301].  
Excessive ECM deposition is a hallmark of tissue fibrosis including lung fibrosis (e.g., 
IPF). ECM components are biologically relevant and regulate many cellular processes 
including autophagy [302]. The pathways linking ECM and autophagy are largely 
unknown but cell surface integrins, lysosome motility and position, and soluble ECM 
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may be relevant to the cross-talk between the two pathways [215, 291]. ECM increases 
basal autophagy in epithelial cells through focal adhesion kinase (FAK) [216]. The 
proposed mechanism is that FAK tyrosine phosphorylates an upstream mTOR regulator 
(TSC2) which suppresses the activation of mTOR and leads to autophagy activation 
[303]. On the other hand, the detachment of epithelial cells from ECM (anoikis) induces 
autophagy which has been proposed as a mechanism to enhance cell survival and 
reattachment [291]. Indeed, cells cultured on low-attachment surfaces have shown 
increased autophagy due to the lack of integrin adhesion [304, 305]. Furthermore, 
adhesion to ECM promoted morphology changes of cells [216], which affects the 
redistribution of lysosomes and enhances the motility of lysosomes [306]. Lysosome 
positioning includes the dynein-mediated retrograde transport of lysosomes which 
promotes its fusion with autophagosomes. Thus, the changes of lysosome positioning 
by the interaction with ECM may affect the degradation of autophagosomes [306]. ECM 
may also modulate many processes in the lungs, such as oxidative stress, that are 
relevant to the autophagy pathway [154, 215]. 
In summary, autophagy as a fundamental mechanism of maintaining cellular 
homoeostasis, is involved in wound healing and tissue repair. Its exact role in IPF needs 
to be closely investigated. 
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1.4 Exosomes: mediating the intercellular 
communication 
Exosomes are small vesicles that are released by almost all cell types. In recent years, 
exosomes have drawn much attention regarding their physiological and pathological 
roles in health and diseases.  
1.4.1 Exosomes, microvesicles and apoptotic bodies  
Intracellular communication is crucial for the maintenance of homoeostasis and the 
response to pathological factors. Exosomes are novel mediators for cell-cell 
communication. They are a group of small vesicles that are composed of a bilayer lipid 
membrane with protein and RNAs contents. Exosomes are released by parent cells and 
captured by recipient cells. Cells produce exosomes continuously under resting 
conditions, but the release of exosomes can be enhanced under certain conditions [307]. 
The release of exosomes causes biological effects in both the parent and the recipient 
cells [308, 309].  
Cells can ‘talk’ to each other through direct contact or by the secretion of certain 
molecules. It is well-known that during apoptosis, apoptotic bodies are released and can 
serve as mediators between cells. The earliest observation of extracellular vesicles 
(EVs) can be traced back to 1946 when Chargaff and West observed pro-coagulant 
platelet-derived particles in plasma [310]. In 1983, the release of exosomes by the fusion 
of multivesicular bodies (MVBs) with plasma membrane was observed during the 
maturation of red blood cells [311, 312]. Later, these vesicles, released from 
lymphocytes, were proven to be functional material that could mediate the antigen-
presentation process [313]. Around a decade ago, different RNAs were found within 
such vesicles and also demonstrated important functions that affect cell biology [314]. 
The significance of these nano-sized vesicles are now well-acknowledged and the 
subject of a new era of studies in many areas relating to health and diseases [315-320].  
The biogenesis of exosomes is through the endocytic pathway. Exosomes are released 
by the fusion of MVBs with cell membrane [311, 321, 322]. MVBs are also known as 
late endosomes or multivesicular endosomes (MVEs) that are matured from early 
endosomes. Early endosomes are generated by endocytosis through the endocytic 
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transport pathway [322-324]. Late endosomes can be either directed to lysosomes for 
membrane recycling or they can be signalled to the cell membrane for the release of 
exosomes [322].  
 
Figure 1-3 Secretion of exosomes and microvesicles. 
Exosomes are released by the fusing of MVBs with plasma membrane; otherwise, MVBs can be 
directed to lysosomes for degradation. Microvesicles are released by the shedding of the plasma 
membrane. Both exosomes and MVs may carry membrane proteins of their parent cells. 
 
MVs and apoptotic bodies are generated by the shedding of the plasma membrane. MVs 
(100 - 1,000 nm) are produced by healthy cells, while the apoptotic bodies (50 - 5,000 
nm) are generated when cells undergo apoptosis [324]. The distinguishing features of 
exosomes, microvesicles and apoptotic bodies are largely dependent on their sizes. The 
size-definition of exosomes reported in the literature has been evolving, but there is an 
agreement that exosomes are small lipid bilayer vesicles ranging from 20 nm to 150 nm 
[324-326]. The most commonly described exosomes are between 40 nm to 100 nm as 
first defined in reticulocyte differentiation [311].  
Besides the difference in size, these three types of vesicles also have different biological 
properties and functions [324]. As exosomes are produced from the endosomal 
compartment, they express shared proteins even if derived from different parent cells. 
The commonly expressed proteins are better described in exosomes than other vesicles. 
These proteins include transmembrane proteins like tetraspanins (e.g., CD9, CD63 and 
CD81); MHC class I and MHC class II; cytosolic proteins (e.g., heat shock proteins-70 
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and actin); and specific proteins that are associated with the endosomal sorting complex 
required for transport (ESCRT), such as tumour susceptibility gene 101 (TSG101) and 
Alix [323]. However, at present, there are no such proteins that can specifically 
distinguish exosomes from other large vesicles [327]. DNA fragments, e.g. double-
stranded DNA (dsDNA) and genomic DNA, are often present on microvesicles and 
apoptotic bodies but are rarely found on the surface of exosomes. DNA is found both 
inside and on the membrane of EVs. The dsDNA is the most common form of DNA 
that located outside the EVs [326, 328-330].  
EVs also carry surface proteins of their parent cells which may help identify their 
origins. Studies suggested that cellular membrane proteins are likely to be expressed on 
MVs. Sometimes, the membrane proteins can also be integrated on exosomes during 
their endosome formation [331, 332].  
1.4.2 Current tools to study exosomes  
Exosomes are released from almost all types of cell. They have been isolated from many 
types of body fluid including semen, blood, urine, saliva, breast milk, cerebrospinal 
fluid bile and bronchoalveolar lavage (BAL) fluid [324]. Exosomes can be studied by 
several methods and each method has its own advantages and limitations in the 
detection and measurement of exosomes [333, 334].  
The most widely accepted practice to purify exosomes from bio-fluids or tissue culture 
media is ultracentrifugation after the sequential centrifugations of removing 
contaminating cellular products. Sequential centrifugations before the isolation of 
exosomes are highly recommended by the International Society for Extracellular 
Vesicles (ISEV). Missing steps between each centrifugation may compromise the 
results [325]. Purified exosomes can be directly visualised under transmission electron 
microscopy (TEM) which provides the physical evidence, i.e. the sizes of the vesicles. 
However, TEM is not a quantitative method and it often requires a lot of material (large 
volumes of fluid) to study. The purified exosomes can also be further studied for 
different purposes. For example, the protein profile of exosomes can be studied by 
western blotting or proteomics and RNAs can also be extracted for RNA analysis.  
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Nanoparticle tracking analysis (NTA) is a relatively new technique to study MVs and 
exosomes [335]. NTA is designed on the principle of Brownian motion and it can 
visualise and analyse vesicles in real time. The advantage of NTA is that it can 
distinguish vesicles of different sizes in the same solution [325, 336]. The 
concentrations of the tracked vesicles can be calculated based on the distance they move 
during a period of time. The concentrations of vesicles within the range of exosomes 
can be calculated and presented as the value of “area under curve” representing the level 
of exosomes. 
Flow cytometry has been used to study the EVs in bio-fluids. Traditional cytometers 
cannot detect vesicles that are smaller than 300 nm. Newly developed cytometers 
specifically designed for MV studies are mainly used to study large vesicles and are not 
useful for exosomes [325]. The most common strategy to study exosomes with flow 
cytometry is to couple exosomes with micrometre-sized beads by targeting specific 
exosome surface proteins. This strategy facilitates the study of exosomal surface 
proteins and an optimised protocol may also be used for exosomal concentration study. 
It has been tested in several types of bio-fluids, but so far there is no study of its 
application in the BAL fluid samples from IPF patients [333, 337]. 
1.4.3 Biogenesis of exosomes 
The biogenesis of exosomes has several steps including the formation of MVBs, the 
transportation of MVBs to the plasma membrane, docking, and fusion with the plasma 
membrane to release exosomes. 
As described, MVBs can be either directed to the plasma membrane (for the release of 
exosomes) or to lysosomes (for degradation). Yeast mutants led to the discovery of the 
molecular machinery that regulates the biogenesis of MVBs for lysosome degradation. 
However, there is very limited understanding of the mechanisms of secretory MVBs for 
exosome production [330]. In mammals, the ESCRT is the key component for MVBs 
production. There are four evolutionarily conserved members of the ESCRT 
complexes: ESCRT-0, -I, -II and –III. Other accessory proteins, such as Alix and VPS4, 
are also implicated in the process [338].  
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Besides the ESCRT pathway, MVBs can also be formed through alternative 
mechanisms that are ESCRT independent. The first reported ESCRT-independent 
exosome production mechanism was observed in oligodendroglial cells. It was found 
that in these cells, the release of exosomes was sphingomyelinase dependent. As a 
result, the ceramide level in these exosomes was increased [339]. Furthermore, cells 
were still able to release CD63-positive MVBs even if the four ESCRT protein 
complexes were depleted by targeted siRNA [340]. Studies in melanocytes suggested 
that there might be other mechanisms of MVBs formation that are independent of both 
ESCRTs [341] and ceramide [342]. 
Following the formation of the MVBs, there are a few more steps before the release of 
exosomes including the traffic/ mobilisation of MVBs to the plasma membrane, 
docking and fusion with the cell surface. There is very little known about the exact 
mechanisms of how MVBs are directed to the plasma membrane. However, MVBs 
following different paths may have different biochemical and morphological properties. 
For example, cholesterol-rich MVBs are prone to be fused with plasma membrane for 
exosome secretion and cholesterol-poor MVBs are targeted by lysosomes for 
degradation [343]. Studies also showed that Rab GTPases, such as Rab 11, Rab 27 and 
Rab 35, are involved in exosome secretion [344-346]. ALIX and VPS4, the accessory 
proteins of the ESCRT pathway, may also play a role in exosome secretion [324, 347]. 
1.4.4 Autophagy in the regulation of exosome production 
Exosomes are produced via the endosomal pathway and they interact closely with the 
autophagy-lysosome pathway to maintain cellular homoeostasis [348, 349].  
The first piece of evidence linking autophagy and the exosome pathways is the 
observation of amphisomes. Amphisomes are formed when autophagosomes fuse with 
late endosomes [350]. There are more complex amphisome-related structures that are 
observed, but the function and mechanism are not yet understood. However, it is 
believed that these structures are formed during autophagosome–endosome interaction 
and they might be important for the maturation of autophagosomes. Furthermore, Rab-
7 and Rab-11 have been demonstrated with essential roles for the interaction between 
autophagosome and the endocytic pathway [351, 352]. 




Figure 1-4 The interaction between autophagy and the exosome pathways.  




Studies have shown that the changes in the autophagy-lysosome pathway affect 
exosome secretion. Fader and colleagues showed that autophagy induction promoted 
the fusion of MVBs with autophagosomes and therefore decreased the secretion of 
exosomes in K562 cells [353]. On the other hand, blockage of autophagosome-
lysosome fusion by bafilomycin A1 increased the secretion of exosomes [354-356]. 
More recently, there is direct evidence showing that Atg12 and Atg3 interact with ALIX 
and regulate late endosome distribution, exosome biogenesis and the fusion of 
autophagosomes with MVBs [357]. Thus, dysregulated autophagy affects the MVBs 
transportation path and thereby affects exosome secretion. 
The status of lysosomes, the common destination for the degradation of both 
autophagosomes and MVBs, also have an impact on the exosome production [327]. In 
conditions of lysosomal dysfunction, MVBs are more likely to be directed away from 
lysosomes to the plasma membrane and eventually increase exosomes secretion [327]. 
Mutations that affect lysosomal functions, such as mutations in Tau and VPS4, 
increased the secretion of EVs and the expression of disease-related proteins [358, 359]. 
More evidence is emerging from the studies in lysosome storage disorders (LSDs) 
where the lysosomes are dysfunctional [327]. 
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Furthermore, there are pathways that regulate both the EVs secretion and autophagy. 
Several ESCRT proteins, for example, ALIX, HRS and TSG101, are implicated in both 
autophagy regulation and EVs secretion [360, 361]. In addition to that, ceramide, which 
has been demonstrated as an ESCRT-independent pathway of exosome secretion, also 
functions through the autophagy pathway. Sphingosine 1-phosphate (S1P) is the 
metabolite of ceramide. It has been shown that the activation of S1P receptor on MVBs 
facilitates the release of exosomes [362]. S1P signalling also affects the autophagy 
pathway and may play a role in pulmonary fibrosis. S1P treatment attenuated LC3 
expression and autophagosome formation in primary lung fibroblasts isolated from IPF 
patients. The upregulated overexpression of S1P lyase (S1PL) found in the fibrotic lung 
tissues is believed to act as a protective mechanism by promoting autophagy [363].  
Lastly, exosomes might have similar roles to autophagosomes in terms of recognising 
toxic proteins or RNAs and releasing them outside of the cells for homeostatic purposes. 
Thus, when the autophagy pathway is over-occupied or compromised, exosome 
production may serve as an alternative method for handling cellular waste [349]. For 
example, exosomes have been shown to assist in the sharing of pathological proteins 
between cells in many neurodegenerative conditions where autophagy is impaired 
[364]. 
1.4.5 Mediating the intercellular communication: 
exosomal lipids, proteins, RNAs and DNA 
Exosomes are found modulating many key biological processes such as immune 
functions, metabolic regulation, and the communication between neurons and stem cells 
[319, 330, 365-367]. They perform these functions via the major components of 
exosomal lipids, proteins, and RNAs. 
Lipids are specifically sorted structural and functional constituents of EVs. They form 
the bilayer membrane of EVs and maintain their stability in the extracellular 
environment [330]. In general, EV lipids contain higher levels of sphingomyelin, 
cholesterol, phosphatidylserine, and glycosphingolipids. The lipid composition varies 
between exosomes from different parent cells [368]. EV lipids can pass the cellular 
information between cells. Some lipids, for example, eicosanoids, fatty acids, and 
cholesterol, can be transferred between cells and affect their functions [368]. Other 
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lipids, such as cholesterol, can regulate the formation and release of EVs [369]. 
Furthermore, vesicle-bound lipid molecules even have more functions, such as dendritic 
cell maturation [370], lymphocyte chemotaxis [370], modulation of the cellular 
signalling pathways [371], induction of cell death [372], mediating angiogenesis [373] 
and facilitating the reproduction activity [374]. 
Exosomes express a group of conserved but distinct proteins as described earlier in 
section 4.1. Exosomes also carry and share disease-relevant proteins between cells. The 
release of exosomes has been proposed as an additional mechanism of removing the 
toxic proteins to alleviate cellular stress. In neurodegenerative diseases, the identified 
toxic proteins include Aβ, APP C-terminal fragments, α-synuclein, SOD1, the prion 
protein (PrP) and many others [375]. For example, the disease protein α-synuclein was 
found in exosomes of Parkinson's disease and may be associated with disease 
progression [376]. The amyloid protein is found on exosomes in Alzheimer diseases 
[377].  
Exosomal RNA cargos are also carefully sorted and packed into exosomes for 
intercellular communication. Exosomal microRNA and messenger RNA (mRNA) 
contain genetic information from the parent cells. Exosomal RNAs can be delivered to 
the recipient cells, thus affecting their RNA expression, protein synthesis and function 
[314]. It is reported that cells increased the sorting and release of microRNA through 
exosomes when treated with endogenous RNAs [378]. Cancer cells not only secrete 
more exosomes but also with increased distinct exosomal microRNAs [379]. Exosomal 
RNAs can be used as specific markers associated with certain diseases. For example, 
exosomal microRNAs have been associated with Alzheimer's disease and have been 
proposed as diagnostic biomarkers [380]. Exosomal RNAs that are associated with 
tumour progression can affect healthy cells and drive tumorigenesis [381]. The RNA 
contents could also affect the immune system and affect the identification and clearance 
of cancer cells [382]. They can induce stromal cell activation, angiogenesis, immune 
escape and drug resistance in cancer [383]. Exosomes have also been associated with 
cancer metastasis and facilitate the formation of a pre-metastatic environment [384].  
DNA is also found in exosomes and it can be found both inside and outside the 
exosomes [326, 385]. Similar to RNA, DNA carries genetic information and can be 
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delivered to other cells through exosomes. It has shown that exosomes can carry the 
modified DNA in cancers and deliver the mutations to other cells [385]. Mutated 
exosomal DNA may be used as biomarkers for diseases. The DNA in exosomes are 
different from that of the MVs and apoptotic bodies [386]. The physiological and 
pathological roles of exosomal DNA are largely unknown.  
Exosomes are proposed as biomarkers in many diseases. In pathological conditions, the 
cellular profile is affected which then changes the exosome profiles. Exosomes serve as 
mediators for cell-cell communication and their presence is associated with many 
pathological conditions such as inflammation, infection, cancer, neurodegenerative 
disorders and tissue fibrosis [333, 387-389]. It has shown that when inflammation is 
active, the production of exosomes and MVs are promoted. For example, 
Mycobacterium tuberculosis (Mtb) infection [390], inflammasome activation [267] and 
in human diseases such as sarcoidosis, the production of exosomes is enhanced [391]. 
Exosome profile is changed in cancers, the adaptation of cells to the adverse 
environment triggered the aberrant exosomal process to promote the survival of cancer 
cells [387].  
There is ongoing active research investigating exosomes as novel therapeutic tools in 
the areas such as drug delivery, anti-tumour therapy, pathogen vaccination, and 
immune-modulatory and regenerative therapies [392].   
1.4.6 Exosomes in the lung and lung fibrosis 
At present, only a handful of studies have been published regarding exosomes in the 
human lung. Exosomes in BAL fluid isolated from the healthy lungs expressed MHC-
I, MHC-II, CD54, CD63, and CD86, but the role of exosomes was not studied [393]. 
BAL fluid exosomes in patients with allergic asthma may contribute to the cytokine and 
leukotriene production [394]. The microRNA profile in BAL fluid exosomes from 
asthma patients showed distinct microRNA patterns and significant changes of 24 
miRNAs and when compared to the healthy controls [395]. BAL exosomes from 
sarcoidosis patients showed an increased level of exosomes and their pro-inflammatory 
role in the lungs when compared to healthy individuals [391]. BAL fluid exosomes from 
sarcoidosis patients also showed significantly higher expression of MHC class I and II, 
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tetraspanins CD9, CD63, and CD81. They also had increased level of neuregulin-1 
which had been associated with cancer progression. PBMC incubated with the 
sarcoidosis exosomes had increased level of IFN-γ and interleukin (IL)-13 compared to 
the controls [391].  
The role of lung exosomes was focused on immunity and it has been studied in different 
models. This includes the response of the lung to different stimuli such as infection with 
different pathogens [396] and nanoparticles [397]. Exosomes from different sources in 
the allergic airways can stimulate systemic immune response in mice [398-400]. 
Mycobacterial pathogen-associated molecular patterns (PAMs) were detected from 
BAL fluid exosomes isolated from mice lungs that were infected with pathogens.  A 
mouse model of LPS induced acute lung injury (ALI) suggested that the mouse alveolar 
macrophage-derived EVs (F4/80 and CD11c positive vesicles) were the major 
population in the early phase of ALI and a major contribution to the inflammatory 
process [401].  
Macrophages are critical for the normal wound healing and they can release 
microvesicles as other immune cells. Macrophage-derived exosomes mediate many 
biological processes [402-404]. Exosomes released from human macrophages contain 
enzymes that are related to the pro-inflammatory cytokine and leukotriene biosynthesis 
and promote granulocyte migration [405]. Macrophage released MVs contain MHC 
class II and have antigen presentation function [406]. In addition, macrophage-derived 
EVs contain high levels of miR-223 which regulates the proliferation and differentiation 
of myeloid cells. Macrophage MVs can induce the differentiation of macrophages and 
promote the transfer of miR-223 [407]. Macrophage MVs cause inflammation-induced 
programmed cell death in vascular smooth muscle cells via transfer of functional 
pyroptotic caspase-1 [408]. 
Inflammation and infection can change the profile and function of macrophage-derived 
exosomes [396, 402]. Exosomes released by macrophages that are pre-treated with a 
few different types of pathogens caused inflammatory responses in vitro and in vivo. 
When macrophages are infected with microbial pathogens, the production of EVs have 
been shown to be enhanced and the contents were changed [409]. Mycobacterial 
products, such as cell wall components, can be sorted to the EVs and promote 
Chapter 1 Introduction. 39 
inflammatory responses in resting macrophages [396]. These EVs also stimulated the 
expression of pro-inflammatory cytokines and chemokines that drive the inflammation 
by facilitating the migration of immune cells and causing tissue damage [410, 411]. EVs 
released by macrophages that are infected with parasites showed down-regulation of the 
immune functions, such as by the inhibition of complement activation and the release 
of TGF-β [412]. In fact, different phenotypes of macrophages release specific exosomes 
with distinct properties [396]. A study of mouse macrophages showed that activated 
macrophages release microvesicles that contain polarised M1 or M2 mRNAs in vitro 
[413].  
In lung diseases, exosomes are proposed as potential biomarkers for the diagnosis of 
asthma, lung cancer, chronic obstructive pulmonary diseases (COPD) and other 
pulmonary diseases [317]. In non-small cell lung cancer, a total of 9 exosomal proteins 
were identified as potential independent makers on the overall survival in the plasma 
from 276 patients and one protein, NY-ESO-1 was validated as a prognostic biomarker 
of survival after the required adjustments [414].  
The persistence of inflammation caused by cigarette smoking in COPD makes 
exosomes a good candidate for a biomarker of the disease [415]. It is found that the 
endothelial-derived MVs are increased in COPD patients. Furthermore, the level of 
these MVs has been correlated with the lung functions [415]. The CYR61/CTGF/NOV 
family 1 (CCN1) has an important role in tissue repair and remodelling in COPD [416]. 
When lung epithelial cells are treated with cigarette smoke (CS), they released CCN1-
enriched exosomes. Exosomes may also serve as a marker for COPD [415]. The level 
of circulating epithelial cell-derived exosomes is increased in CS-treated mice [417]. 
Muscular wasting is a common comorbidity of COPD [418]. Muscle-specific miRNAs 
is different in COPD patients and exosomal miRNA in plasma can be used as a 
biomarker to reflect the changes in the muscles in COPD patients [419]. BAL fluid 
miRNAs were also found to be different in COPD patients than healthy controls [420].  
With the potentially important role of exosomes in lung diseases, little is known about 
exosomes in lung fibrosis and IPF [317, 421-423]. However, evidence suggests that 
exosomes can mediate fibrotic diseases. Exosomes have been proposed as a useful tool 
for diagnostic and therapeutic purposes in kidney and liver fibrosis [318, 424]. TGF-β1, 
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a key mediator of fibrosis, has been found enclosed in exosomes upon epithelial injury 
in a model of kidney fibrosis. These TGF-β1 enclosed exosomes further increased tissue 
injury [425]. Epithelial-mesenchymal-transition is regarded as one of the potential 
mechanisms for lung fibrosis and a role of exosomes in EMT has been proposed in 
cancer [426]. Furthermore, a small study showed that in IPF serum exosomes miR-141 
(anti-fibrotic) had decreased and miR-7 (fibrogenic) had increased [422]. Accumulating 
evidence suggests that the autophagy-lysosome pathway, which has a regulatory role in 
exosome secretion, is impaired in the IPF lungs [297, 298, 301]. The increased 
deposition of extracellular matrix (ECM) in the lung has a tremendous impact on the 
structure of the lungs and the resident cells. The aberrant, bioactive ECM in IPF could 
affect the homeostatic and cell signalling and communication among the resident cells. 
However, little is known about the role of autophagy and exosomes in lung fibrosis and 
IPF, thus requiring further investigation.  
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Hypothesis and aims  
The primary goal of this study was to investigate the autophagy pathway in alveolar 
macrophages in the setting of lung fibrosis and the effect of increased fibrotic ECM on 
the autophagy pathway. Furthermore, I aimed to define the consequences of an altered 
autophagy pathway on exosome production in the fibrotic lungs and to test the 
feasibility of utilising exosomes as a marker for fibrotic lung diseases.  
The overarching hypothesis of this study was that fibrotic ECM modulates exosome 
biogenesis in alveolar macrophages through the regulation of the autophagy-lysosome 
pathway.  
The following research aims were addressed in the study: 
 To establish an ‘easy-detach’ method for the differentiation of human primary 
monocytes into macrophages 
 To determine the effect of collagen-I and collagen-IV on macrophage autophagy 
 To assay LC3 and p62 expression in alveolar macrophages from patients with 
fibrotic and non-fibrotic interstitial lung diseases (ILD) 
 To measure the effect of primary lung fibroblast-derived ECM on macrophage 
autophagy 
 To study the concentrations of alveolar macrophage-released exosomes in vitro 
 To determine effect of modulating autophagy pathway (activation or blockage) 
on exosomes release in macrophages 
 To compare the concentration of exosomes in BAL fluid from ILD patients with 
or without lung fibrosis 
 To establish a flow cytometry assay for exosomal protein study in BAL fluid 
from patients with ILD conditions 
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Chapter 2 Materials and Methods 
 
2.1 Monocyte-derived macrophage: culture and 
detachment techniques  
 
2.1.1 Cell isolation from whole blood of healthy volunteers 
Blood from healthy donors was collected into 50 mL Falcon tubes containing 3.8% 
sodium citrate (Sigma, PHR1416) to achieve a final concentration of 0.38%. After 
centrifugation (350 g, 20 minutes, low acceleration, no brake), the platelet-rich plasma 
was removed from the remaining cells. Leucocytes were isolated after removal of 
erythrocytes by sedimentation using 6% (w/v) dextran (Sigma, 31387) which was 
topped up to 50 mL with pre-warmed (37°C) 0.9% NaCl (UKF7124, Baxter). The 
leucocyte-rich layer was collected and washed with 0.9% NaCl (350 g, 10 minutes). 
Peripheral blood mononuclear cells (PBMC) and granulocytes were separated by 
centrifugation (700 g, 20 minutes) through a discontinuous Percoll® gradient (Sigma, 
P1644). Isotonic Percoll solutions (49.5%, 63%, and 72.9%) were made in Ca2+/Mg2+-
free PBS (CMFPBS, ThermoFisher, 14190250). Leucocytes were re-suspended in 3 mL 
49.5% Percoll and laid on top of 4 mL of 72.9% and 63% Percoll solution. After the 
centrifugation, mononuclear cells were aspirated from the 49.5%/ 63% interface and 
neutrophils from the 63%/ 72.9% interface. Cells were washed twice in PBS before 
other applications.  
2.1.2 Isolation of CD14+ monocytes from PBMC 
CD14+ monocytes were isolated from the mononuclear cell fraction using MACS® 
monocyte selection kit and the supplied LS columns (Miltenyi Biotec). Briefly, PBMC 
were counted and resuspended to the appropriate concentration in phosphate-buffered 
saline (PBS) with 5% heat-inactivated foetal bovine serum (FBS). Cells were incubated 
with Fc receptor (FcR) inhibitor and CD14 antibody cocktail before the incubation with 
MACS® beads, then cells were washed and passed through an LS column. CD14+ 
monocytes were passed through the column and collected in the efflux. Monocytes were 
washed again with PBS before use. 
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2.1.3 Monocyte-derived macrophages (MDM) on standard 
tissue culture (TC) plates 
PBMC were counted, pelleted and resuspended at 4.0×106 cells/mL in Iscove's 
Modified Dulbecco's Media (IMDM) without FBS. PBMC were plated out in tissue 
culture (TC) 24-well plates with 0.5 mL/well and left for 45 minutes at 37°C to enrich 
monocytes by adhesion. After adhesion, the non-adherent lymphocytes were washed 
away with PBS and complete medium was added to the monocytes. Monocytes were 
then cultured for 7 days in the complete medium at 37°C in a 5% CO2 atmosphere. The 
medium was changed every 3 days before day-7. The complete medium is IMDM 
containing 10% FBS, 1% L-glutamine and 100 units/mL (1%) penicillin and 
streptomycin (pen/strep). 
2.1.4 Differentiation of CD14+ monocytes in ultra-low 
attachment flasks 
The purified CD14+ monocytes were counted, pelleted and then resuspended at 1×106/ 
mL in complete IMDM medium. Cells were transferred into ultra-low attachment flasks 
(Corning CLS3814) with 5 mL culture medium and differentiated for 7 days in a 
humidified incubator 37 °C (95% O2 and 5% CO2). The additional 5 mL fresh medium 
was added into the flask on day-4 of culture. For long-term culture, medium was 
collected and centrifuged at 300 g for 5 minutes to collect any floating monocytes and 
then resuspended in completed IMDM and transferred back to the original flask for 
culture. 
2.1.5 Detachment of CD14+ monocyte-differentiated cells 
from the ultra-low attachment flasks 
On day-7 or the end of culture, the culture medium was collected and replaced with cold 
PBS. The flask with cells was placed on ice and left for 15 minutes to let cells detach. 
After the incubation on ice, cells were further detached by tapping on the side of the 
flasks. Then the cells were collected and centrifuged at 300 g for 5 minutes.  
2.1.6 Detachment of MDM on standard TC plates with 
enzymatic disassociation solutions  
Trypsin and ethylenediaminetetraacetic acid solution (trypsin-EDTA, 0.25%, 
ThermoFisher, 25200056) was warmed up to 37°C in a water bath before use. Accutase 
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(Sigma, A6964) was warmed up to room temperature before use. MDM were rinsed 
twice with CMFPBS before the pre-warmed disassociation solutions were added. Cells 
were incubated for 15 minutes in a 37°C incubator (trypsin/EDTA) or at room 
temperature (accutase) for up to 30 minutes before the detached cells were collected. 
The remaining cells in plates were washed off by applying PBS against the cells with 
repeated pipetting for three times.  
2.1.7 Detachment of MDM on standard TC plate with 
enzyme-free disassociation solutions 
MDM were washed with cold CMFPBS before the disassociation solutions or control 
solutions were added to the plate for the incubation on ice to detach. After the incubation 
of up to 30 minutes, cells were collected by repeated pipetting for 3 - 5 times with cold 
CMFPBS. The enzyme-free solutions were as follows, Gibco buffer (Gibco, 13151014), 
Sigma buffer (Sigma, C5914) and 5 mM EDTA solution. 
2.1.8 Flow cytometry 
Flow cytometry was performed with all incubations conducted on ice unless stated 
otherwise. All antibodies were purchased from BioLegend if not specified otherwise. 
CD14+ monocytes derived macrophages were detached and stained for cell surface 
markers on day-7 of culture. Cells were incubated with specific antibodies at 1 in 20 
dilutions. The following antibodies were used CD3-PE (321106), HLA-DR (FITC), 
CD14-PerCP/Cy5.5 (302018), CD-16-APC/cy7 (302018), CD206-PE (141706), 
CD163-APC (333610), 25F9-FITC eFluor 660 (eBio-sciences, 50-0115-42). Cells were 
incubated with the antibody on ice for 30 minutes and then washed in PBS containing 
0.5% FBS. Cells were gated to exclude cell debris and analysed on 5-LSR Fortessa flow 
cytometer (Beckton Dickenson). Data were analysed using Flowjo software (Treestar, 
Oregon, USA). 
2.1.9 Cytocentrifuge preparations and Diff-Quik® stain 
Cells were counted and re-suspended in PBS. For each slide of the cytocentrifuge 
preparation, 50,000 cells were loaded into each of the chambers. Cells were centrifuged 
onto the slide at 300 g for 3 minutes. After the centrifugation, the cells on the slides 
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were fixed with methanol and then followed by the staining with Diff-Quik® staining 
kit (FisherScientific, NC0674866).  
2.1.10 Phagocytosis assay 
Neutrophils were isolated from peripheral blood of healthy donors by Percoll gradient 
method as described above. Cells were counted and resuspended to 4×106/mL in IMDM 
without serum and stained with CellTracker™ Orange (Invitrogen, C2927) for 30 
minutes. Autologous serum was prepared from the platelet-rich plasma by adding 220 
µL of 1 M CaCl2 (Sigma, 449709) per 10 mL plasma in glass tubes and incubated at 
37°C for 60 minutes. Autologous serum (10%) was then added to IMDM and cells were 
incubated for 24h in an incubator to become apoptotic. Neutrophils were collected by 
centrifugation at 230g (Acc 9/ Dec 5) for 5 minutes. Cells were washed with pre-
warmed PBS (37°C) and counted before adding to macrophages at a ratio of 5:1 
(neutrophils vs macrophages) and incubated for 30minutes.  After the incubation, cells 
were gently rinsed for a couple of times using pre-warmed PBS (37°C) with calcium to 
remove unengaged neutrophils. The samples were then observed under a microscope. 
2.1.11 Macrophage stimulation with LPS/ IFN-γ 
Monocytes were cultured for 7 days to be differentiated into unpolarized macrophages 
(“M0”). M0 macrophages were then washed with PBS before adding the culture media 
with a cocktail of lipopolysaccharides (LPS) (Sigma, 100 ng/mL) and interferon (IFN)-
γ (Life Technologies, 20 ng/mL) and cultured for 48 hours to be stimulated to the 
classically activated macrophages (“M1”). Cells were stimulated in standard TC plates 
or in the ultra-low attachment flasks.  
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2.2.1 Edinburgh lung fibrosis cohort and Patient 
information  
The study is part of the Edinburgh Lung Fibrosis Cohort project which was registered 
and had been approved by University of Edinburgh /NHS Ethics Committee (regional 
ethic committee numbers are 07/S1102/02 and 06/S0703/81). All patients participated 
in this study had been fully informed and consent forms were signed.  
Patients were referred to the interstitial lung disease clinic in the Royal Infirmary of 
Edinburgh by local general practitioners. The diagnosis of fibrotic ILD (mainly IPF) 
was made following the ATS/ERS guidelines by a multidisciplinary team including 
lung physicians and radiologists. The diagnosis was primarily based on the HRCT scans 
with the typical feature of lung fibrosis, including reticulation, architectural distortion, 
and honeycombing. Patients with ILD but no features of lung fibrosis on HRCT scans 
(such as “ground-glass”) were served as controls. Both groups of patients were cared 
for a special clinical team. Details of patients in this study can be found in Appendix-
B. 
2.2.2 Bronchoalveolar lavage and isolation of the BAL fluid 
cells 
Bronchoscopy with bronchoalveolar lavage (BAL) (five aliquots of 50 mL saline) was 
performed routinely by a dedicated team under the supervision of a consultant in 
respiratory medicine. The BAL fluid was then strained through a 40 µm double layer of 
Dacron strainers (Millipore, Bedford, Ireland), and centrifuged at 300 g for 5 minutes 
at 4°C.  
2.2.3 Purification of BAL fluid exosomes by 
ultracentrifugation 
BAL fluid supernatant was collected after the removal of tissue debris and cells. The 
supernatant was transferred to a fresh tube and then centrifuged at 3,000g for 20 minutes 
to pellet dead cells and apoptotic bodies (50 - 50,000 nm). The remaining BAL fluid 
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was centrifuged at 10,000 g (30 minutes, 4°C) to remove cell debris and large vesicles 
(100 - 1,000 nm). Exosomes, remaining in the BAL fluid after the sequential 
centrifugation, were pelleted at 100,000 g (70 minutes, 4°C) when a gel-like pellet was 
observed at the bottom of the tube. Pelleted exosomes were washed once by 
resuspending in 6 mL PBS and pelleted again at 100,000 g (70 minutes, 4°C). The total 
protein concentrations of the re-suspended exosomes were measured with bicinchoninic 
acid (BCA) assay (Pierce®, Thermo, USA). 
2.2.4 BAL fluid exosome RNA extraction and Nano-drop®  
Exosomes were purified from the same volume (6 mL) of BAL fluid samples by 
ultracentrifugation after the sequential centrifugations. Pelleted exosomes were re-
suspended in 250 µL of PBS after an additional wash. Exosome RNA was extracted 
with Trizol reagent (ThermoFisher, 15596026) by following the manufacturer's manual. 
Extracted RNA was dissolved in 60 µL RNAase free water before the determination of 
concentration with Nanodrop® (Life Technology) and stored at -80°C.  
2.2.5 Purification and culture of AM  
To purify alveolar macrophages from the BAL fluid cells, the cells were resuspended 
in IMDM (5×106/mL) and plated out at 5×105 in each well in a 24-well plate. AM were 
purified by adhesion to the standard tissue culture plate for 45 minutes. The non-
adherent cells were washed away with pre-warmed PBS (37°C). The remaining cells 
were purified AM (as examined with cytocentrifuge preparations) and they were 
maintained in IMDM with full supplements. 
2.2.6 Transmission/ scanning electron microscope (TEM/ 
SEM)  
Pelleted exosomes from ultracentrifugation were fixed in 2% paraformaldehyde (PFA) 
before the examination under TEM. Pelleted exosomes were compared against their 
size-definition (40 nm to 100 nm) in diameter. Or, exosomes were captured by the 
incubation with anti-CD9 magnetic beads and washed once with PBS before they were 
resuspended in 2% PFA and examined under TEM in parallel with control beads 
(without incubation with exosomes). 
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AM were purified by adhesion to plastic coverslips (Thermonox® Nunc, USA) in a 24-
well TC plate for 45 minutes in IMDM media without serum. Purified AM were 
extensively washed with PBS to remove any non-adhesive BAL fluid cells. AM were 
then fixed for 1-2 hours in 0.1 M sodium cacodylate buffer containing 3% 
glutaraldehyde. Samples were the delivered for further processing by the TEM/SEM 
lab. Basically, the plastic coverslips were fixed in 1% osmium tetroxide, embedded in 
araldite resin and before they were cut into ultra-thin sections (around 60 nm thick). 
Samples were then were examined by TEM (JEOL, JEM-1400 Plus). Under TEM, 
autophagosomes were identified as classic double layer membrane structure. Other 
organelles with double membranes, mainly mitochondria were excluded by their feature 
of cristae/ ridges.  
For SEM, samples were fixed as TEM in 3% glutaraldehyde and further processed by 
TEM/SEM lab before the examination under SEM (Hitachi S-4700). Basically, samples 
need to be dried by the critical point drier and mounted on the stubs to be studied. 
2.2.7 Flow cytometry 
Bronchoalveolar lavage (BAL) fluid was collected from the clinic and transported to 
the lab on ice. BAL fluid was first filtered through 0.45 µm filters to remove large pieces 
of tissue and debris before the centrifugation at 300 g for 10 minutes to pellet BAL fluid 
cells. BAL fluid cells were stained with Cyto-ID (Enzo, ENZ-51031) alive following 
the manufacturer's manual and analysed with BD FACSCaliburTM (with 488 nm laser). 
Otherwise, BAL fluid cells were fixed and permeabilised with a commercially available 
kit (BD Cytofix/Cytoperm, 554714) and stained with anti-LC3 antibodies (MBL, 
PM036) overnight. Samples were stained with secondary antibody (Alexa Fluor® 594 
Phalloidin anti-rabbit) for 30 minutes and washed with PBS on the following day before 
the analysis with FACSCaliburTM (with 635 nm laser). 
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2.3 ECM and macrophage autophagy study 
 
2.3.1 Compounds and reagents 
Rapamycin (R8781), bafilomycin A1 (B1793), DMSO (D4540) and phorbol 12-
myristate 13-acetate (PMA, P8139) were purchased from Sigma. The proteinase 
inhibitors leupeptin (L2884), pepstatin (P5318) and PMSF (93482) were also purchased 
from Sigma. All cell culture media and other reagents were purchased from Life 
Sciences. 
2.3.2 Tissue culture-ware used in the study 
Standard 24-well tissue culture plates (Sigma, Corning®, CLS3524), standard 35 mm 
tissue culture dishes (Sigma, Corning®, CLS430165), BioCoat™ Collagen type-I 
precoated 35 mm dishes (Scientific Laboratory Supplies, 354456) and BioCoat™ 
Collagen type-IV precoated 35 mm dishes (Scientific Laboratory Supplies, 354459). 
The Corning® ultra-low attachment cell culture flasks were purchased from Sigma 
(CLS3815).   
2.3.3 Tissue culture and sub-culture of macrophages  
RAW264.7 mouse macrophages and THP-1 human monocytic cells were kindly 
provided by Prof. Sarah Howie (University of Edinburgh, UK). RAW264.7 cells were 
cultured in DMEM and THP-1 cells were maintained in Roswell Park Memorial 
Institute (RPMI)-1640 medium both with supplements. Cells were grown in media with 
full supplements to the mid-logarithmic stage before they were seeded in plates or 
dishes for treatment protocols. For adherent cells, when they grew to 80% confluent 
approximately, cells were washed with CMFPBS and detached by trypsin-EDTA. THP-
1 cells were cultured in suspension with complete RPMI medium and passaged every 3 
days at a splitting ratio of 1:3.  
THP-1 cells were treated with phorbol 12-myristate 13-acetate (PMA) to be 
differentiated into macrophage-like cells. After the cells were centrifuged at 300 g for 
5 minutes. They were then resuspended in pre-made different complete RPMI-1640 
media containing PMA at different concentrations at 1×106/mL. For each well of a 
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standard 24-well tissue culture plate, 0.5×106 cells were seeded. Cells were cultured 3 
days for macrophages differentiation. 
Tissue culture supplements included 10% FBS, 1% L-glutamine and 100 units/mL (1%) 
penicillin and streptomycin (pen/strep). All cells were maintained in a humidified 
incubator (Thermo Scientific, USA) 37°C with 95% O2 and 5% CO2. 
2.3.4 Autophagy induction  
For starvation-induced autophagy, once the cells were ready for treatments the culture 
media was discarded. Cells were gently washed with pre-warmed PBS (37°C) for a 
minimum of 3 times before the addition of the starvation agents. Hank's Balanced Salt 
Solution (HBSS, 14025050) and Earle's Balanced Salt Solution (EBSS, 24010043) were 
used as the starvation buffer.  
For rapamycin-induced autophagy, rapamycin was diluted in complete culture media 
with full nutrients and supplements and added to the cells after the removal the previous 
media.  
2.3.5 Confocal microscopy 
After treatment, RAW 264.7 macrophages were gently rinsed with PBS before they 
were fixed and permeabilised with a commercially available kit (BD Cytofix/ 
Cytoperm, 554714). Then the cells were stained with rabbit anti-LC3 antibodies (1 in 
200 dilution, MBL, PM036) overnight. On the next day, cells were washed and 
incubated with an anti-rabbit secondary antibody (1 in 200 dilution, Alexa Fluor® 594 
Phalloidin anti-rabbit) for 45 minutes in the fridge. Cells were washed with Cytoperm 
buffer and analysed by confocal microscopy (Leica SP5). 
2.3.6 Live cell staining of autophagic vacuoles and 
lysosomes 
Cyto-ID (Enzo, ENZ-51031) was purchased and aliquoted and stored at -20°C before 
use. Fresh BAL fluid cells were stained alive with Cyto-ID for subsequent flow 
cytometry analysis. For fluorescent microscopy, purified AM were cultured at the 
standard condition for 20 hours before they were stained with Cyto-ID for analysis.  
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The staining for both flow cytometry and fluorescent microscopy was done by 
following the manufacturer’s instruction. Briefly, for flow cytometry, 1 µL of Cyto-ID 
detection reagent was diluted with 1 mL assay buffer supplemented with 5% FBS. For 
fluorescent microscopy, another 1 µL detection reagent and 1 µL Hoechst nuclear stain 
(included in the Cyto-ID kit) were added. Cells were stained for 30 minutes at 37°C 
before they were washed and analysed with a flow cytometer (with a 488nm laser, BD 
FACSCalibur) or a fluorescent microscope (FITC filter, EVOS FL, ThermoFisher).  
Lysosomes were stained with LysoTracker Red DND-99 (working concentration 50 
nM, ThermoFisher, L7528) for 30 minutes at 37°C. They were also stained together 
with Cyto-ID. After the staining, cells were washed with PBS (37°C) before they were 
visualised with EVOS FL Cell Imaging System (ThermoFisher).  
2.3.7 Culture of primary human lung fibroblasts 
Primary lung fibroblasts were isolated from the surgical lung biopsies of patients for 
diagnostic purposes. Biopsy tissues were cut into small pieces (approximately 2×2 
millimetres in size) while emerging in complete culture medium using forceps and 
scalpel under a biological safety cabinet. Pieces of small lung tissues were seeded in a 
6-well tissue culture plate with a minimum amount of complete medium (0.5 -0.75 mL). 
Fibroblasts were grown out of the tissue before they were detached and passaged. Once 
the cell line were generated, they were frozen in freezing medium (20% DMSO and 
80% FBS) and kept in liquid nitrogen. Primary human fibroblasts were generated 
throughout the years due to the low biopsy rate by different members of the group 
including myself.  
For the experiments, fibroblasts were brought back from liquid nitrogen and maintained 
in a humidified incubator (Thermo Scientific, USA) 37°C with 95% O2 and 5% CO2. 
Normally, cells can be passaged for 5 times before they were rounded up and lost the 
morphology of normal fibroblasts. The complete culture medium included Dulbecco's 
Modified Eagle Medium (DMEM) with 10% FBS, 1% L-glutamine and 100 units/mL 
(1%) penicillin and streptomycin (pen/strep). 
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2.3.8 Primary human lung fibroblast-derived ECM 
Fibroblasts were maintained at low passage numbers (up to 5) to keep their fibroblast 
phenotype as described above. Fibroblasts were plated in 24-well plate at 0.25×106/well 
and cultured until confluent which was observed with an inverted light microscope. 
Confluent fibroblasts were cultured for another 72 hours to enhance ECM deposition.  
After the ECM deposition, the culture medium was removed and cells were washed 
with warm PBS (37°C). The cells in the plates were de-cellularized with 6 freeze-thaw 
cycles (freeze 40 minutes at -80°C and thaw 15 minutes at room temperature). ECM 
left on the plate was washed with sterile water between each cycle. Any remaining cells 
were checked with DAPI (D1306, ThermoFisher) staining. After the de-cellularization, 
the remaining ECM scaffold was washed with 25 mM NH4OH aqueous solution 
(Sigma, 221228) and incubated for 20 minutes on a slowly moving four-way shaker at 
room temperature to remove any cell debris. The synthesised ECM was washed with 
sterile water for 3 times and then washed again with PBS for 3 times. Before use, ECM 
was treated with 20U/mL DNase I (ThermoFisher, EN0525) in sterile H2O for 60 
minutes at 37°C and washed with PBS for 3 times.  
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2.4 Protein extraction and western blotting 
 
2.4.1 Protein extraction 
To extract proteins from cells, once the treatment was finished, the supernatant was 
collected. Then, the culture plates containing cells were put on a tray of ice and cells 
were washed with ice-cold PBS for 3 times before adding RIPA Buffer (Thermo, 
89900) with proteinase inhibitors to extract proteins. The proteinase inhibitors included: 
leupeptin (1 µg/mL), pepstatin (1 µg/mL) and phenylmethylsulfonyl fluoride (PMSF, 1 
mM). Cells were lysed on ice for 30 minutes and then scraped off the plates. Cell lysate 
was centrifuged at 10,000 g for 30 minutes at 4°C. The supernatant was collected and 
the protein concentrations were measured with bicinchoninic acid (BCA) assay 
(Pierce®, Thermo, USA) before they were stored at -20°C. 
2.4.2 Western blotting 
Total protein concentrations were measured by BCA Protein Assays (Pierce®, Thermo, 
USA). Same amount of proteins (20 µg or 30 µg) from each sample was aliquoted and 
mixed with loading buffer (NuPAGE™, NP0007) and reducing agent (NuPAGE™, 
NP0004) and heated at 95°C for 5 minutes. Then the samples were quickly centrifuged 
at room temperature for a few seconds at the maximum speed of a bench-top centrifuge. 
Samples were loaded into the each of the wells of a 4-12% Bis-Tris protein gel 
(NuPAGE™, NP0321). The proteins were separated using Mini-Cell Electrophoresis 
System® (ThermoFisher, XCell SureLock™, EI0001) in 1× MES SDS running buffer 
(NuPAGE™, NP0002) with a pre-stained protein standard (SeeBlue™ Plus2, LC5925) 
as an indicator. After the electrophoresis, the proteins on the gel were transferred to a 
piece of pre-activated PVDF membrane (GE, 10600023) with the XCell II™ Blot 
Module (ThermoFisher, EI9051) transfer system while immersed in the transfer buffer 
(NuPAGE™, NP0006) at 32V for 70 minutes.  
The PVDF membrane with proteins was kept moisture between the procedures. It was 
blocked in 5% non-fat milk protein (Marvel, UK) in PBS. The membrane was then 
incubated with primary antibody overnight at 4°C with 5% non-fat milk proteins in 
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PBS. Proteins were visualised with an appropriate horseradish peroxidase-conjugated 
secondary antibody and chemiluminescent substrate (Thermo 32109). Densitometry 
analysis on the immunoblots was quantified by Image-J software. Results were 
expressed in arbitrary units. 
2.4.3 Antibodies for western blotting 
Exosome antibodies (CD9, CD63 and CD81) were purchased from SBI (EXOAB-KIT-
1) and used at 1:1000 dilution. TSG-101 (ab30871), HSP-70 (ab2787), and β-actin 
(ab8227) were purchased from Abcam and used at 1:1000 dilution.  
Monoclonal antibody to LC3B (NanoTool, 0231-100/LC3-5F10) was used at 1:1000 
dilution. Anti-p62/SQSTM1 antibody (Sigma, P0067) was used at 1:70,000 dilution and 
anti-GAPDH antibody (Santa Cruz, sc-25778) was used at 1:5000 dilution. 
HRP-conjugated secondary antibodies goat anti-rabbit IgG-HRP (Santa Cruz, sc-2004) 
and goat anti-mouse IgG-HRP (Dako, P044701-2) were used at 1:5000 dilution. 
  
Chapter 2 Materials and Methods. 55 
2.5 Exosome study 
 
2.5.1 Nanoparticle tracking analysis (NTA)  
NTA LM10 (NTA Ltd., Amesbury, United Kingdom), was used to determine the 
concentration of exosomes. A video of 60 seconds was taken for each of the samples 
and at least 6 measurements were performed with each sample. Data were analysed with 
NTA software on a frame-by-frame basis and the concentrations were calculated based 
on the Brownian movement and Stokes-Einstein equation. The concentrations of 
vesicles of interest (40 – 100 nm) were represented as a value of “area under curve” and 
the mean of 6 measurements was used for statistical analysis.  
2.5.2 Exosome labelling 
Following the manufacturer's protocol, Qtracker® 655 Cell Labelling Kits 
(Q25021MP) was used for the exosome labelling. Briefly, the working solution (10 nM 
labelling solution) was prepared before use and added to the pelleted exosomes and 
incubated for 60 minutes at 37ºC. After the labelling, the exosomes were further diluted 
(final volume 0.75 mL) with complete IMDM culture media and incubated with MDM 
for 24 hours. After the incubation, stained exosomes were examined with EVOS 
microscope under RFP filter (531/40 nm excitation; 593/40 nm emission). 
2.5.3 Exosome treatment assay in vitro 
Monocytes were derived for 7 days to become mature macrophages in standard tissue 
culture plate before they were treated with pelleted exosomes (30 µg) purified from the 
BAL fluid samples. Final volumes of BAL fluid from different samples were topped up 
to 0.75 mL with complete IMDM media. Macrophages were incubated with BAL fluid 
exosomes for 24 hours before they were lysed for western blotting. 
2.5.4 Anti-CD9 beads coupling 
Human anti-CD9 pre-coated magnetic beads were purchased from ThermoFisher 
(10620D). The product was vortexed for 1 minute before adding 10 µL beads into 100 
µL (1:10 dilution) of the solution with BAL fluid exosomes. The samples were mixed 
on an end-over-end rotator at 4°C for the time required. Then the magnetic bead-
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captured exosomes were removed from the solution using a magnet before further 
analysis or experiment. 
2.5.5 Flow cytometry 
For the anti-CD9 beads captured exosomes, after the bead-captured exosomes were 
washed with PBS, they were resuspended in PBS and stained for CD9-FITC (312104), 
CD63-PE (353004), MHC-I-PE (BD, 565291), Sytox blue® nucleic acid stain 
(ThermoFisher, S11348), or the corresponding isotype controls at room temperature for 
30 minutes. Samples were washed and resuspended in PBS for flow cytometry analysis.  
2.5.6 Repeated freeze-thaw cycle of BAL-fluid samples 
Frozen BAL fluid samples were defrosted and aliquoted for the coupling with anti-CD9 
beads for flow analysis. Another aliquot was returned to -80°C and defrosted again 24 
hours later to study the effect of “repeated freeze-thaw cycle” on BAL-fluid exosomes. 
 
2.6 Statistical analysis 
Data are presented as mean ± SEM (standard error of the mean) unless otherwise stated. 
Statistical analysis was performed with GraphPad Prism (GraphPad Software, La Jolla, 
CA, USA) using one-way ANOVA with Tukey's Multiple Comparison Test or student 
t-test as indicated. Statistical significance was taken at p≤0.05. 
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Chapter 3 An easy-detach method to 




Monocyte-derived macrophages (MDM) are very difficult to detach from surfaces (e.g., 
plastic or matrix-coated surfaces) in vitro. Thus, an easy-detach method of macrophage 
differentiation was developed and investigated. 
Current protocols to detach MDM using enzymatic and non-enzymatic disassociation 
solutions resulted in a very limited harvest of cells. None of the disassociation solutions 
achieved 50% recovery of macrophages and increase of the incubation time did not 
improve recovery. 
In order to avoid the difficulties in detaching macrophages after differentiation, CD14+ 
cells were isolated by negative bead-selection and cultured in ultra-low attachment 
flasks to be differentiated to mature macrophages. They formed cell aggregates when 
first seeded in the flasks, but on day-3 they migrated away from each other and spread 
out as a monolayer of cells. On day-7 of differentiation, cells increased in size and 
acquired macrophage morphologies such as “fried-egg” and “spindle” shapes. To 
achieve 50 - 70% confluence on day-7, the initial density of CD14+ monocytes was 
determined as 3 - 4 million cells per flask. Cell morphology started to change after 4 
weeks of culture, multinucleated foreign body giant cells started to appear in the flask. 
After differentiation, cells were easily detached by replacing culture media with ice-
cold PBS and incubated on ice for 15 minutes. The recovery rate was more than 95%. 
CD14+ monocyte-derived cells in the low-attachment flasks were CD14, CD16 and 
HLA-DR positive. Flow cytometry showed that they were CD163-/CD206+/Mac-
2+/25F9+ macrophages. MDM from this easy-detach method (MDM-ED) displayed 
macrophage morphology when observed by microscopy of cytocentrifuge preparations. 
MDM-ED were also functional macrophages in that they phagocytosed apoptotic 
human neutrophils. MDM-ED responded to IFN-γ/LPS stimulation and changed 
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morphology towards the spindle-shaped, “classically activated” macrophages on 
standard tissue culture (TC) plates.  
In summary, an easy-detach method to acquire macrophages was successfully 
developed which harvested over 95% of morphological and functional macrophages 
with polarisation plasticity.  
3.2 Introduction 
Macrophages are versatile immune cells that are often the first cells involved in immune 
cell defence. They can engulf and degrade apoptotic cells, debris, pathogens and foreign 
materials and can initiate the inflammatory process [427, 428].  
Monocytes/macrophages are strongly adhesive cells and monocytes require adhesion 
processes to successfully differentiate into macrophages [429, 430]. MDM are strongly 
adhesive to the TC plastic that researchers often find difficult to detach without 
compromising cell viability and function [431, 432]. The typical differentiation time of 
MDM is a period of 7 days. It has been demonstrated that MDM are metabolically and 
morphologically stable for at least 4 weeks in culture [431, 433, 434]. Human 
autologous serum or heat-inactivated foetal bovine serum (FBS) can facilitate 
macrophage differentiation [434, 435]. Autologous serum contains different levels of 
cytokines and growth factors which might affect macrophage differentiation in vitro 
between different donors [436]. Adding supplements to the differentiation media may 
polarise the cells to different phenotypes [436, 437]. Macrophage colony-stimulating 
factor (M-CSF) promotes macrophages towards the alternatively activated (anti-
inflammation, “M2”) phenotype; while granulocyte-macrophage colony-stimulating 
factor (GM-CSF) leads to classically activated macrophages (pro-inflammation, “M1”) 
[438, 439].  
The most common practice to detach cells is to use disassociation solutions. In general, 
there are two types of disassociation solutions: solutions with enzymes such as trypsin 
or accutase, and solutions without enzymes (enzyme-free) such as 
ethylenediaminetetraacetic acid (EDTA) solution. Trypsin breaks the linking peptide 
chains by cleaving the peptide chains at the carboxyl side of the amino acids lysine or 
arginine unless followed by proline which makes the cells detached and individualised 
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in a suspension. However, trypsin can cause damage to the cells and even cause cell 
death. Accutase is a relatively newly found mixture of marine-origin enzymes that has 
proteolytic and collagenolytic activity thus can individualise cells. Accutase does not 
need a neutralising solution and it auto-inhibits at 37°C. Accutase maintains high cell 
viability and can be incubated with cells for a longer period which makes it an ideal 
candidate for detaching macrophages. EDTA alone can detach and de-clump cells and 
by weakening the function of adhesion molecules, such as cadherins. EDTA also binds 
to Mg2+ and Ca2+ which can weaken function of calcium-dependent adhesion molecules. 
Cells can also be detached by mechanical approaches, such as using cell scrapers or by 
vigorous shaking. However, these procedures may introduce cell death and cause cell 
aggregation which is not ideal for subsequent experiments.  
To avoid the firm attachment of MDM to the standard TC plates, the alternative is to 
have monocytes differentiated on a non- or less adhesive surface in the first place [431]. 
Among these surfaces, plastic dishes [430, 433], Teflon-coated pots/ bags [431, 432, 
440] and low-attachment expansion bags [441] have been used. Though many methods 
were studied, none of them had been used for regular laboratory practice. A relatively 
newly designed ultra-low attachment surface has been designed to avoid cell attachment 
for 3-D cell culture [442]. The ultra-low attachment surface has a covalently bound 
hydrogel layer which is hydrophilic and neutrally charged. This design inhibits the 
attachment of proteins and biomolecules via passive hydrophobic adsorption and ionic 
interactions. The coating is biological, non-cytotoxic, stable and non-degradable. 
Similar materials have shown temperature sensitivity [443]. In fact,  leaving the culture 
plate on ice facilitated macrophage detachment [444].  
Macrophages are highly heterogeneous and plastic cells. They represent a spectrum of 
different phenotypes that include pro-inflammatory (M1) and anti-inflammatory (M2) 
macrophages [427]. They can respond to the local signals and rapidly change their 
phenotype and function [427]. They can even switch from one phenotype to another in 
response to the signals in the local microenvironment [445-449]. Upon the stimulation 
of IFN-γ and LPS, MDM can change their morphology to a “spindle” shape M1 
macrophage in vitro [436]. Commonly used human macrophage surface markers 
include Mac-2 and 25F9. CD68 is predominantly expressed intracellularly but can be 
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found on cell surface of both M1 and M2 macrophages [441, 450]. CD206 and CD163 
are used to phenotype M2 macrophages subgroups [451].  
Differentiation of macrophages on ultra-low attachment surface may affect their 
phenotype, functions, and plasticity. By addressing all these questions, this potential 
method may bring good technical advantages to understand the basics of human 
macrophage biology.  
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 Human monocytes can differentiate to mature macrophages on ultra-low 
attachment surface  
 
 Macrophages differentiated on ultra-low attachment surface can be easily 
detached by changing the environmental temperature 
 
 CD14+ monocyte-derived cells on ultra-low attachment surface are functional 




 To compare different methods of detaching macrophages derived in standard 
tissue culture plates 
 
 To optimise the protocol of cell density, time of differentiation and detachment 
method of CD14+ monocytes derived cells on ultra-low attachment surface 
 
 To culture and characterise CD14+ monocytes derived cells on ultra-low 
attachment surface 
 
 To test the phagocytosis and polarisation plasticity of CD14+ monocytes derived 
cells on ultra-low attachment surface  
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3.4 Results 
In the first place, the efficiency of detaching MDM using enzymatic (Fig 3-1) and non-
enzymatic (Fig 3-2) disassociation solutions was studied. Data showed MDM were very 
difficult to be detached after differentiation. 
Since the results showed different disassociation solutions achieved poor recovery of 
macrophages (less than 50%), a protocol of culturing CD14+ monocytes in ultra-low 
attachment flasks was designed and then optimised. Firstly, CD14+ monocytes were 
purified and the purity was examined by flow cytometry (Fig 3-3). When these cells 
were cultured in ultra-low attachment flasks, they underwent unique morphological 
changes (Fig 3-4). Secondly, the cell density (Fig 3-5), time of differentiation (Fig 3-6) 
and method of detachment were optimised (Fig 3-7). The recovery rate of differentiated 
MDM from low-attachment flasks was more than 95% which was significantly higher 
when compared to the rates achieved by other methods (Fig 3-7). 
After the establishment of the protocol, the expression of macrophage markers on the 
CD14+ monocyte-derived cells was studied. The differentiated cells were characterised 
as mature macrophages by the expression of macrophage markers including CD206+, 
Mac-2+ and 25F9+ on flow cytometry (Fig 3-8). Furthermore, the function of MDM-ED 
macrophages was examined by the successful phagocytosis of apoptotic human 
neutrophils (Fig 3-9). Finally, the plasticity of MDM-ED was studied by stimulating 
them with IFN-γ and LPS on different surfaces (Fig 3-10).  
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3.4.1 MDM derived on standard TC plate were difficult to 




Figure 3-1 MDM derived on standard TC plate were difficult to detach by enzymatic 
disassociation solutions. 
Fibroblasts were disassociated by accutase (B) and trypsin-EDTA (C) within a couple of minutes but 
not by PBS control (A); MDM were washed with PBS and treated with either solution for up to 15 
minutes (trypsin-EDTA, F) or 30 minutes (accutase, E). Neither solutions detached MDM efficiently, 
as there were many MDM remaining on the plates (D), though statistically the number of cells per 
image was decreased (G). ** p<0.01, one-way ANOVA with Tukey's Multiple Comparison Test, n=3, 
scale bar=200 µm. 
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3.4.2 MDM derived on standard TC plates were difficult to 




Figure 3-2 MDM derived on standard TC plates were difficult to detach by enzyme-free 
disassociation solutions. 
MDM were incubated with enzyme-free solutions for 30 minutes while the plate was placed on ice. 
MDM were incubated in culture media (A) as a negative control, or in PBS (B), EDTA (5 mM, C), 
Gibco buffer (D) and in Sigma buffer (E). The number of the remaining MDM adherent to the plates 
was compared (F). Gibco: enzyme-free disassociation buffer from Gibco; Sigma: non-enzymatic 
disassociation solution from Sigma. ** p<0.01, one-way ANOVA with Tukey's Multiple Comparison 
Test, n=3, scale bar=200 µm.  
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3.4.3 Isolation of CD14+ monocytes from peripheral blood 
mononuclear cells (PBMC) 
 
 
Figure 3-3 Isolation of CD14+ monocytes from the PBMC. 
The monocyte pan isolation kit was used to purify CD14+ monocytes from PBMC after the separation 
of leucocytes using Percoll gradients. (A) Before the isolation, there were CD3+ lymphocytes (42.9%) 
among the PBMC; (B) after the isolation, there were very few CD3+ lymphocytes (0.49%); (C) the 
remaining cells were mainly CD14+ monocytes (86.3%). Representative flow cytometry analysis of 
the CD14+ and CD3+ cells before and after the isolation (n=3). Gates were set up based on the isotype-
control antibody stained cells. 
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3.4.4 Morphology changes of CD14+ monocytes in the 





Figure 3-4 Morphology changes of CD14+ monocytes in the ultra-low attachment flasks during the 7-day 
differentiation. 
(A) On day-0, when CD14+ monocytes were seeded in the ultra-low attachment flasks, cells were spread out evenly; 
(B) on day-1, cells formed aggregates and clumped together after the overnight incubation; (C) from day-3 or 4, 
cells started to migrate away from the centre of the aggregation and spread out to form a monolayer of individual 
cells; (D) on day-7, cells took over their individual spaces in the flask and their sizes were increased.  
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3.4.5 Defining the cell density of CD14+ monocyte for 
macrophage differentiation in the ultra-low 
attachment flask  
To determine the density of CD14+ monocyte to culture in the ultra-low attachment 
flasks, different numbers of cells were seeded and cultured for 7 days.  
 
 
Figure 3-5 Defining the cell density of CD14+ monocyte for macrophage differentiation in the 
ultra-low attachment flask. 
Different numbers of CD14+ monocytes were seeded and cultured in the flasks for 7 days before the 
images were taken (magnification ×20). (A-C) The numbers of cells in each flask on day-0 were 3×106 
(A), 4×106 (B) and 5×106 (C) cells; (D) the number of cells per image on day-7; (E) cell confluence 
was calculated by comparing to the number of cells per image against that of 5×106 per flask on day-
0. One-way ANOVA with Tukey's Multiple Comparison Test, ** p<0.01, *** p<0.001.  
Chapter-3: An easy-detach method to differentiate human macrophages. 68 
3.4.6 Long-term (beyond 4 weeks) culture of CD14+ 
monocytes on ultra-low attachment flask formed 
multinuclear foreign body giant cells 
 
 
Figure 3-6 Long-term (beyond 4 weeks) culture of CD14+ monocytes on ultra-low attachment 
flask formed multinuclear foreign body giant cells. 
Cell morphology dramatically changed when CD14+ monocytes were cultured for a period longer than 
4 weeks. Some cells became very large cells with a multinuclear feature (solid arrow) which were 
recognised as foreign body giant cells; other cells shrunk in size (dashed arrow) and getting 
disappeared. A small number of macrophages with normal morphology were also observed 
(arrowhead) (magnification ×40). 
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3.4.7 CD14+ monocyte-derived cells were easily detached 
from ultra-low attachment flask after differentiation 
 
Figure 3-7 CD14+ monocyte-derived cells were easily detached from the ultra-low attachment 
flasks after differentiation. 
Culture media was replaced with ice-cold PBS and the flask with cells was left on ice for 15 minutes. 
(A) CD14+ monocyte-derived cells in ultra-low attachment flasks on day-7 before detachment; (B) 
image of the remaining cells after the detachment; (C) the number of cells per image before and after 
detachment was compared, n=6; (D) comparing the percentage of detached cells (n=4) with that of the 
enzymatic solutions (n=3); (E) comparing the percentage of detached cells with that of the enzyme-
free solutions, n=4. Gibco: enzyme-free disassociation buffer from Gibco; Sigma: non-enzymatic 
disassociation solution from Sigma. *p<0.05. ** p<0.01, *** p<0.001, student t-test (C), one-way 
ANOVA with Tukey’s multiple comparison test (D & E). 
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3.4.8 CD14+ monocyte-derived cells from the easy-detach 




Figure 3-8 CD14+ monocyte-derived cells from the easy-detach method were CD163-
/CD206+/Mac-2+/25F9+ macrophages. 
CD14+ monocytes were differentiated using the easy-detach method and collected for flow cytometry 
analysis. (A) MDM-ED displayed on forward and side scatters; (B) singlets were gated for analysis; 
(C) MDM-ED were CD14+ and CD16+; (D) HLA-DR positive gate was set up based on isotype 
controls; (E) MDM-ED were HLA-DR+; (F) the majority of MDM-ED were CD206+ and CD163- cells; 
(G) MDM-ED were Mac-2+; (H) MDM-ED were 25F9+; (I) MDM-ED were CD68- on surface. A 
representative of n=4 experiments on different occasions.   
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Figure 3-9 MDM-ED successfully phagocytosed apoptotic neutrophils in vitro. 
MDM-ED (250,000 per well) were plated out in each well of a standard 24-well TC plate and apoptotic 
neutrophils (1.25×106 per well) were incubated with MDM-ED for 30 minutes. Cells were prepared as 
described in section 2.1.10 and 2.1.9 in the Materials and Methods. (A) Diff-Quick stain of MDM-ED 
cytocentrifuge preparation on day-7 showed ruffles and blebs on the cell surface with abundant 
cytoplasm (magnification ×40); (B) apoptotic neutrophils (arrows) after the 24 hours ageing process 
showed the loss of multi-lobed nucleus and nuclear condensation and fragmentation (magnification 
×40); (C) apoptotic neutrophils (red, pre-stained with CellTracker™ Orange) were phagocytosed by 
MDM-ED during co-culture. Scale bars, A (20 µm); B (10 µm) and C (100 µm). 
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Figure 3-10 MDM-ED in response to IFN-γ (20 ng/mL) and LPS (100 ng/mL). 
(A1) unstimulated MDM in standard TC plates (TC); (A2) IFN-γ/ LPS stimulated MDM in standard 
TC plates; (B1) unstimulated MDM-ED in ultra-low attachment flask (UL); (B2) IFN-γ/ LPS 
stimulated MDM-ED in ultra-low attachment flask. MDM-ED were detached and plated out in normal 
TC plates the day before IFN-γ/ LPS treatment and then treated with control media (C1) or IFN-γ/ LPS 
(C2). All treatments were for 48 hours. Scale bar = 400 µm. 
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IFN-γ and LPS are the archetypal M1 macrophage-polarising stimuli. MDM cultured 
on standard TC plates were treated with IFN-γ/ LPS (A2) or media control (A1) for 48 
hours. By the end of the treatment, IFN-γ/ LPS treated MDM changed their morphology 
to a dominating “spindle” shape as shown in A2. 
MDM-ED on day-7 contained a variety of macrophages with “fried-egg” and “spindle” 
shapes in the ultra-low attachment flask (B1). When they were stimulated with IFN-γ 
and LPS in the ultra-low attachment flasks, the evenly spread-out monolayer of cells 
before the treatment (B1) were disrupted and became cell aggregates (B2).  
MDM-ED were detached and seeded in the standard TC plates the day before the 
treatment. IFN-γ/ LPS treatment changed the morphology of MDM-ED to a dominating 
“spindle” shape (C2) similar to that of A2. Thus, macrophages differentiated from low-
attachment flask were able to adopt morphology change when stimulated with type-1 
cytokines IFN-γ and LPS. 
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3.5 Summary and Discussion 
In this study, I closely studied and optimised an easy-detach method to differentiate 
monocytes into macrophages using low-attachment flasks. Cells recovered from this 
method were characterised as CD206-positive macrophages. They were functional 
macrophages in that they engulfed apoptotic neutrophils and they exhibited polarisation 
plasticity.  
3.5.1 Easy-detach method, a technical advantage 
It has been speculated that adhesion is critical in the differentiation of monocyte to 
macrophages. The attachment of monocytes to plastic is commonly used to differentiate 
these cells into macrophages. However, the differentiated macrophages are too adhesive 
and cannot be easily detached 
In this study, I compared the performance of different disassociation solutions on 
detaching MDM from standard TC plates. In general, all the methods resulted in less 
than 50% recovery (Fig 3.1 and Fig 3.2). Increasing the incubation time with 
disassociation solutions did not enhance the recovery. The best results were with 5 mM 
EDTA which on average detached just over 40% of MDM (Fig 3.1 and Fig 3.2). Earlier 
studies showed that the overall yield of macrophages on plastic was 35% [431]. 
Although a recent study showed better results of detaching MDM from plastic (over 80% 
recovery) with extended incubation time, the viability was compromised and the 
expression of certain receptors on the cell surface was reduced [452]. Furthermore, 
studies have shown that incubation with trypsin inhibits protein production by 
macrophages [453] and trypsin may decrease the response of macrophages to the pro-
phagocytosis or pro-migration signals [454]. It is clear that the adherence-structures 
formed during macrophage differentiation are very difficult to disrupt and thus the cells 
are difficult to detach [431, 432].  
With ultra-low attachment flasks, MDM were easily detached by leaving on ice. 
Furthermore, more than 95% of attached cells were collected (Fig 3.7). The cell loss 
was about 5% and this may be due to pipetting as not all the cells can be rinsed off and 
collected from the flask. The detachment of MDM by the easy-detach method was 
effortless and more predictable (about 15 minutes) than other methods. Technically, this 
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easy-detach method of macrophage differentiation is a great improvement and could 
serve as a good tool for macrophage study. 
3.5.2 Macrophage differentiation and the development of 
adhesion molecules 
In the protocol, CD14-positive monocytes were cultured in ultra-low attachment flasks 
to differentiate into macrophages (Fig 3.3). On day-0, the cells were more adherent to 
each other than to the surface of the flask (Fig 3.4-B). On day-3, the cells began to 
migrate away from each other and started to attach to the low-attachment surface (Fig 
3.4-C). As the hydrophilic and neutrally charged attributes of the culture surface were 
not altered, it was more likely that the cells started to acquire more adhesion abilities by 
the development of specific adhesion molecules (Fig 3.4-D). Furthermore, when MDM-
ED were detached and seeded back to an unused low-attachment flask, they attached 
well to the surface (data not shown). This suggested that differentiation of macrophages 
in ultra-low attachment flask had increased the expression of certain adhesion molecules 
on macrophages rather than forming a structure between the cells and the surface. In 
fact, a study has closely investigated the changes of adhesion molecule expression 
during the differentiation to macrophages on standard conditions [455]. 
Clearly, during the differentiation to macrophages, monocytes started to acquire some 
features of macrophages and may be accompanied by the expression of specific 
adhesion molecule(s). Indeed, the exact mechanisms and specific molecules of the 
attachment during macrophage differentiation need to be further studied. Such adhesion 
molecules could be used as potential phenotyping and functional markers for 
macrophages in the future.  
3.5.3 MDM-ED are functional and plastic CD206+ 
macrophages 
MDM-ED were morphologically macrophage-like cells (Fig 3.8 and Fig 3.9). 
Phagocytosis assays showed that MDM-ED were able to uptake apoptotic neutrophils 
in vitro, demonstrating these cells are phagocytically functional macrophages. 
Importantly, these cells expressed coldmmon macrophage markers including HLA-DR, 
CD14, CD16, Mac-2 and 25F9. They uniformly expressed CD206, a macrophage 
marker that is present on M2 polarised cells but did not express CD163 or CD68 (Fig 
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3.8). It is documented that alternatively activated or M2 macrophages (CD206-positive) 
are the most common type of macrophages related to fibrosis and tissue repair [151, 
157]. In our group, AM from patients with IPF are shown to be CD206-positive cells 
(unpublished data), though with different expressions of CD163. This suggests that 
macrophages from the easy-detach method may have some similarities with the general 
phenotype of AM from IPF patients.  
Multinucleated giant cells (MGC) were observed after the prolonged culture after 4 
weeks (Fig 3.6). It is known that MGC are at the terminal stage of macrophage 
differentiation and they are formed by the fusion of highly differentiated macrophages 
[456, 457]. In other studies, MGC was also observed when cells were cultured for more 
than 4 weeks [433, 458, 459]. This suggested that the macrophage differentiation course 
of this easy-detach method is comparable to the traditional and standard process.  
As previously mentioned in the introduction, macrophages are heterogeneous and 
plastic cells. The change of their environment can switch the cells from one phenotype 
to another [445-449]. When macrophages are stimulated with LPS/IFN-γ, they are 
activated to a “pro-inflammation” (M1) type and normally change their morphology to 
a “spindle” shape [436]. When MDM-ED were plated out on the standard TC plates, 
they adhered well and showed round shaped macrophages (Fig 3.10-C1). Upon the 
stimulation with LPS/IFN-γ, the cells changed their morphology accordingly to an M1 
type (Fig 3.10-C2). Interestingly, when the cells were treated with LPS/IFN-γ in the 
ultra-low attachment flasks, they aggregated together into clumps shortly after the 
stimulation and stayed as aggregates until the end of the 48 hours stimulation without 
adopting a typical spindle shape. (Fig 3.10-B2). This suggested that when macrophages 
are poorly attached or in a low-attachment environment they may fail to adopt an M1 
phenotype with stimulation. However, when MDM-ED cells were transferred to normal 
plastic and stimulated with LPS/IFN-γ, these cells adopt a typical spindle-shaped 
morphology. It could be that cells differentiated on ultra-low attachment surface lack 
IFN-γ receptors. Addressing such questions will offer helpful information for 
macrophage biology in diseases such as IPF which the microenvironment is altered. 
In summary, macrophages derived from this easy-detach method are functional CD206-
positive macrophages with polarisation plasticity. 
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Chapter 4 Developing an anti-CD9 bead-
based flow cytometry assay for 




This study was designed to establish a flow cytometry assay for the investigation of 
exosomes in human bronchoalveolar lavage (BAL) fluid samples retrieved from 
patients with interstitial lung diseases (ILD).  
Exosomes were purified from fresh BAL-fluid samples by ultracentrifugation after the 
removal of cells, cell debris and large vesicles by sequential centrifugation steps. 
Transmission electron microscope (TEM) showed that the pelleted vesicles were small 
in size (less than 100 nm in diameter) which were within the size definition of exosomes. 
Western blotting experiments confirmed the expression of exosome surface markers in 
these vesicles including CD9, CD63, TSG-101 and HSP-70, but they did not express 
CD81. Exosomes pelleted from defrosted BAL-fluid samples showed a consistently 
strong CD9 expression, however, the other exosome markers were hardly detectable. 
Thus, CD9 was chosen as the target protein for exosome isolation in BAL fluid. There 
was no recognised pattern of expression of exosomal proteins in the BAL-fluid 
exosomes in relation to lung fibrosis.   
The anti-CD9 bead-based flow cytometry assay showed good specificity and sensitivity 
in the isolation of pelleted exosomes. Exosomes captured by anti-CD9 beads were 
confirmed by the expression of CD63 and MHC-I. A simplified method was also 
developed which spared the ultracentrifugation step as exosomes were shown as the 
major CD9+ vesicles in the BAL fluid with little contamination of other CD9+ vesicles. 
Using the simplified method, BAL-fluid exosomes were stable for exosomal surface 
protein study within the first 72 hours of retrieval when they were stored at 4°C. Time-
course experiments defined 5 hours as the optimal time point for determining exosome 
concentration. In addition, the concentration of exosomes was decreased to 2/3 of the 
original value after the freeze-thaw cycle when the BAL fluid was stored at -80°C. 
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In summary, I carefully studied the exosomes in BAL fluid from patients with ILD and 
present a simple and powerful method for the isolation and analysis of BAL-fluid 
exosomes. 
4.2 Introduction 
Exosomes are recently discovered biological entities that are important in biological 
and pathological conditions [322, 326]. The size of exosomes that have been reported 
in the literature has been varied although there is agreement that exosomes are small 
lipid bilayered vesicles [324-326]. In this study, I chose to define exosomes by the most 
widely reported range of size (40 - 100 nm) which avoids the “smaller” exosomes (< 40 
nm) or the “bigger” ones (> 100 nm) reported in a few studies.  
Exosomes are released from cells by the fusion of multi-vesicular bodies (MVBs) with 
the cell membrane [322]. MVBs are also known as the late endosomes and they are 
generated through endocytosis and processed from early endosomes to be matured as 
late endosomes by the endocytic transport pathway [322-324]. Late endosomes can be 
directed to lysosomes for membrane recycling or signalled to merge with the cell 
membrane and release their internal vesicles as exosomes [322]. Besides exosomes, 
there are two other members in the extracellular vesicle (EVs) family which are 1) 
microvesicles (100 - 1,000 nm) and 2) apoptotic bodies (50 - 5,000 nm) [324]. The latter 
two are also lipid bilayered vesicles, but they are secreted from the cells by shedding of 
the plasma membrane and results in vesicles with bigger sizes when compared with 
exosomes [324].  
These three types of vesicles also have different biological properties and functions 
[324]. Exosomes are a more defined population with distinct RNAs and proteins. The 
commonly used markers for exosomes are better described than other vesicles which 
include: transmembrane proteins like tetraspanins (e.g., CD9, CD63, and CD81); MHC 
class I and MHC class II proteins; cytosolic proteins (e.g., heat shock proteins -70/ HSP-
70); and specific proteins that are associated with the endosomal sorting complex 
required for transport (ESCRT), such as tumour susceptibility gene 101 (TSG101) 
protein [323, 324]. There is no such protein that specifically distinguishes exosomes 
from other large vesicles at present [327]. However, nucleic acid materials (e.g., DNA 
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fragments) are often present in the other two EVs, especially apoptotic bodies, but not 
on the surface of exosomes [326, 328, 329]. 
Bronchoalveolar lavage (BAL) fluid is a very important material to study lung diseases 
[147, 460]. It gives useful information for the lung conditions and the nature of the 
diseases under scrutiny. The cell types and mediator levels (especially cytokines) in 
BAL fluid are generally used as important clinical data for diagnosis, monitoring 
progression and the effectiveness of treatments for diseases such as idiopathic 
pulmonary fibrosis (IPF) [460]. In IPF, the most common type of lung fibrosis, the BAL 
cell differential count has been correlated to disease progression, and it is useful 
evidence for differential diagnosis and making treatment plans [50, 66, 68]. So far, 
exosomes have been studied in different types of bio-fluids and their presence is 
associated with many diseases including cancer, neurodegenerative disorders and 
kidney fibrosis [333, 387-389]. At present, only a handful of studies have been 
published regarding exosomes in human lung BAL fluid which included a study in 
healthy lungs [393] and in conditions such as asthma and sarcoidosis [391, 395]. With 
the potential pathological role of exosomes in lung diseases, little is known about 
exosomes in IPF lungs [317, 421-423]. This is largely due to the technical barriers and 
lack of specific tools to study these biologically important nano-size vesicles [327]. 
Isolation of exosomes is achievable in many types of fluid using different methods [333, 
334]. Ultracentrifugation after the removal of the other cellular products by sequential 
centrifugation is the widely accepted practice to purify exosomes from bio-fluids or 
tissue culture media. The sequential centrifugation steps are highly recommended by 
the International Society for Extracellular Vesicles (ISEV) and missing steps could 
compromise the results [325]. Nanoparticle tracking analysis (NTA) is relatively a new 
technique to study MVs [335]. NTA is designed on the principle of Brownian motion. 
NTA can visualise and analyse the vesicles in real time and can distinguish vesicles 
with different sizes in the same solution [325, 336].  
Flow cytometry has been used to study EVs in bio-fluids. However, exosomes (40 - 100 
nm) cannot be detected reliably by current flow cytometry. There are newly developed 
micro-vesicle cytometers which are expensive and they are used to study mainly large 
vesicles and not useful for exosome measurement [325]. In fact, binding with 
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micrometre-sized beads targeting on specific exosome surface proteins can enable the 
study of exosomes by flow cytometry. It has been tested in several types of bio-fluids, 
but there is no study of its application in ILD/IPF BAL-fluid samples [333, 337].  
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 Exosomes are present in BAL-fluid samples from ILD patients  
 
 Lung fibrosis may affect the expression of exosomal proteins in BAL-fluid 
exosomes  
 
 Targeting abundantly expressed protein(s) on the surface of BAL-fluid 





 To enrich and confirm exosomes in ILD/IPF BAL-fluid samples 
 
 To detect and compare the expression of proteins on ILD BAL-fluid exosomes 
 
 To identify candidate target protein(s) for immuno-beads isolation of exosomes 
 
 To develop a flow cytometry assay to study BAL-fluid exosomes 
 
 To determine the stability of BAL-fluid exosomes  
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4.4 Results 
To develop an immuno-magnetic bead assay for flow cytometry study of exosomes in 
ILD BAL fluid, a number of technical challenges were solved by the following 
experiments. 
Alveolar exosomes were firstly isolated and purified from BAL fluid using sequential 
centrifugation and ultracentrifugation. Purified exosomes were confirmed by their sizes 
with TEM (Fig 4-1) and the expression of exosome markers by western blotting (Fig 4-
2). A candidate target surface protein (CD9) for flow cytometry assay was determined 
by comparing the expression of exosome proteins (Fig 4-3 and Fig 4-4). The specificity 
and reproducibility of the designed assay were studied (Fig 4-5, Fig 4-6, and Fig 4-7). 
The expression of exosome surface proteins of BAL fluid exosomes captured by anti-
CD-9 beads was confirmed (Fig 4-8 and Fig 4-9).  
Then, a simplified method of the established protocol was designed (Fig 4-10) and the 
results were reproducible (Fig 4-11). The purity of exosomes was tested by the staining 
of DNA which can be found on the surface of large extracellular vesicles (Fig 4-12).  
To apply the established method as a tool for studying exosomes in BAL fluid, the 
established assay was used to determine the efficiency of ultracentrifugation and the 
contamination of free exosome proteins (Fig 4-13). Furthermore, the stability of 
exosomes in BAL fluid (Fig 4-14) was studied. The optimal incubation time for 
exosome concentration study was determined (Fig 4-15) and the concentrations of fresh 
BAL fluid sample and the effect of the freeze-thaw cycle was investigated (Fig 4-16 




Chapter 4 An anti-CD9 bead-based flow cytometry assay for exosome study. 83 
4.4.1 Pelleted BAL-fluid exosomes were confirmed by TEM 
 
 
Figure 4-1 Ultracentrifugation pelleted BAL-fluid exosomes were confirmed by TEM.  
BAL fluid was collected and kept on ice before sequential centrifugations and then ultracentrifugation 
at 100,000g to collect exosomes. (A) Pelleted BAL-fluid cells (300g); (B) pelleted dead cells and 
apoptotic bodies (3,000g); (C) pelleted exosomes (100,000g); (D) pelleted exosomes visualised by 
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BAL fluid was collected from the clinic and transported to the laboratory on ice. BAL 
fluid was first filtered through 0.45 µm filters to remove large pieces of tissue before it 
was centrifuged at 300g for 10 minutes to pellet BAL cells (A). The supernatant was 
transferred into a new tube and then centrifuged at 3,000g for 20 minutes to pellet dead 
cells, cell debris and apoptotic bodies (B). After the removal of cell debris and large 
particles at 10,000g for 30 minutes at 4°C (not shown as the pellet was invisible), 
exosomes were finally pelleted at 100,000g (70 minutes, 4°C) when a pellet was 
observed at the bottom of the tube (C) which was difficult to be broken up and 
resuspended by pipetting.  
Exosomes were resuspended in 6 mL of PBS and pelleted again at 100,000g (70 
minutes, 4°C) before the fixation with 2% PFA. Fixed samples were visualised and 
examined by TEM (D). Pelleted exosomes were confirmed by the sizes of the vesicles 
as the diameters of the vesicles were smaller than 100 nm when compared to the scale 
bar.  
Then, the expression of exosome marker proteins was probed in the pelleted exosomes 
using western blotting. Furthermore, banked exosomes in frozen BAL fluid were 
isolated and probed for candidate target protein for the immuno-magnetic bead isolation 
protocol. 
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4.4.2 Pelleted exosomes from fresh BAL-fluid samples 




Figure 4-2 Pelleted exosomes from fresh ILD BAL-fluid samples expressed common exosome 
proteins. 
Sample-1, sample-2, and sample-3 were pelleted exosomes from three different ILD BAL-fluid 
samples. Western blot showed that the pelleted vesicles express some common exosomal proteins, 
including HSP-70, TSG-101, CD63, and CD9. CD81 was not detected in any of the samples. The 
RAW264.7 macrophage cell lysate was used as positive control.  
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4.4.3 Pelleted exosomes from defrosted BAL fluid 




Figure 4-3 Pelleted exosomes from defrosted BAL-fluid samples consistently expressed CD9.  
Exosomes were pelleted from defrosted BAL-fluid samples, washed and analysed by western blotting 
and a panel of exosome proteins was analysed. FR: fibrotic ILD (n=4); NF: non-fibrotic ILD (n=4); 
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4.4.4 Protocol design: isolation of BAL-fluid exosomes 





Figure 4-4 Isolation of BAL-fluid exosomes with anti-CD9 magnetic beads. 
 (A) Fresh BAL fluid with exosomes; (B) pelleted BAL-fluid exosomes by ultracentrifugation; (C) the 
bead-coupled exosomes for the staining with detection antibody (anti-CD9 FITC) before the analysis 
with flow cytometry.  
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By targeting CD9 on exosomes, an immuno-magnetic bead isolation protocol was 
designed. BAL-fluid exosomes were pelleted after the removal of cells, cell debris and 
large particles. Pelleted BAL-fluid exosomes were washed in PBS before they were 
resuspended in 250 µL PBS. Resuspended exosomes were coupled with pre-coated anti-
CD9 beads (2.7 µm) for 24 hours at 4°C on a rotator. After the coupling, beads were 
washed and incubated with the anti-CD9-FITC antibody (detection antibody) for 30 
minutes at room temperature. Samples were washed and analysed by flow cytometry.  
The following experiments were done to test the efficiency and specificity of the 
designed method. Furthermore, by comparing the expression of CD9-positive 
population between each of the purification steps, a simplified method was designed 
and studied. 
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4.4.5 Anti-CD9 beads displayed three populations by flow 





Figure 4-5 Anti-CD9 beads displayed three populations by flow cytometry.  
(A) Diagram of the structure for flow analysis: anti-CD9 beads pre-conjugated with anti-CD9 
antibody; (B) flow cytometry analysis of the structure; (C) pelleted BAL-fluid exosomes showed as 
debris. Representative data of experiments performed 3 times on different occasions (n=3).   
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4.4.6 Anti-CD9 beads were not auto-fluorescent and did not 




Figure 4-6 Anti-CD9 beads were not auto-fluorescent. 
(A) Diagram of the structure for flow analysis: anti-CD9 beads stained with detection antibody (anti-
CD9-FITC antibody) or its isotype control; (B) flow analysis of the structure with isotype staining; (C) 
flow analysis of the structure with anti-CD9-FITC staining. Representative data of experiments 
performed 3 times on different occasions (n=3).  
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Figure 4-7 Anti-CD9 bead-coupled exosomes were not auto-fluorescent. 
(A) Diagram of the structure for flow analysis: anti-CD9 beads were coupled with pelleted BAL-fluid 
exosomes; (B & C) TEM image of the surface of anti-CD9 beads before (B) and after (C) the coupling 
with pelleted exosomes; (D) flow cytometry analysis of the structure. Representative data of 
experiments performed 3 times on different occasions (n=3). 
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4.4.8 Anti-CD9 bead-coupled BAL-fluid exosomes were 




Figure 4-8 Anti-CD9 bead-coupled BAL-fluid exosomes were analysed by flow cytometry. 
(A) Diagram of the structure for flow analysis: bead-coupled pelleted exosomes stained for CD9-FITC 
or isotype; (B) Flow analysis of the structure with isotype antibody staining; (C) Flow analysis of the 
structure with anti-CD9-FITC staining. Representative data of experiments performed 3 times on 
different occasions (n=3). 
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Figure 4-9 Pelleted BAL-fluid exosomes were CD63+ and MHC-I+ vesicles. 
Bead-captured exosomes were CD63+ (B) and MHC-I+ (D) when compared to their isotype controls 
(MHC-I, A or CD63, C). Representative data of experiments performed 3 times on different occasions 
(n=3). 
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4.4.10 Simplified method: anti-CD9 bead-captured CD9+ 




Figure 4-10 Simplified method: anti-CD9 bead-captured CD9+ vesicles from BAL fluid after 
sequential centrifugations. 
(A) Exosomes were the major CD9+ vesicles in ILD BAL fluid; (B) BAL-fluid exosomes was shown 
as debris on flow cytometer; (C) bead-captured CD9+ vesicles were identified as three populations; 
(D) isotype control staining showed no CD9+ population; (E) anti-CD9 bead-captured vesicles were 
CD9+. Representative data of experiments performed 3 times on different occasions (n=3). 
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Exosomes in BAL fluid from each of the centrifugation steps were coupled with anti-
CD9 beads and analysed for the CD9 expression by flow cytometry (A). It showed that 
dead cells and apoptotic bodies (before 3,000g) contributed to the CD9+ population 
(brown). The overlapping histograms of CD9 expression of the BAL fluid after 3,000g 
(blue) and 10,000g (red) suggested that there were very few large vesicles in the BAL 
fluid. Thus, exosomes were the major CD9+ vesicles in the ILD BAL fluid.  
Exosomes in the BAL fluid could not be identified by flow cytometer (B), but after the 
incubation with anti-CD9 beads, the bead-coupled exosomes were identified as three 
populations by flow cytometry (C). Most of them were identified as singlets (gated). 
Anti-CD9-FITC staining confirmed the bead-captured vesicles express CD9 when 
compared to the isotype staining (D).  
For the validation of the simplified method, the expression of exosome surface proteins 
was probed. Furthermore, the contamination of large vesicle was studied by the staining 
of DNA which was more likely bound to their surface. To further validate the immuno-
magnetic bead method, the level of exosomes before and after ultracentrifugation was 
compared.  
Chapter 4 An anti-CD9 bead-based flow cytometry assay for exosome study. 96 
4.4.11 Simplified method: anti-CD9 bead-captured CD9+ 
vesicles were CD63+ and MHC-I+ 
 
 
Figure 4-11 Anti-CD9 bead-captured vesicles from BAL fluid were CD63+ and MHC-I+. 
CD9+ vesicles captured by the simplified method were CD63+ (A & B) and MHC-I+ (C & D). 
Representative data of experiments performed 3 times on different occasions (n=3). 
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4.4.12 Simplified method: anti-CD9 bead-captured vesicles 





Figure 4-12 Anti-CD9 bead-captured vesicles from BAL fluid were free of surface nucleic acid. 
(A) Apoptotic neutrophils were stained with Sytox blue as a positive control; (B) bead-captured CD9+ 
vesicles were Sytox blue negative. Representative data of experiments performed 3 times on different 
occasions (n=3). 
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4.4.13 Ultracentrifugation enriched exosomes 
 
 
Figure 4-13 Ultracentrifugation enriched exosome concentrations. 
The expression of CD9 of exosomes captured in BAL fluid before (A, B) and after (C, D) 
ultracentrifugation. Pelleted BAL exosomes were re-suspended in 250 µL PBS before analysed by 
flow cytometry (E, F). The statistical analysis of CD9 expression and the percentage of CD9+ 
population (G-I). Student paired t-test (G & H), one way ANOVA (I), Tukey's Multiple Comparison 
Test, **p<0.01, ***p<0.001. Representative data of experiments performed 6 times on different 
occasions (n=6).  
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BAL fluid (containing vesicles) after the sequential centrifugations was incubated with 
anti-CD9 beads before (A, B) and after (C, D) ultracentrifugation to capture the 
exosomes before the analysis with flow cytometry. The expression of CD9 showed a 
significant decrease after the ultracentrifugation (G).  
Pelleted exosomes were washed and resuspended in 250 µL PBS, then analysed with 
anti-CD9 beads flow assay (E, F). As expected, ultracentrifugation enriched the 
concentration of exosomes and increased the shift of CD9 fluorescence (E, F). CD9 
expression was increased in the re-suspended exosomes (H). 
The percentage of CD9+ population was increased from 95% before ultracentrifugation 
to approximately 100% in the resuspended solution of pelleted exosomes (I). After the 
ultracentrifugation, there were no CD9+ vesicles in the remaining BAL fluid (I), which 
also suggested that there was no soluble/ free CD9 protein in the BAL fluid.  
These data suggested that before the ultracentrifugation, the anti-CD9 beads were 
sensitive enough to bind with the exosomes in BAL fluid even though they are at low 
concentrations. The isolation of exosomes from the BAL fluid without 
ultracentrifugation is achievable.  
To expand the application of this anti-CD9 bead-based method, especially for the study 
of alveolar exosomes in IPF/ILD patients, a few other experiments were carried out. 
These experiments included the stability of exosomes for surface protein studies, 
defining the coupling time for exosome-concentration studies and the freeze-thaw effect 
on alveolar exosomes in BAL fluid. 
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4.4.14 Simplified method: exosomes in BAL fluid were 




Figure 4-14 Exosomes in BAL fluid were stable in the first 72 hours. 
Anti-CD9 beads were coupled with exosomes in fresh BAL fluid (A & B), after 24 hours (C & D), 
and again after 72 hours (E & F) before the analysis of CD9 and CD63 expression. The mean 
fluorescence of CD9 (G) and CD63 (H) expression or the percentage of CD9+ (I) and CD63+ (J) 
population were analysed which showed no difference. One-way ANOVA, Tukey's Multiple 
Comparison Test, n.s., not significant. Representative data of experiments performed 3 times on 
different occasions (n=3).  
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4.4.15 Simplified method: defining the beads coupling time 




Figure 4-15 Defining the beads coupling time for exosome concentration study. 
Half of the beads were coupled with BAL-fluid exosomes at approximately 5 hours. (A & B) 
Percentage of CD9+ (A) and CD63+ (B) populations. (C & D) Incubation of 5 hours reached about half 
of the maximum mean fluorescence of CD9 (C) and CD63 (D). Representative data of experiments 
performed 4 times on different occasions (n=4). 
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4.4.16 Simplified method: BAL fluid from fibrotic lungs 




Figure 4-16 BAL fluid from fibrotic lungs may have less exosomes than non-fibrotic lungs. 
(A)  BAL fluid from fibrotic lungs needed longer coupling time to reach 50% of CD9+in the whole 
population; (B) coupling for 5 hours showed lower percentages of the CD9+ population with fibrotic 
BAL fluid; (C) coupling for 5 hours showed lower mean CD9 fluorescence with fibrotic BAL fluid. 
Fibrotic ILD n=2 (in red), and non-fibrotic ILD n=2 (in black).  
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4.4.17 Simplified method: the number of exosomes 
decreased after repeated freeze-thaw cycle in ILD 




Figure 4-17 The number of exosomes decreased in human ILD BAL fluid after repeated freeze-
thaw cycle. 
BAL-fluid exosomes were analysed by anti-CD9 beads flow cytometry assay. Fold change of CD9 
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BAL fluid was defrosted and coupled with anti-CD9 beads for CD9 staining. The same 
set of samples were returned to -80°C and defrosted again 24 hours later for analysis. 
The fold change of CD9 fluorescence between stained and unstained was calculated to 
represent the exosome concentrations. Statistical analysis showed that the CD9 
expression dropped 2.84±1.32 to 1.79±0.68 after the freeze-thaw cycle (n=7, p<0.01). 
The CD9 expression was decreased by 33.05 ± 12.80 % on average which suggested 
that 1/3 of the vesicles was lost during the freeze-thaw cycle. 
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4.5 Summary and Discussion 
In this study, I have presented an easy but powerful tool to assist in the investigation of 
BAL-fluid exosomes, particularly in ILD/IPF patients.  
Using immuno-magnetic beads is a common method to “enlarge” the size of exosomes 
and make them visible by flow cytometry [325, 333]. In fact, a number of different 
immuno-magnetic beads have been used for the isolation of exosomes in different 
samples. This includes anti-CD9, anti-CD63, anti-CD81, anti-MHC-I, anti-HLA-DR 
and anti-EpCAM magnetic beads [461-463]. Immuno-magnetic bead isolation is 
designed according to the protein expression on exosomes, and thus using this technique 
may not capture the whole exosome population [325]. In order to capture the majority 
of exosomes, the pre-coated beads should target the most common protein that is 
expressed on the exosome surface. Prior to this study, there were no established 
immuno-magnetic bead protocols for the study of BAL-fluid exosomes in ILD/IPF.  
In this study, I have shown that exosomes from ILD/IPF BAL fluid did not express 
CD81, weakly expressed CD63 but expressed CD9 abundantly (Fig 4.2 and Fig 4.3). 
Thus, CD9 was identified as the target for exosome immuno-magnetic beads isolation. 
The materials used for the assay did not cause unspecific binding or generate false 
positive signals such as auto-fluorescence (Fig 4.4 – Fig 4.7). Anti-CD9 bead-captured 
exosomes also expressed CD63 and MHC-I on flow cytometry, common exosome-
associated proteins, which further confirmed these were indeed captured exosomes. A 
simplified method was further developed to make it a more efficient technique.  
The stability of exosomes is critical for experimental studies of exosomes [325, 337]. 
Exosomes in ILD/IPF BAL fluid were abundant in proteins with different molecular 
weights (SDS-PAGE silver stain, data not shown), however, the freeze-thaw cycle may 
lose a significant amount of exosomes. In fact, this study showed repeated freeze-thaw 
cycle have lost 30% of the original exosomes when stored in BAL fluid (Fig. 4.17) at -
80°C. For the surface protein study, exosomes were stable in BAL fluid at least in the 
first 72 hours (Fig 4.14) when they were stored at 4 °C. 
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The protein expression on exosomes gives information such as their origins, functions 
and whether they are disease relevant [322, 388, 391, 461]. The cellular proteins are 
actively sorted to exosomes for different purposes and the exosome pathway also 
coordinates with other mechanisms such as autophagy to maintain cellular 
homoeostasis [349]. CD81, a tetraspanin protein that expresses on almost all exosome 
varieties, was not present in ILD/IPF BAL-fluid exosomes. CD81 is essential for T cell 
development at early stages [464] and CD81 knockout mice showed compromised 
immune responses in vivo [465]. CD81 also mediates the signal transduction and cell 
adhesion of immune cells [466] and can also form molecular complexes with CD9 that 
may have specific roles in many cellular functions [467]. CD9- and CD81-null mice 
resulted in multinucleated cells, and CD9/CD81 double-null mice spontaneously 
developed multinucleated giant cells in the lungs, which highlighted the function of 
both tetraspanin proteins in monocyte/ macrophage biology [468]. CD81 has also been 
shown crucial in liver HCV infection and female fertility [469, 470]. In vitro, it has been 
shown that the expression of CD9, CD81 and CD63 changes during the differentiation 
of monocyte to macrophages [471]. The role of CD81 and CD9 in ILD/IPF exosomes 
needs to be further studied. CD81 negative exosomes might be used for the profile of 
this distinct exosome population in ILD/IPF lungs. The high expression of CD9 and the 
absence of CD81 may offer clues to identify the parent cells of the BAL fluid exosomes. 
Furthermore, cells in ILD/IPF lungs may also have been affected which led to the lack 
of CD81 in the alveolar exosomes. For future studies, it will be useful to examine the 
expression of CD81 and CD9 in the alveolar cells. It might be very useful to compare 
the protein expression of alveolar exosomes of other lung conditions with ILD/IPF as 
well, for example, COPD, acute lung injury (ALI) and lung cancer.  
Regardless of their protein composition, the actual concentration of exosomes may be 
very informative and disease-relevant. In fact, the level of exosomes in plasma had been 
correlated with the stage of lung cancer and plasma exosomal RNA has shown a fibrotic 
profile in IPF which was also correlated with disease severity [422, 423]. The level of 
BAL fluid exosomes which better represent the condition of the diseased lungs 
compared to plasma exosomes may be more sensitive and thus more informative. Prior 
to my study, there was no established methodology for quantifying exosomes in IPF 
BAL fluid. In this study, the optimal ‘coupling time’ (that is the incubation time for 
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CD9-immuno-magnetic beads to couple with CD9-expressing exosomes) was shown to 
be 5 hours. This is important for the standardisation of measuring exosome 
concentrations in the ILD/IPF BAL fluid between samples. The standardised anti-CD-
9 bead-assay also suggested fewer exosomes in BAL fluid from patients with lung 
fibrosis (Fig 4.16), which has been confirmed with larger number of samples by NTA 
as presented in chapter 7 of this thesis. 
In summary, by observing that CD9 was abundantly expressed on ILD BAL-fluid 
exosomes, an easy and user-friendly method was developed and tested to study the 
BAL-fluid exosomes by flow cytometry. This technique could be used as a reliable tool 
to study exosome protein expression and concentrations in BAL fluid, particularly in 
ILD/IPF. 
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Chapter 5 Collagen-I and collagen-IV 
modulate both the formation and 




This study was designed to establish an in vitro model in which to investigate the role 
of extracellular matrix (ECM), specifically collagen-I and collagen-IV, on macrophage 
autophagy.   
The formation and degradation of autophagosomes were studied with starvation 
(limited nutrients), rapamycin and bafilomycin A1 in three types of macrophages: 
RAW264.7, THP-1 and human peripheral blood monocyte-derived macrophages 
(MDM). Confocal microscopy and western blotting were used to measure the 
expression of microtubule-associated protein light chain 3 (LC3) and p62.  
Starvation induced weak LC3-II expression. Rapamycin-induced autophagy achieved 
robust and reproducible LC3-II expression in a time- and concentration-dependent 
manner. The optimal condition for autophagy induction with rapamycin was determined 
as 25 µM for 4 hours. Bafilomycin A1 blocked LC3/p62 degradation and 50 nM was 
determined as the optimal concentration for 4 hours treatment. Bafilomycin A1 
increased the LC3-II expression in rapamycin-induced autophagy. The classic pattern 
of LC3 changes, the increase in LC3-II and decrease in LC3-I, were observed in 
RAW264.7 macrophages upon autophagy induction. In human monocyte/ macrophages, 
only LC3-II was observed whereas LC3-I was not detected. 
Differentiation up-regulated autophagy in MDM which was reduced to basal level by 
collage-I and collagen-IV (p<0.001). Collagen-I and collagen-IV increased basal 
autophagy in RAW264.7 macrophages (p<0.001 and p<0.05) but only collagen-I 
increased basal autophagy in MDM (p<0.05). Collectively, ECM, particularly collagen-
I, regulates both the formation and degradation steps of autophagy in macrophages.  
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These data suggest that the surrounding environment of cells can dictate their 
autophagic response, a finding that is relevant in diseases where ECM composition is 
altered.  
5.2 Introduction 
The excessive deposition of ECM is a feature of idiopathic pulmonary fibrosis (IPF) 
and the composition of ECM changes at different stages of IPF. Collagen type-I, III and 
IV may be associated with early stage of lung fibrosis [203]. At the later stage of IPF, 
type-I collagen is found increased and type-IV collagen, the major collagen in the 
basement membrane, is found decreased [204]. 
Macrophages are key regulators of the wound-healing process which is likely impaired 
in IPF [15, 136]. In IPF, the number of alveolar macrophages (AM) is greatly increased, 
and they also exhibited a distinct “wound-healing” phenotype [151, 157]. 
Studies have suggested that ECM plays an important role in determining innate cell 
function in inflammation [156]. It is known that the interaction between macrophages 
and ECM influences the inflammation effector functions of macrophages [214]. ECM 
increases basal autophagy in epithelial cells through adhesion molecules [216] and the 
detachment from ECM also induces autophagy[217]. ECM also modulates many 
processes that are relevant to autophagy in the lungs [154, 215].  
Autophagy is necessary for macrophage biology. Intact autophagy is required for 
monocyte differentiation to macrophages [472, 473], the antigen presentation process 
[474, 475] and the polarisation of macrophages (against and in favour of the alternative 
activation) [476, 477]. The impaired autophagic activity can lead to the accumulation 
of protein aggregates and damaged organelles which may impair macrophage function. 
Monick and colleagues have demonstrated that AM isolated from smokers have 
compromised autophagy [478]. Studies in bleomycin-induced lung fibrosis have shown 
that the degree of lung fibrosis was improved by inducing autophagy [297, 298, 479].  
The primary feature of autophagy is the formation of autophagosomes upon its 
activation through mTOR-dependent and -independent pathways. Both starvation and 
rapamycin can induce autophagy by inhibiting the mTOR [256]. Once autophagy is 
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activated, the cytosolic LC3-I is conjugated with phosphatidylethanolamine (PE) to 
form LC3-II by an ubiquitination-like enzymatic reaction. LC3-II, but not LC3-I, 
associates with both the outer and inner membranes of autophagosomes. And, therefore, 
LC3-II is regarded as the marker of autophagosomes and autophagy activation [237, 
480, 481]. The archetypical cellular response in active autophagy is an increase in LC3-
II expression and a decrease in LC3-I expression. Autophagy substrate protein, p62, 
also known as SQSTM1/ sequestosome-1, is selectively incorporated into 
autophagosomes through direct binding to LC3-II [269, 482-484]. Bafilomycin A1 is 
an inhibitor of the v-type ATPase that blocks the fusion of the autophagosome and 
lysosome by inhibiting lysosomal acidification [276]. By blocking the autophagosome 
degradation, neither LC3-II nor p62 proteins can be degraded. Therefore, the 
accumulation of the autophagy marker (LC3-II) by bafilomycin A1 represents the 
“autophagy activity” in cells.   
Taken together, the interaction between ECM and macrophages might regulate 
macrophage autophagy and result in functional consequences that may be relevant to 
lung fibrosis.  
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5.3 Hypothesis and aims 
 
5.3.1 Hypothesis:  
 
Extracellular matrix proteins modulate autophagy in macrophages 
 
5.3.2 Aims:  
 To demonstrate autophagy induction in mouse and human macrophages 
 
 To determine the effect of different ECM proteins (type-I and type-IV collagens) 
on the autophagy pathway in macrophages 
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5.4 Results 
In this chapter, I first established the consistent autophagy induction in RAW264.7 
mouse macrophages by targeting the mTOR using the starvation medium (Fig 5-1) and 
rapamycin (Fig 5-2 and Fig 5-3). Results showed that successful autophagy induction 
with rapamycin was dose- and time-dependent. Bafilomycin A1 increased the 
expression of LC3-I, LC3-II, and p62 by blocking the fusion of autophagosomes and 
lysosomes (Fig 5-4 and Fig 5-5) which can be used to study the dynamic of the 
autophagy pathway.  
The same effect of rapamycin and bafilomycin was observed in human monocytic cell 
THP-1-derived macrophages (Fig 5-6 and Fig 5-7) and human peripheral blood 
monocyte-derived macrophages (Fig 5-8 and Fig 5-9).  
With the established model of autophagy induction, the effect of ECM, specifically 
type-I and type-IV collagen, was studied with RAW264.7 mouse macrophages (Fig 5-
10) and human monocyte-derived macrophages (Fig 5-11 and Fig 5-12). 
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5.4.1 Starvation-induced autophagy in RAW264.7 
macrophages  
Starvation, or nutrient depletion, is a classic stimulus for the activation of autophagy in 
mammalian cells. Without amino acids or serum proteins, Hanks' Balanced Salt 
Solution (HBSS) and Earle's Balanced Salt Solution (EBSS) were used as starvation 
media for autophagy induction in RAW264.7 mouse macrophages.  
 
Figure 5-1 Starvation-induced autophagy in RAW264.7 mouse macrophages. 
Cells (1×106) were seeded in a six-well plate the day before starvation treatment. The following day, 
cells were rinsed with pre-warmed (37°C) PBS 3 times before starvation with HBSS (A, B)  or EBSS 
(C) for different lengths of time. Cell lysates were prepared and subjected to western blotting. Positive 
control: Neuro-2A cell lysate; medium control: DMEM with 10% FBS. Representative blots are shown 
for A (performed once) and for B and C (each performed 3 times on separate occasions). 
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When the culture medium was removed and replaced with HBSS or EBSS starvation 
medium, autophagy, as determined by the changes of LC3-I and LC3-II expression, was 
induced (A and C) in RAW264.7 macrophages.  
HBSS starvation showed the classic pattern of LC3 expression in autophagy induction: 
the increase of LC3-II expression and the decrease of LC3-I expression (A). Cells left 
in medium control did not have any expression of LC3-II, but in the starvation medium, 
LC3-II expression was observed. The longer the cells were starved, the more LC3-II 
expression was observed on the blot.  
The induction of autophagy with HBSS, however, was not consistent (B). As mentioned 
in the figure legend, this experiment was repeated several times (n=3), however, LC3-
II expression was barely detachable. On the contrary, LC3-I was consistently expressed 
and easily visualised.  
EBSS is another commonly used starvation medium for autophagy induction. As shown 
in the blot (C), LC3-I was expressed in the medium control, but no LC3-II was detected. 
When the cells were cultured in EBSS medium, the LC3-I level was decreased and 
gradually weak LC3-II expression was detected from 8 hours of incubation onwards. 
This again showed the changes of the LC3-I and LC3-II proteins during autophagy 
induction. Furthermore, autophagy induction with EBSS was more consistent and was 
repeated on 3 separate occasions.  
To establish a consistent model of autophagy induction, rapamycin was used in 
experiments. LC3-II expression was not observed with low concentrations of rapamycin 
at different time points of treatment (additional data in Appendix-A), so higher 
concentration of rapamycin was used. 
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5.4.2 Rapamycin-induced autophagy in RAW264.7 
macrophages in a concentration-dependent manner 
 
Figure 5-2 Rapamycin-induced autophagy in RAW264.7 mouse macrophages in a 
concentration-dependent manner. 
(A) Representative blot of experiments performed 4 times on different occasions (n=4); (B-C) 
densitometry analysis of LC3-I and LC3-II  expression. Cells were treated as indicated for 4 hours 
before the cell lysates were prepared for western blotting. Positive control: Neuro 2A cell lysate; 
vehicle control: DMSO diluted in complete DMEM medium (as 50 µM rapamycin). One-way 
ANOVA, Tukey's Multiple Comparison Test, ** p<0.01, *** p<0.001, n.s. not significant. 
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RAW264.7 macrophages were treated for 4 hours with rapamycin or control media. As 
shown in the blot and densitometry graphs (A & C), at lower concentrations of 
rapamycin there was no expression of LC3-II, but LC3-II protein was increased when 
treated with 25 µM and 50 µM rapamycin.  
The expression of LC3-I (A & B), the free cytosolic LC3 protein, also changed. LC3-I 
expression was higher at lower concentrations of rapamycin (eg. 5 µM) and decreased 
at higher concentrations of rapamycin (25 µM and 50 µM). 
The rapamycin titration experiments (4 hours of incubation), showed that rapamycin-
induced autophagy in RAW264.7 macrophages was concentration-dependent.  
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5.4.3 Rapamycin-induced autophagy in RAW264.7 
macrophages in a time-dependent manner 
 
Figure 5-3 Rapamycin-induced autophagy in RAW264.7 mouse macrophages in a time-
dependent manner. 
(A) Representative blot of experiments performed 4 times on different occasions (n=4); (B-C) 
densitometry analysis of LC3-I and LC3-II  expression. Cells were treated with 25 µM rapamycin at 
the indicated lengths of time before the cell lysates were prepared for western blotting. Positive control: 
Neuro 2A cell lysate; vehicle control: DMSO diluted in complete DMEM medium (as 25 µM 
rapamycin). One-way ANOVA, Tukey's Multiple Comparison Test, *p<0.05, ** p<0.01, *** p<0.001, 
n.s. not significant. 
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To determine the optimal time-point for 25 µM rapamycin treatment, RAW264.7 cells 
were treated with 25 µM rapamycin for different time period.  
As shown in the representative blot (A), there was no LC3-II expression under culture 
media control or vehicle control, but consistent LC3-I expression was observed. With 
25 µM of rapamycin, LC3-I started to convert to LC3-II. From 1-hour onwards, LC3-I 
expression began to decrease and LC3-II expression started to increase. By 4 hours there 
was significant LC3-II detected in the cells. Incubation for an additional 4 hours (8-hour 
treatment) did not increase the LC3-II expression.  
Densitometry analysis confirmed the observation on the blots, that during autophagy 
induction, LC3-I decreased from early time-point (0.5-hour) to later time-point (4 
hours); and LC3-II increased during the incubation with different lengths of time. Thus, 
rapamycin-induced autophagy in RAW264.7 macrophages was time-dependent 
Collectively, with the results from the rapamycin titration experiments, the optimal 
autophagy induction was achieved with rapamycin at 25 µM by 4 hours in RAW264.7 
cells. Thus, in the following experiment, the concentration of blocking the 
autophagosome degradation by bafilomycin A1 was determined at different 
concentrations of 4-hour incubation. 
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5.4.4 Bafilomycin A1 blocked LC3 and p62 degradation in 
RAW264.7 macrophages 
 
Figure 5-4 Degradation of LC3 and p62 was blocked by bafilomycin A1 at 50 nM by 4 hours. 
(A) Representative blot of experiments performed 3 times on different occasions (n=3); (B-D) 
densitometry analysis of LC3-I, LC3-II, and p62 expression. RAW264.7 cells were treated as indicated 
for 4 hours. Positive control: Neuro 2A cell lysate; vehicle control: DMSO diluted in complete DMEM 
(as 400 nM bafilomycin.). One-way ANOVA, Tukey's Multiple Comparison Test, *p<0.05, ** p<0.01, 
n.s. not significant. 
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Bafilomycin A1 blocks the fusion of autophagosome with lysosome by inhibiting 
vacuolar H+-ATPase (V-ATPase) through changing the cellular pH values. Blocking 
the degradation step results in the accumulation of p62 and LC3 proteins.  
As shown in the rapamycin experiments, the optimal time-point for autophagy induction 
was 4 hours, thus it was used as the end-point for bafilomycin A1 treatments.  
As shown in the blot (A), there was a very little expression of both LC3-I and LC3-II 
in the cells cultured in vehicle control media. Both LC3-I and LC3-II proteins began to 
accumulate in cells when they were treated with bafilomycin A1 at different 
concentrations. From 50 nM onwards, LC3-I (B) and LC3-II (C) expression were both 
significantly higher than the controls.  
There was p62 expressed in the vehicle control as shown in the example blot (A) and 
treatment with bafilomycin A1 increased p62 expression. At 50 nM of bafilomycin A1, 
p62 expression was significantly higher than the controls (D). From 50 nM of 
bafilomycin A1 onwards, there was not much difference in p62 expression, which 
suggested that fusion of autophagosome with lysosome was completely blocked. 
For the next experiment, the effect of using rapamycin and bafilomycin was further 
studied to establish the methodology of studying the dynamic autophagy activities, 
especially the formation and degradation of LC3 proteins. 
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5.4.5 Bafilomycin A1 increased rapamycin-induced LC3 
expression in RAW264.7 cells 
 
Figure 5-5 Bafilomycin A1 enhanced rapamycin-induced LC3 expression in RAW264.7 
macrophages. 
RAW264.7 cells were treated as indicated for 4 hours before they were fixed and stained for LC3.Cells 
were processed as described in section 2.3.5 in the Materials and Methods chapter. Representative 
images of experiments performed 3 times on different occasions (n=3). (A) vehicle control, DMSO 
diluted in completed DMEM (as rapamycin + Bafilomycin.A1); (B) rapamycin, 25 µM; (C) 
Bafilomycin A1 (Baf. A1), 50 nM; (D) double treatment with 25 µM rapamycin and 50 nM 
Bafilomycin A1; (E) percentage of LC3 punctated cells. punctated cells in each of the frame was 
counted, the average percentage of three frames were used for statistical analysis; (F) western blotting 
comparing different treatments for autophagy induction. ** p<0.01; *** p<0.001, n.s. not significant, 
one-way ANOVA, Tukey's Multiple Comparison Test.  
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Adding bafilomycin A1 to rapamycin, in theory, should block the degradation of the 
increased LC3-II expression by rapamycin.  
To test this hypothesis, RAW264.7 macrophages were treated with individual 
compound alone or in combination (A-D). Results showed (E) that the percentage of 
LC3-puncta positive cells was significantly increased in the double treatment compared 
with vehicle control, rapamycin alone and bafilomycin A1 alone (90.60% ± 2.04% vs 
27.90% ± 1.50% vs 43.10% ± 1.74% vs 46.63 ± 1.96%).  
Western blot results (F) confirmed the confocal data. As shown in the blot, there was 
almost no LC3-II expressed in the medium control or vehicle control. LC3-II expression 
was not increased when cells were cultured in HBSS or EBSS media. Increased LC3-II 
and decreased LC3-I was observed when RAW264.7 cells were treated with rapamycin. 
Both LC3-I and LC3-II expression was further increased when bafilomycin A1 was 
added into the culture medium containing rapamycin.  
With the results of successfully modulating and measuring the autophagy pathway in 
mouse RAW264.7 macrophages, the autophagy pathway with human monocyte-
derived macrophages (THP-1 monocytic cell-line and primary peripheral blood 
monocyte from healthy donors) were further investigated.  
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Figure 5-6 Rapamycin induced autophagy in THP-1 macrophages. 
THP-1 monocyte-derived macrophages were treated as indicated and the cell lysates were prepared 
for western blotting. (A) PMA differentiation increased LC3-II expression. (B) rapamycin-induced 
autophagy by 4 hours of incubation. (C) densitometry analysis of LC3-II expression. THP-1 cells were 
incubated with 50 ng/ mL PMA for three days before rapamycin treatment. Medium control: 
RPMI1640+10%FBS; vehicle control: DMSO diluted in complete RPMI medium (as 50 µM 
rapamycin). Positive control: Neuro 2A cell lysate. **p<0.01, n.s. not significant, one-way ANOVA, 
Tukey's Multiple Comparison Test. Representative blots are shown for (A) performed 3 times (n=3) 
and (B) performed 4 times (n=4) on different occasions. 
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THP-1 human monocytic cells were differentiated to macrophages with PMA for 3 
days. When THP-1 cells were treated with PMA, they became adherent and began to 
differentiate to mature macrophages. In the study, it is found that THP-1 cells only 
became adherent when treated with PMA at 50 ng/ mL or higher concentrations. 
Western blot (A) showed that the increased LC3-II expression was observed in all THP-
1 macrophages differentiated with PMA at different concentrations. LC3-II was barely 
detected in THP-1 cells that were cultured in vehicle control medium. It suggested that 
the successful differentiation of THP-1 macrophages by PMA inevitably upregulated 
the LC3-II expression. 
THP-1 macrophages, with up-regulated LC3-II expression, were treated with 
rapamycin at different concentrations for 4 hours (B & C). THP-1 macrophages 
responded to rapamycin in a concentration-dependent manner. LC3-II was barely 
detected in the controls but increased when they were treated with rapamycin at 
different concentrations. Densitometry analysis showed that at 25 µM and 50 µM, the 
LC3-II expression induced by rapamycin was significantly higher than the expression 
in vehicle control.  
Of note, LC3-I was barely detected in THP-1 macrophages in all the experiments (A & 
B). Referring to the consistent expression of LC3-I in RAW264.7 mouse macrophages, 
results suggest that LC3-I may be at very low levels in this human macrophage. 
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5.4.7 Blockage of autophagosome degradation increased 
p62 and LC3-II expression in THP-1 macrophages 
 
Figure 5-7 Blockage of autophagosome degradation showed increased LC3-II but no LC3-I 
expression in THP-1 macrophages. 
THP-1 macrophages were treated with bafilomycin A1 at indicated concentrations for 4 hours and the 
cell lysates were prepared for western blotting. (A) Representative blot of experiments performed 3 
times on different occasions (n=3); (B-C) densitometry analysis for p62 and LC3-II expression. 
Vehicle control: DMSO diluted in culture medium (as 400 nM bafilomycin A1); Positive control: 
Neuro 2A cell lysates. THP-1 cells were differentiated with 50 ng/mL PMA for 3 days before use. 
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THP-1 macrophages were treated with bafilomycin A1 at different concentrations for 4 
hours to study the changes in the expression of LC3 proteins. The expression of p62 
was probed as an indicator for the successful blockage of autophagosome degradation. 
The expression of p62 was increased when THP-1 macrophages were cultured in 
bafilomycin A1 for 4 hours (A & B). Densitometry analysis showed that the 
autophagosome degradation was blocked by bafilomycin A1 at 50 nM and higher 
concentrations (B). 
After bafilomycin A1 treatment, the LC3-II expression was also increased (A & C). At 
50 nM of bafilomycin, LC3-II expression was significantly higher than the vehicle 
control (C). Higher concentrations of bafilomycin did not further increase the 
expression of LC3-II (C). 
LC3-I expression, however, was barely detected when autophagosome degradation was 
successfully blocked (A). This confirmed that LC3-I was not highly expressed in human 
THP-1 macrophages, otherwise by blocking its degradation the existing LC3-I would 
have been detected.  
Leaving aside LC3-I, both rapamycin and bafilomycin A1 had successfully modulated 
the autophagy pathway in this human THP-1 macrophages.  
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5.4.8 Rapamycin-induced autophagy in MDM in a 
concentration-dependent manner 
As shown in RAW264.7 macrophages and THP-1 macrophages, rapamycin induced 
autophagy in a concentration- and time-dependent manner. Thus the same strategy was 
extended to human MDM. 
 
Figure 5-8 Rapamycin-increased autophagy in MDM. 
MDM were treated with rapamycin at the indicated concentrations for 4 hours and cell lysates were 
prepared for western blotting. (A) Representative blot of experiments performed 4 times on different 
occasions (n=4); (B) densitometry analysis of LC3-II expression. Medium control: IMDM + 10% FBS; 
vehicle control: DMSO diluted in culture medium (as 50 µM rapamycin); positive control: Neuro 2A 
cell lysate. *p<0.05, **p<0.01, ***p<0.001, n.s. not significant, one-way ANOVA, Tukey's Multiple 
Comparison Test.  
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Monocytes were isolated from peripheral blood and differentiated to mature 
macrophage on standard tissue culture (TC) plates for 7 days before the rapamycin 
treatment.  
As shown in the blot (A), there was little LC3-II expressed in MDM when cells were 
cultured in the control medium or the vehicle control. LC3-II expression was increased 
in MDM when they were cultured in rapamycin at 25 µM, and the expression was 
further increased at 50 µM.  
Densitometry analysis (B) of the blots suggested that the optimal concentration for 
autophagy induction in MDM was 25 µM with 4-hour of incubation.  
Of note, again LC3-I was not detected in the human peripheral blood MDM, which was 
observed in the human THP-1 macrophages.  
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5.4.9 Blockage of autophagosome degradation increased 
p62 and LC3-II expression in MDM 
 
Figure 5-9 Blockage of autophagosome degradation increased p62 and LC3-II expression in 
MDM. 
MDM were treated as indicated for 4 hours before the cell lysates were prepared for western blotting. 
(A) Bafilomycin A1 blocked the degradation of autophagosomes in MDM; (B & C) densitometry 
analysis of p62 and LC3-II; (D) LC3-I was not expressed in human peripheral blood. Medium control: 
IMDM+10%FBS; vehicle control: DMSO diluted in culture medium (as 100 nM Baf.- A1). Positive 
control: bafilomycin A1 treated RAW264.7 cells (50 nM, 4 hours). *p<0.05, **p<0.01, ***p<0.001, 
n.s. not significant, one-way ANOVA, Tukey's Multiple Comparison Test. Representative blots were 
shown for A and D, both were performed 3 times on different occasions (n=3). 
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The expression of p62 was probed as another indicator of autophagy following 
bafilomycin A1 treatment. Increased expression of p62 was observed in MDM from 10 
nM of bafilomycin onwards (A & B). The expression of p62 remained constant (A) and 
the densitometry analysis did not show any statistical significance (B).  
LC3-II expression, however, was not detected at 10 nM of bafilomycin (A). LC3-II 
expression began to increase from 25 nM and was significantly increased at 50 nM and 
100 nM of bafilomycin (A & C).  
Collectively, the expression of p62 and LC3-II data suggested that the accumulation of 
p62 happened earlier than the accumulation of LC3-II. The optimal concentration for 
bafilomycin A1 treatment in MDM was 50 nM.  
The expression of LC3-I was not detected in MDM by blocking the degradation of 
autophagosomes (A).  
To address whether the differentiation process from monocyte to macrophages had 
changed the LC3 protein profile, human peripheral blood monocytes were isolated and 
treated with rapamycin or bafilomycin A1.  
As shown in the example blot (D), LC3 proteins were not detected in monocytes that 
were cultured in the control media and the vehicle control. LC3-II expression was 
detected in cells that were treated with rapamycin (25 µM) and bafilomycin A1 (50 
nM). LC3-I protein, however, was not detected. Thus, similar to the data with THP-1 
cells, LC3-II protein may be the major LC3 protein presented in human monocytes/ 
macrophages with the absence of LC3-I protein. 
As a consistent model of studying the autophagy in macrophages was established with 
rapamycin and bafilomycin A1, the effect of ECM, particularly type-I and type-IV 
collagen, was investigated in the following experiments with RAW264.7 mouse 
macrophages and MDM from the easy-detach method. As the differentiation to 
macrophages had increased LC3-II expression, the baseline autophagy level was 
measured in MDM-ED.  
Chapter 5 Collagen-I and collagen-IV modulate autophagy in macrophages.  131 
5.4.10 Type-I and type-IV collagens increased basal 
autophagy (autophagosome formation) in RAW264.7 
macrophages 
RAW264.7 macrophages were treated with 50 nM bafilomycin A1 in the presence of 
type-I and type-IV collagen to study the effect of ECM on basal autophagy. 
 
Figure 5-10 Type-I and type-IV collagens increased basal autophagy in RAW264.7 cells.  
RAW264.7 macrophages were seeded on TC dishes or dishes pre-coated with type-I or type-IV 
collagen before the cells were treated as indicated (with  50 nM bafilomycin A1 or vehicle control) for 
4 hours. The cell lysates were prepared and subjected to western blotting. (A) Representative blot of 8 
experiments performed on different occasions (n=8); (B-E) densitometry analysis of p62 (B), LC3-II 
in cells under vehicle control condition (C), LC3-I in cells under Baf.- A1 condition (D), and LC3-II 
in cells under Baf.- A1 condition (E). Control: DMSO diluted in culture medium (as 50 nM Baf.- A1); 
Baf 50 nM: Bafilomycin A1, 50 nM for 4 hours. Positive control: Neuro 2A cell lysate. *p<0.05, 
**p<0.01, ***p<0.001, n.s. not significant, paired student t-test (B) and one-way ANOVA, Tukey's 
Multiple Comparison Test (C, D & E). 
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As shown in the representative blot and densitometry analysis (A & B), RAW264.7 
macrophages had increased p62 expression on all culture dishes after bafilomycin A1 
treatment. The increased p62 expression confirmed that the autophagosome degradation 
was blocked. Thus, the basal autophagy can be studied with LC3-II expression. 
LC3-II was barely expressed in RAW264.7 macrophages that were cultured with the 
vehicle control (A). Densitometry analysis showed there was no difference in LC3-II 
expression on the three types of culture dishes in vehicle control media (C). This showed 
that neither the vehicle control medium nor the contact with collagen had induced 
autophagy in RAW264.7 cells.  
Compared to the low LC3-II expression in the control media, LC3-II expression was 
increased in RAW264.7 cells when they were treated with bafilomycin A1 (A). 
Densitometry analysis (D) showed that LC3-II expression was increased in cells when 
they were in contact with both type-I and type-IV collagens compared to cells on TC 
dishes (1.98 ± 0.12 vs 1.66 ± 0.07 vs 1.28 ± 0.12). In addition, there was no difference 
in LC3-II expression between cells that were cultured on type-I and type-IV collagens 
(D). These data suggested that the basal autophagy was increased in RAW264.7 cells 
in the presence of type-I and type-IV collagens.  
LC3-II was synthesized from LC3-I, thus the level of LC3-I might have been decreased 
if LC3-II was increased.  However, the densitometry analysis showed that the LC3-I 
expression was not statistically different among the conditions (E).  
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5.4.11 Differentiation to MDM by the easy-detach method 
up-regulated autophagy  
 
Figure 5-11 Differentiation to MDM by the easy detach method (MDM-ED) up-regulated 
autophagy. 
(A & B) Cyto-ID staining of monocytes before culture to macrophages (day-0); (C & D) cyto-ID 
staining of MDM-ED on day-7; (E) analysis of fold changes of Cyto-ID mean fluorescence  (n=4). 
**p<0.01, student t-test.  
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To examine the baseline level of autophagy after the differentiation process, 
macrophages from the easy-detach method were stained with Cyto-ID and compared 
with freshly purified monocytes from the peripheral blood mononuclear cells (PBMC).  
Monocytes were gated from the PBMC population (A) and compared with the unstained 
cells. Flow cytometry analysis (B) showed an increased Cyto-ID expression in 
monocytes.   
MDM-ED showed a uniformed population (C) and when compared the Cyto-ID 
expression with the unstained cells, the histogram shifted further to the right (D).  
When comparing the fold changes of Cyto-ID expression to the unstained (E), MDM-
ED had up-regulated autophagy and increased fold change of Cyto-ID fluoresce than 
the freshly isolated monocytes (42.08 ± 6.39 vs 7.37 ± 0.69, n=4, p<0.01, unpaired 
student t-test). The Cyto-ID expression in MDM-ED was almost 6 times higher after 
the differentiation.  
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5.4.12 Collagen modulated both autophagosome 
degradation and formation in MDM-ED 
 
Figure 5-12 Collagen modulated autophagy in MDM-ED. 
(A & B) analysis of LC3-II expression cultured in the control media; (C & D) analysis of LC3-II 
expression cultured in 50 nM bafilomycin A1 for 4 hours; (E) calculations for the change of LC3-II 
expression (ΔLC3); (F) Experiment control:bafilomycin A1 increased LC3-II expression compared 
with vehicle control; (G & H) ΔLC3 presented as values of subtraction (G) or percentage (H). MDM-
ED were seeded on different culture dishes and cultured for 20 hours before Baf.- A1 or vehicle control 
treatments as indicated. Cell lysates were prepared and proteins were extracted after the treatments 
and the expression of LC3 was analysised by western blotting. Control: DMSO in culture medium (as 
Baf.- A1); Baf 50 nM: bafilomycin A1, 50 nM. Positive control, human neuro-2A cell lysate. *p<0.05, 
**p<0.01, ***p<0.001, n.s. not significant, paired student t-test (F) and one-way ANOVA, Tukey's 
Multiple Comparison Test (B, D, G & H). Representative blot of 6 experiments performed on different 
occasions (n=6). 
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MDM from the easy-detach method (MDM-ED) were seeded on the culture dishes (TC, 
collagen type-I and type-IV) the day before and cells were cultured for 20 hours before 
the experimental treatments. 
As shown on the blot and densitometry (A), the expression of LC3-II was different in 
MDM-ED on the three surfaces when they were cultured in the control media. The 
upregulated autophagy in MDM-ED (Figure 5.11) was decreased in the presence of 
type-I and type-IV collagen compared with cells from TC dishes (1.61 ± 0.09 vs 0.58 ± 
0.08 vs 0.81 ± 0.08, n=8, p<0.001). Thus, both type-I and type-IV collagens assisted in 
the decrease of up-regulated autophagy, by enhancing autophagosomes degradation.  
When compared with the LC3-II expression in MDM-ED that were treated with 
bafilomycin A1 (C & D), no difference was observed on the 3 surfaces. After the down-
regulation of autophagy on collagen dishes (A & B), there were active autophagic 
activities in MDM-ED and blockage of LC3 degradation revealed the underlying active 
LC3-II formation (C & D).  
Since the initial LC3-II expression was higher in cells on the TC dishes (A & B), the 
change of LC3-II (ΔLC3) was calculated to demonstrate the accumulation of LC3-II 
after bafilomycin treatment (E, G &H) during the 4 hours.  
Bafilomycin treatment had increased the LC3-II expression in MDM-ED on all the three 
dishes (F), which enabled the calculations of ΔLC3. 
When ΔLC3 was presented as a value of subtraction, the analysis showed no difference 
on the 3 surfaces (G). When ΔLC3 was presented as a percentage (F), it made the values 
more comparable to each other. Results (F) showed that ΔLC3% was significantly 
higher when MDM-ED were in contact with collagen-I than in the TC control (p<0.05). 
There was no difference in ΔLC3% between cells cultured on type-I and type-IV 
collagens or between cells cultured on type-IV and the TC control (1.14 ± 0.06 vs 1.01 
± 0.07 vs 0.84 ± 0.06, n=6).  
The ΔLC3% results suggested that 1) contact with collagen-I had increased the basal 
autophagy; 2) the existing up-regulated autophagy in MDM-ED on TC control (B) may 
have affected the formation of LC3-II in basal autophagy.   
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5.5 Summary and Discussion 
The interaction between ECM and the surrounding cells has been investigated intensely 
over recent years. Collagen-I is the most common type of fibrotic ECM found in late-
stage IPF [204] and it may influence macrophage autophagy and lead to important 
consequences. This study has demonstrated that ECM, particular type-I collagen, 
participates in both the formation and degradation steps of autophagy in macrophages. 
5.5.1 Macrophages may be refractory to autophagy 
induction through mTOR 
Normally, autophagy is rapidly induced by starvation or low concentration of 
rapamycin in different types of cells. However, this study shows starvation induced very 
weak LC3-II expression in RAW264.7 macrophages. LC3-II expression only became 
consistent and robust when macrophages were treated with relatively high 
concentrations of rapamycin.  
Starvation and rapamycin activate the autophagy pathway by inhibiting the mTOR 
[256]. In my experiments, both rapamycin- and starvation-induced LC3-II formation in 
macrophages, but this required relatively high concentrations of rapamycin (25 µM or 
higher). Lower concentrations of rapamycin (250 nM to 5 µM) was also used to induce 
autophagy in macrophages for 24 hours (additional results in Appendix-A), but the 
results were not reproducible and the LC3 expression was similar to that induced by 
starvation (Fig 5.1). In fact, in many other types of cells, LC3-II is successfully induced 
with 100 nM to 400 nM of rapamycin or by starvation for a period of 24 hours [485-
487]. It is known that low concentrations of rapamycin (0.5–100 nM) act through 
mTOR complex-1 (mTOR1) and high concentrations of rapamycin (0.2 µM and above) 
targets at mTORC2 [488]. In fact, the inhibition of both mTORC1 and mTORC2 
activates autophagy. mTORC1 is associated with autophagy which is induced by 
starvation, reduced growth factors and stress, whereas mTORC2 is responsible for the 
autophagy that is achieved by affecting autophagy gene expression mainly via a 
downstream transcription factor of Akt, i.e., FoxO3 [256]. High concentrations of 
rapamycin (10 µM and above, including 25 µM) has been used as positive controls of 
inhibiting mTOR, however, higher concentrations may also activate other mechanisms 
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that are independent of autophagy induction and need to be further understood [489]. 
Nevertheless, these data imply that macrophages may be relatively refractory to mTOR-
targeted autophagy or it may be related to the mTOR complexes and their functions 
within macrophages. 
In contrast, and consistent with other studies, LC3-II was found rapidly accumulated in 
macrophages when they were treated with bafilomycin A1 within a short period of time 
(4 hours) and at low concentrations [483, 490]. The rapid accumulation of LC3-II 
proteins implies that the formation of LC3 is active within the macrophages. Thus, the 
response of macrophages to starvation and rapamycin might appear to be refractory, but 
in fact, the autophagy machinery within macrophages is very active as demonstrated by 
blocking the downstream autophagy pathway by bafilomycin A1. 
A further observation that normal macrophages have enhanced autophagy machinery is 
that macrophages are abundant in lysosomes [491]. Autophagosomes, once formed, are 
directed to lysosomes and are then rapidly degraded. Lysosomes have been described 
as the “Achilles' heel” in the autophagy-lysosome pathway because disruption at this 
stage leads to a complete break-down in the autophagy machinery [492]. An abundant 
lysosomal stock suggests that macrophages have high capacities to support the very 
active formation and degradation of LC3-II proteins. 
5.5.2 Autophagy and macrophage differentiation 
In human THP-1 macrophages, consistent LC3-II expression was observed after the 
treatment with PMA. Adjusting PMA concentrations did not modify the increased LC3-
II expression. Other studies also have shown that the LC3-II expression was increased 
with PMA treatment, although Behura suggested that with 50 ng/ mL of PMA only 
limited LC3-II expression was detected [493, 494]. In neutrophils, the activation of 
autophagy is required for their production of neutrophil extracellular traps (NETs) 
which can be triggered by PMA through the PKC pathway [495, 496]. However, a study 
with HEK-263 cells showed that the inhibition of PKC increased LC3-II expression, 
but activation by PMA attenuated the conversion of LC-I to LC-II [497]. However, the 
mechanism of PMA induced autophagy needs to be further studied. 
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The exact mechanism for macrophage differentiation is not yet elucidated, but 
accumulating evidence suggested that autophagy may be involved. Many monocyte 
maturation strategies have increased autophagy in cells, such as vitamin D3 [498], GM-
CSF [499], PMA (Fig 5.6) [493, 494] and on the low-attachment surface (Fig 5.11). The 
activation of autophagy during macrophage differentiation is inevitable in these 
strategies but the mechanisms might be different. Though autophagy is observed in 
these conditions, it needs to be clarified whether autophagy is involved in the 
differentiation or the differentiation activates autophagy.  
5.5.3 LC3 proteins in human monocyte/ macrophages 
In this study, I found consistent LC3-I expression in RAW264.7 mouse macrophages, 
but not in human monocyte/ macrophages where LC3-I was not detected. In previous 
studies, LC3-I is found weakly expressed or absent in THP-1 cells [494] and human 
macrophages [478]. However, LC3-I was consistently present in THP-1 cells in the data 
presented by Behura [493]. The expression of LC3 proteins and their roles in monocyte/ 
macrophages needs to be better understood. 
In this study, different antibodies against human LC3 proteins were tested and LC3-I 
was not detected in human monocyte/ macrophages. In fact, the LC3 antibody worked 
very well with human Neuro-2A cell lysate, which was supplied from the supplier as 
the positive control, and both LC3-I and LC3-II proteins were consistently detected. 
Furthermore, lysate from rapamycin-treated HeLa cells, a human epithelial cell line, 
was also used to test the antibodies and both LC3-I and LC3-II were detected (data not 
shown). Increasing the exposure time for the luminescence detection step in western 
blotting did not reveal any expression of LC3-I (data not shown).  
There were very few occasions in these experiments when LC3-I was observed those 
were when MDM were left in “extreme” conditions such as treated with Bafilomycin 
A1 for 24 hours (data not shown). These “extreme” conditions may lead to cell death 
and in fact, dysregulation of autophagy is implicated in cell death [500]. These data 
suggested that in “normal homeostatic” conditions, LC3-I is rapidly conjugated to form 
LC3-II in macrophages. However, in “extreme” conditions more LC3-I proteins can be 
synthesized to enhance the autophagy pathway. The failure of the completion of 
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autophagy may lead to cell death [500]. Thus, in human macrophages, LC3-II is the 
“pro-survival” signal and LC3-I might be more relevant to the “pro-cell death” signal 
but need to be further studied. 
LC3-I converting to LC3-II requires other Atg proteins such as Atg4, Atg7, Atg5 and 
Atg12 [226]. Bafilomycin A1 blocked the fusion of autophagosomes but did not stop 
the conjugation of PE to LC3-I for LC3-II production. To better understand LC3-I and 
LC3-II in human macrophages, future work should probably focus on the Atg proteins 
responsible for the conjugation process. Nevertheless, a lack of LC3-I expression has 
been observed and the LC3-II proteins might be the major LC3 proteins in human 
macrophages in “normal homeostatic” conditions. These data suggest LC3 proteins may 
have unique functions in macrophages.  
5.5.4 ECM regulates LC3 formation and degradation 
The pathways linking ECM and autophagy remain elusive and the function of ECM in 
cellular biology is largely unknown. The cell surface integrins, lysosome motility and 
position, and soluble ECM may be relevant to the cross-talk between ECM and 
autophagy-lysosome pathway [215, 291].  
The integrin-mediated cell adhesion is required for many cellular processes [501]. The 
main mechanism of cell-matrix interaction is through integrins which are heterodimers 
of associated α subunit and β subunit [502]. There are 24 distinct integrins and they are 
clustered to form focal adhesions (FAs) on cell surface which are the areas for cell-
ECM adhesion [503]. A similar study to ours has shown that collagen-IV, not collagen-
I, had increased basal autophagy in HeLa cells. Silencing of the FA kinase (FAK) using 
siRNA had diminished the effect of increased autophagy in HeLa cells on collagen-IV 
[216]. The proposed mechanism is that FAK tyrosine phosphorylates an upstream 
mTOR regulator (TSC2) and thus suppresses the activation of mTOR and leads to 
autophagy activation [303]. The data in my study showed that contact with both type-I 
and type-IV collagens increased basal autophagy in macrophages, and collagen-I had a 
greater influence. The mechanism could also be related to the FAs that are formed when 
macrophages attached to collagen surfaces. 
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The detachment of epithelial cells from ECM (anoikis) induces autophagy and it is 
proposed as a mechanism to enhance cell survival and reattachment [291]. In fact, cells 
cultured on low-attachment surfaces have showed increased autophagy due to the lack 
of integrin adhesion [304, 305]. In this study, I also showed that the autophagy level 
was upregulated in human macrophages after the low-attachment differentiation (Fig 
5.11). Low-attachment and lack of FAs could be at least part of the reason of the 
upregulated autophagy. 
More interestingly, my data also suggested that ECM modulates LC3-II degradation as 
the upregulated autophagy in MDM returned back to the normal level rapidly in the 
presence of type-I and type-IV collagens. The degradation of LC3/autophagsosomes 
occurs when they fused with lysosomes. Adhesion to ECM promoted changes in cellular 
morphology [216] which can trigger the redistribution of lysosomes and enhance the 
motility of lysosomes [306]. The lysosome positioning includes the dynein-mediated 
retrograde transport of lysosomes which promotes their fusion with autophagosomes 
and eventually could enhance the degradation of LC3 [306].  
When macrophages attached to ECM, they do not just adhere, they can also digest ECM 
proteins by releasing MMPs and part of ECM can be recognized and engulfed by 
macrophages for further degradation [504-506]. The proteolysis of ECM by 
macrophages not only promote the degradation pathways within the cells, but also 
increase the production of bio-active peptides (termed ‘matrikines’) [507]. Proteolysis 
of collage-I and collagen-IV also generate matrikines and collagen-I derived  DGGRYY 
can activate human neutrophils [508]. Such bioactive peptide might also be able to 
mediate the autophagy pathway. For example, there is evidence that soluble matrix 
constituents can modulate the autophagy pathway both positively (eg. decorin, collagen 
VI and endostatin) and negatively (eg. laminin a2) [215]. 
In summary, ECM components actively regulate the autophagy pathway regarding both 
LC3-II formation and its degradation in macrophages. The underlying mechanisms and 
the effect on macrophage biology are yet to be addressed.  
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Chapter 6 Fibrotic ECM potentiates the 
impairment of the autophagy 




This study was designed to investigate the autophagy pathway in alveolar macrophages 
(AM) and determine the role of fibroblast-derived ECM in macrophage autophagy. 
A range of techniques was used to study the autophagy-lysosome pathway in AM from 
patients with interstitial lung diseases (ILD). Transmission electron microscopy (TEM) 
confirmed the presence of double-layer membrane autophagosomes in AM. Flow-
cytometry showed that AM were the major autophagic cells in the BAL fluid cell 
population. AM were purified by adhesion and rested ex vivo for 20 hours. With 
fluorescent microscopy, AM from fibrotic ILD patients were shown to have a 
significantly higher percentage of autophagic vacuole positive cells than AM from non-
fibrotic ILD patients (p<0.01). Western blotting showed increased LC3-II (p<0.001) 
and p62 (p<0.001) expression in fibrotic AM. TEM revealed the presence of 
membranous cytoplasmic bodies (MCBs) in fibrotic AM and dual staining of 
autophagic vacuoles and lysosomes showed co-localisation of these two structures. 
These data suggest that AM from fibrotic ILD have impaired autophagy through 
blockage of processing of autophagic vacuoles. 
Lung fibroblasts were purified from human lung biopsies with (fibrotic) or without 
(non-fibrotic) lung fibrosis. TEM confirmed the presence of synthesised 3-dimensional 
extracellular matrix (ECM) by primary lung fibroblasts in vitro. Culture of healthy 
monocyte-derived macrophages on ECM showed that fibrotic ECM increased both 
basal autophagy (p<0.05) and rapamycin-induced autophagy (p<0.001) in MDM but 
did not show ECM caused blockage of autophagy.  
This study demonstrated that the autophagy pathway was blocked in AM from patients 
with fibrotic ILD. Fibrotic ECM does not cause blockage of autophagy, but potentiates 
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the upstream autophagy pathway and thus may further impair macrophage function in 
cells that exhibit blockage of autophagy.  
6.2 Introduction 
Autophagy is a constitutive and continuous homeostatic process. It is a rapid process 
and in yeast an autophagy cycle takes about 7-9 minutes [253]. The formation of 
autophagosomes takes about 4-5 minutes in yeast and in mammals it takes about 5-10 
minutes [252-254]. Disrupted autophagy may have pathological consequences [229]. In 
fact, some of the pathological processes associated with lung fibrosis are known to 
activate autophagy, such as high levels of endoplasmic reticulum (ER) stress, elevated 
reactive oxygen species (ROS), significant low oxygen (hypoxia) and accumulated 
protein aggregates and/or malfunctioning cellular organelles. Exposure to these 
autophagy activators should provide the alveolar space with a “pro-autophagic 
microenvironment”. 
The association of autophagy with fibrosis is complex. Collagen and ECM deposition 
is a hallmark of IPF and other fibrotic lung diseases. In patients with IPF, previous 
studies have shown that autophagy is reduced, as measured by immunohistochemistry 
and western blotting of LC3 expression in whole lung tissue section or homogenate 
compared to patients with COPD [297]. In bleomycin-treated mice, rapamycin-induced 
autophagy decreased the level of hydroxyproline and alpha-smooth muscle actin (alpha-
SMA) and increased survival in treated mice [297, 298]. In a genetically manipulated 
Beclin-1 deficient mice model, lack of autophagy showed increased collagen deposition 
in mouse kidneys in vivo. Induction of autophagy by TFP, an autophagy inducer, in 
primary mesangial cells from these mice decreased TGF-β-induced collagen-I protein 
level in vitro [293]. There is evidence, however, that autophagy can be a “double-edged 
sword” in organ fibrosis. In liver fibrosis, enhanced autophagy can attenuate liver 
fibrosis by inhibiting tissue inflammation, but can also active hepatic stellate cells 
(HSCs) and increase collagen synthesis [299]. 
The autophagy pathway and fibrosis are thought to be linked but “the cause and effect” 
relationship needs to be better understood. Autophagy is tissue- and cell-dependent, and 
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autophagy may have distinct roles at different stages of fibrosis. There is very little 
information regarding the autophagy-lysosome pathway in AM in lung fibrosis.  
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Contact with extracellular matrix modulates the autophagy-lysosome pathway in AM 




 To assay the autophagy pathway in AM by multiple methods 
 
 To optimise the protocol of human lung fibroblast-derived ECM for in vitro 
studies 
 
 To determine the effect of lung fibroblast-derived ECM on the autophagy 
pathway in macrophages 
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6.4 Results 
In chapter 6, the autophagy pathway in AM was investigated using several methods. 
The autophagy structure, autophagosome, was identified and confirmed using TEM 
(Fig 6-1). The autophagy level of AM from ILD conditions with or without lung fibrosis 
was further studied with flow cytometry by the staining of autophagic vacuoles and LC3 
proteins (Fig 6-2). To stabilise the AM and reveal the function/dysfunction of the 
autophagy pathway, cells were rested for 20 hours before they were further studied. The 
percentage of autophagic vacuole positive AM (Fig 6-3) and the expression of LC3-II 
and p62 in AM from the fibrotic and non-fibrotic ILDs were compared (Fig 6-4). The 
results suggested a blockage of autophagosome degradation in AM from ILD patients 
with lung fibrosis. Furthermore, dysfunctional lysosomes were observed with TEM (Fig 
6-5 and Fig 6-6) and the colocalisation of lysosomes with autophagosomes confirmed 
the blockage of autophagosome degradation was primarily due to dysfunctional 
lysosomes (Fig 6-7). 
Then a few experiments were designed to understand the role of fibrotic ECM on the 
regulation of macrophage autophagy in fibrotic lungs. Lung fibroblasts were derived 
from lung biopsies with or without lung fibrosis. ECM was derived from these lung 
fibroblasts (Fig 6-8) and different ECM did not change the adhesion of MDM (Fig 6-9-
1). Finally, the effect of ECM on basal level autophagy (Fig 6-9-2) and rapamycin-
induced autophagy (Fig 6-10) in MDM were studied.  
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6.4.1 The presence of autophagosomes in alveolar 
macrophages were confirmed with TEM  
The observation of autophagosomes with TEM is the gold standard method to confirm 
the presence and occurrence of autophagy. AM from ILD patients were purified, fixed 
and examined under TEM. 
 
 
Figure 6-1 Presence of autophagosomes in AM were confirmed with TEM. 
AM in human BAL fluid were purified and fixed for TEM. Autophagosomes and autophagy-related 
double-layer membrane structures (autophagic vacuoles) were observed (arrowed). The presence of 
“classic” autophagosome containing cargos for degradation was also observed (top right insert). Scale 
bar = 200 nm. 
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Autophagosomes and autophagy-related double-layer membrane structures (autophagic 
vacuoles) were observed under TEM. “Classic” functional autophagosomes (Fig 6.1) 
were seen confirming the presence of an autophagy pathway in AM. Thus, the 
autophagy pathway in AM was further studied by quantitative methods in the following 
experiments.   
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6.4.2 AM were autophagic positive (Cyto-ID and anti-LC3 
staining)  
To determine the autophagy in BAL fluid cell populations, freshly isolated BAL fluid 
cells were stained with Cyto-ID or anti-LC3 antibody for the detection of autophagic 
vacuoles and the autophagy protein LC3.  
 
 
Figure 6-2 AM were autophagic positive (Cyto-ID and anti-LC3 staining). 
BAL fluid cells from ILD patients were stained with Cyto-ID or anti-LC3 antibody. (A) Cyto-ID 
negative gates were set-up with unstained cells; (B) Cyto-ID positive cells were presented against the 
unstained; (C) Cyto-ID positive cells (in red) were shown on the forward and side scatter profiles to 
identify autophagic-positive population (n=3); (D) alveolar macrophages were gated based on their 
sizes on the forward and side scatter profiles; (E) Macrophages were LC3 positive cells (LC3 stained, 
blue; secondary antibody control, red), average of LC3 positive cells 71.25 ± 4.91% (n=4). (F) AM 
from ID patients were LC3 positive, ** p<0.01, paired student t-test, n=4.  
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The BAL fluid autophagic positive cells were gated back on the whole population and 
they appeared at the location of AM (Fig 6.2 A-C).  
LC3 antibody staining (Fig 6.2 D & E) showed that the majority of macrophages were 
LC3 positive (71.25 ± 4.91% (mean ± SEM, n=4). The mean fluorescence of LC3 
staining was significantly higher than the (secondary only) control (4605 ± 717.3 vs 
850.0 ± 226.5, n=4). 
Flow cytometry showed that AM from ILD were ‘autophagic positive’ cells. Because 
these cells were freshly isolated from BAL, the induction of autophagy markers may 
have been due to the BAL procedure or sample handling.  
These data show that in AM from fibrotic ILD patients, there was increased LC3-II 
expression. The increased LC3-II expression could be the outcome of the increased 
autophagy induction, or the blockage of autophagosome degradation, or maybe both.   
To address this, autophagy expression was measured in purified alveolar macrophages 
that were firstly ‘rested’ in tissue culture for 20 hours. This strategy was to minimise 
the effect of autophagy activation that might have been triggered by the BAL procedures 
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6.4.3 AM from fibrotic ILD patients had an increased 
percentage of Cyto-ID positive cells  
 
 
Figure 6-3 AM from fibrotic ILD patients had an increased percentage of Cyto-ID positive cells 
than cells from non-fibrotic ILD patients 
AM were purified by adhesion and rested for 20 hours before the staining with Cyto-ID as described 
in section 2.3.6 in the Materials and Methods. Photos were taken and cells were analysed from at least 
4 frames of each sample. An average of positive cells was used for analysis and the diagnosis was 
revealed just before the grouping of samples. (A) Purified AM were stained with Cyto-ID. Solid circle, 
Cyto-ID positive (puncta≥3) and dashed circle, Cyto-ID negative (puncta<3). Top left insert, an 
example of an extremely positive cell, magnified (2.5×). (B & C) examples of Cyto-ID staining of AM 
from fibrotic and non-fibrotic ILD; (D) analysis of Cyto-ID positive cells, student t-test, ** p<0.01. 
Green, Cyto-ID stain; blue, Hoechst stain for nuclei; scale bar =200 µm (A) and 100 µm (B & C). 
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As shown in the example (Fig 6.3A), both the occurrence and sizes of autophagic 
vacuoles (puncta) were different among AM. For analysis, cells were regarded as Cyto-
ID positive only if they contained at least three puncta.  
AM from the fibrotic ILD had a higher percentage of Cyto-ID positive cells (Fig 6.3B) 
than the AM from non-fibrotic ILD (56.91 ± 3.11%, n=4 vs 29.60 ± 5.21%, n=6, 
p<0.01).  
Besides the live staining of autophagic-positive AM, the expression of LC3-II and p62 
was compared using western blotting.  
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6.4.4 AM from fibrotic ILD had increased LC3-II and p62 
expressions  
Protein lysates of AM were prepared after 20 hours of tissue culture. The expression of 
LC3-II and p62 was analysed by western blotting. 
 
 
Figure 6-4 AM from fibrotic ILD (FR) had increased LC3-II and p62 expressions than AM from 
non-fibrotic ILD (NF). 
AM were purified by adhesion, cells were rested for 20 hours before the extraction of proteins. The 
investigator was blinded from the diagnosis and the group of samples until analysing the data. (A) 
Western blotting probing for LC3-II, p62 and actin. (B & C) densitometry analysis of LC3-II and p62 
expressions. Control: Neuro 2A cell lysate. Student t-test, *** p<0.001, n=7. 
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Samples were described as ‘fibrotic’ (FR) or ‘non-fibrotic’ (NF) ILD according to the 
patients’ HRCT pattern as described in the introduction. The data were normally 
distributed and thus a student’s t-test was employed for statistical analysis.  
Densitometry analysis showed that in AM from the fibrotic ILD LC3-II and p62 
expression was significantly higher than that from the non-fibrotic ILD (LC3-II, 0.55 ± 
0.05 vs 0.16 ± 0.06, n=7, p<0.001) and p62 (0.41 ± 0.05 vs 0.14 ± 0.02, n=7, p<0.001).  
The increased P62 expression in fibrotic AM implies that autophagy-pathway blockage 
was at probably at least in part least in part responsible for the increased LC3-II 
expression. The blockage of autophagosome degradation could be because of the fusion 
of autophagosomes and lysosomes or it could be because of lysosomes dysfunctions. 
This is further explored in the following experiments. 
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6.4.5 Undigested cargos were observed in lysosomes in 




Figure 6-5 Undigested cargos were observed in lysosomes in AM from IPF lungs. 
Lysosomes with undigested cargos (arrowed) were observed in AM from an IPF patient under TEM, 
scale bar = 500 nm. 
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6.4.6 Membranous cytoplasmic bodies in AM were 
observed under TEM  
 
 
Figure 6-6 Membranous cytoplasmic bodies were observed under TEM in AM. 
(A) “Classic” Membranous cytoplasmic bodies (MCBs) with sheets of stacked membranes were 
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Classic membranous cytoplasmic bodies, with sheets of stacked membranes (Fig 6.6A), 
were observed in AM. MCB is evidence of dysfunctional lysosomes and they were in 
different shapes/ at different stages (Fig 6.6 B-D). CMBs were present in AM from both 
fibrotic (n=2) and non-fibrotic (n=2) ILD patients. 
The observation of undigested contents in (autophago)lysosomes and dysfunctional 
lysosome structures suggested a defect in the lysosomes. The localisation of autophagic 
structures and lysosomes were further studied with fluorescent microscopy. 
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6.4.7 Co-localisation of lysosomes and autophagic 





Figure 6-7 Co-localisation of lysosomes and autophagic vacuoles in AM suggested blockage of 
autophagosome degradation. 
Cells were processed as described in section 2.2.5 and 2.3.6 in the Materials and Methods before 
imaging. Briefly, AM were purified by adhesion and rested for 20 hours before the staining of 
autophagic vacuoles and lysosomes. (A) Cyto-ID channel (green); (B) LysoTracker channel (red); (C) 
fused of both channels (yellow). Scale bar = 100 µm. This is a representative of AM that purified from 
4 different patients.  
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AM were stained with Cyto-ID (Fig 6.7A, autophagic vacuoles) and LysoTracker (Fig 
6.7B, lysosomes). Co-localisation of lysosomes and autophagic vacuoles were observed 
(Fig 6.7 C) in Cyto-ID positive cells which suggested the incomplete degradation of 
autophagosomes in AM even after 20 hours of culture ex-vivo.  
Since the AM cells were rested for 20 hours after retrieval thus any form of functional 
autophagy should have been completed. These studies did not explain the contribution 
of the enhanced induction of autophagy to the increased autophagy in AM that are 
originally observed in fibrotic lungs. However, it clearly showed that the blockage of 
autophagy-degradation in AM in fibrotic lungs. Furthermore, the blockage of autophagy 
degradation was likely due to the lysosomes dysfunctions.  
In the following experiments, the role of ECM on the autophagy pathway was 
investigated with MDM form healthy volunteers. ECM was derived from primary 
human lung fibroblasts as described in section 2.3.7 and 2.3.8 in the Materials and 
Methods chapter. 
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Figure 6-8 Primary human lung fibroblast-derived ECM. 
Fibroblasts were cultured and processed for fluorescent imaging or SEM as described in section 2.3.7, 
2.3.8, and 2.2.6. Briefly, cells were cultured for another 3 days when became confluent to enhance 
ECM production. ECM structures were left in situ after decellularisation by repeated freeze-thaw 
cycles. (A) The over-confluent culture of human lung fibroblasts; (B) DAPI (blue) staining for the 
quality control of freeze-thaw de-cellularization; (C) After 6 freeze-thaw cycles, cells were removed 
and confirmed by DAPI stain; (D) fibroblast-derived ECM were observed under SEM. Scale bar = 200 
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The extracellular matrix structures derived from lung fibroblasts were confirmed by 
SEM. After the decellularisation (Fig 6.8 A-C), ECM derived from fibroblasts showed 
an interconnected meshwork of macromolecules (Fig 6.8 D). 
Using this method, fibroblast-derived ECM was produced and used in the following 
experiments. Firstly, the effect of the structures on macrophage adhesion was compared 
between ECM derived from fibrotic and non-fibrotic fibroblasts. Then, the effect of 
different ECM on basal and rapamycin-induced autophagy was investigated. 
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6.4.9 Fibrotic ECM did not affect the attachment of MDM 




Figure 6-9-1 Fibrotic ECM did not affect the attachment of MDM. 
Macrophages were acquired with the easy-detach method (MDM-ED) then plated on ECM derived 
from fibrotic (n=3) and non-fibrotic (n=3) fibroblasts. After adhesion for 24 hours, non-adherent cells 
were washed away with PBS before the images were taken. The number of cells in each frame was 
counted and an average of 4 frames of each sample was used for analysis. (A) MDM-ED attached to 
non-fibrotic ECM; (B) MDM-ED attached to fibrotic ECM; (C) analysis of the numbers of attached 
MDM-ED per image. Fibrotic vs non-fibrotic = 108.0 ± 8.1 vs 90.67 ± 6.8, n=3, p=0.18, student’s t-
test, scale bar = 200 µm. 
  





Figure 6-9-2 Fibrotic ECM increased basal LC3-II expression in MDM. 
MDM-ED were seeded on human lung fibroblast-derived extracellular matrix. Cells were treated as 
indicated for 4 hours and proteins were extracted for Western Blotting. (A) Western Blot for p62, LC3-
II and actin; (B & C) densitometry analysis of p62 and LC3-II; (D & E) densitometry analysis of 
∆LC3-II (in subtraction and percentage). NF: non-fibrotic ECM; FR: fibrotic ECM. B: bafilomycin 
A1, 50 nM. C: vehicle control (DMSO in complete IMDM as Baf. A1 50 nM); *p<0.05, ** p<0.01, 
n.s. not significant, one-way ANOVA with Tukey's Multiple Comparison Test (B & C) and student t-
test (D & E). 
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The expression of p62 was probed as an experimental control for the effectiveness 
(autophagosome blockage) of bafilomycin A1 treatment (Fig 6-9-2 A & B). The p62 
expression was significantly increased in MDM-ED that were treated with Baf. A1 
(Baf-NF vs con-NF = 1.55 ± 0.23 vs 1.00 ± 0.17, p<0.01, n=3 and Baf-FR vs con-Baf, 
1.85 ± 0.16 vs 1.10 ± 0.20, n=4, p<0.05). 
More importantly, there was no difference in p62 expression in MDM on non-fibrotic 
and fibrotic ECM when they were cultured in control media. This showed that fibrotic 
ECM itself did not block the degradation step of the autophagy pathway as the p62 
expression was the same. 
LC3-II protein was not detected in MDM-ED cultured in the control medium (Fig 6-9-
2 A & C). There was no difference between the cells that were cultured on non-fibrotic 
and fibrotic ECM (con-NF, 1.00 ± 0.19, n=3 vs con-FR, 1.10 ± 0.20, n=4, Fig 6-9-2 C). 
This suggested that fibroblast-derived ECM alone did not induce LC3-II expression.  
The LC3-II expression was significantly increased in MDM on fibrotic ECM after 
bafilomycin A1 treatment (Fig 6-9-2 A & C): con-FR vs Baf-FR = 0.91 ± 0.07, n=3 vs 
4.04 ± 1.01, n=4, p<0.05, suggesting enhanced autophagy in MDM. In contrast, this 
was not observed in cells on non-fibrotic ECM (con-NF vs Baf-NF = 1.00 ± 0.08 vs 
1.33 ± 0.37, n=3). Furthermore, the LC3-II expression after bafilomycin A1 treatment 
was significantly higher on fibrotic ECM than the non-fibrotic ECM (Baf-FR vs Baf-
NF = 4.04 ± 1.01, n=4 vs 1.33 ± 0.37, n=3, p<0.05). This suggested that the formation 
of LC3-II through basal autophagy in MDM was increased on fibrotic but not non-
fibrotic ECM. 
The change in LC3 (∆LC3) expression between control and bafilomycin A1-treated is 
another way of describing these data. ∆LC3 is presented as whole values (Fig 6-9-2 D) 
and as a percentage (Fig 6-9-2 E). Fibrotic ECM increased ∆LC3-II compared with non-
fibrotic ECM: 3.22 ± 0.912, n=4 vs 0.29 ± 0.39, n=3, p<0.05 and ∆LC3%, 68.06 ± 
13.31%, n=4 vs 12.18 ± 23.41%, n=3, p=0.07. This confirmed the increase in LC3 
expression in MDM cultured on fibrotic ECM.  
Collectively these data show that fibrotic ECM increased the basal autophagic activity.  
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6.4.10 Fibrotic ECM increased rapamycin-induced 




Figure 6-10 Fibrotic ECM increased rapamycin-induced autophagy in MDM. 
MDM-ED were seeded on human lung fibroblast-derived ECMs. MDM-ED were treated as indicated 
for 4 hours and proteins were extracted for Western Blotting. (A) Western Blot for p62, LC3-II, and 
actin; (B & C) densitometry analysis of p62 and LC3-II; (D & E) densitometry analysis of ∆LC3 (in 
subtraction and percentage). B/Baf: Bafilomycin A1, 50 nM. RB/R+B: rapamycin (25 µM) with Baf. 
A1 (50 nM); NF: non-fibrotic ECM; FR: fibrotic ECM. **p<0.01, *** p<0.001, n.s. not significant, 
one-way ANOVA with Tukey's Multiple Comparison Test (B & C) and student t-test (D & E). 
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As shown in Fig 6-10-C, the basal LC3-II expression (bafilomycin A1 alone) was 
significantly higher on fibrotic ECM when compared with the non-fibrotic ECM (Baf-
FR vs Baf-NF= 2.37 ± 0.14, n=4 vs 1.00 ± 0.25, n=3, p<0.01). This confirmed the results 
presented in Fig 6-9-2 and showed fibrotic ECM increased basal autophagy. 
The rapamycin-induced LC3-II expression on fibrotic ECM was higher than that on 
non-fibrotic ECM (RB-FR vs RB-NF=3.68 ± 0.16, n=4 vs 1.88 ± 0.33, n=3, p<0.001). 
This showed that fibrotic ECM potentiated rapamycin-induced autophagy in MDM.  
When autophagy was induced with rapamycin, however, p62 expression was also 
increased significantly when compared cells cultured on fibrotic ECM versus non-
fibrotic ECM (RB-FR vs RB-NF = 1.30 ± 0.07, n=4 vs 0.95 ± 0.01, n=3, p<0.01). This 
suggested that more p62 may have been recruited for selective autophagy on fibrotic 
ECM when the autophagy pathway was activated. 
Collectively these data show that fibrotic ECM enhances or potentiates the upstream 
autophagy pathway (increased LC3-II expression) and that if the downstream 
autophagy pathway is blocked, fibrotic ECM exacerbates autophagy impairment as 
shown by increased autophagosome accumulation  (LC3-II and p62 expression). 
There was p62 expressed in all conditions. Densitometry showed p62 expression was 
not significantly different when cells were cultured on the same surface: Baf-NF vs RB-
NF =1.00 ± 0.17 vs 0.95 ± 0.01 (n=3) and vs Baf-FR vs RB-FR = 1.34 ± 0.08 vs 1.30 ± 
0.07 (n=4). This means that on both fibrotic ECM and non-fibrotic ECM, the blockage 
of autophagy was successful and adding rapamycin to bafilomycin did not recruit more 
p62. 
The change in LC3-II (∆LC3) was not significantly different between the fibrotic and 
non-fibrotic ECM: ∆LC3, 1.31± 0.19, n=4 vs 0.88 ± 0.40, n=3 and ∆LC3 %, 35.33 ± 
4.06%, n=4 vs 43.60 ± 14.27%, n=3. This suggested that LC3-II expression triggered 
by rapamycin were the same on both fibrotic and non-fibrotic ECMs. The higher LC3-
II expression by rapamycin on fibrotic ECM was due to the nature of the fibrotic ECM 
and its effect on basal autophagy in MDM. 
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6.5 Summary and Discussion 
The autophagy pathway in IPF is not fully understood. My study has shown that AM 
from fibrotic ILD patients had increased LC3-II and p62 expression which was 
primarily due to the blockage of autophagosome degradation. The colocalisation of 
autophagosome and lysosome suggested the fusion of the two compartments was not 
compromised. Thus, the blockage of autophagosome degradation was most likely the 
consequence of dysfunctional lysosomes.  
Both fibrotic and non-fibrotic ECM facilitate the damping of upregulated autophagy 
and they do not cause blockage of the autophagy pathway. Fibrotic ECM also promotes 
basal LC3-II formation, and in the setting of dysfunctional lysosomes, the increased 
basal autophagy may exacerbate the impairment of the autophagy pathway. 
6.5.1 AM express markers of autophagy in the fibrotic lung 
Autophagosomes were observed in AM from ILD patients by TEM which is the gold 
standard method for the confirmation of the presence of autophagy. TEM is not readily 
quantifiable. Staining with Cyto–ID and LC3 proteins in fresh BAL fluid cells 
demonstrated that AM were positive in autophagic vacuoles and LC3 staining. On 
average over 70% of AM were LC3 positive in fresh AM from ILD patients. Autophagy 
could have been activated by lavaging and processing the BAL fluid cells. However, 
autophagy is a rapid process, and leaving cells in a unstimulated condition will quickly 
help them return to their basal status [257-260]. In order to reveal the genuine autophagy 
level in AM, purified AM were rested in tissue culture for 20 hours. Even after the 20-
hour incubation, Cyto-ID showed significantly increased staining of autophagic vacuole 
positive cells and significantly increased LC3-II expression in AM from fibrotic ILD 
patients. 
Previous studies showed that the ‘autophagy level’ was decreased in IPF lung tissue 
[297, 301]. Whole lung tissue section or homogenate from IPF patients had decreased 
levels of LC3 and p62 as determined by western blotting and fluorescent microscopy 
[297]. Immunohistochemistry staining also showed similar results but with no 
expression of autophagy markers in (myo)fibroblasts or type-I epithelial cells, but the 
accumulation of p62 was specifically increased in type-II epithelial cells within the 
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fibroblastic foci (FF) [301]. Although AM were not specifically described in this study, 
immunohistochemistry (IHC) images of IPF tissue in this paper showed p62,  ubiquitin 
and beclin expression in AM, similar to that in type-II epithelial cells [301]. A mTOR 
downstream effector protein, p-S6, was weakly expressed in healthy lungs but was 
found strongly expressed in IPF lung myofibroblasts suggesting an activation of mTOR 
signalling in IPF lungs which suppressed autophagy induction [298]. Again in this study 
AM were not specifically described in the paper which only included a small number 
of IPF tissue samples [298]. My results showed that AM had increased LC3-II and p62 
in fibrotic lungs, suggesting the occurrence of autophagy in these cells. My data also 
suggested that the contact with ECM can alleviate the upregulated autophagy. The low 
expression of autophagy-related proteins seen in the lung tissues from other studies 
could be because of contact with tissue ECM, and our in vitro studies of macrophages 
suggest that ECM modulated autophagy to maintain a low and homeostatic level. 
6.5.2  Lysosome dysfunction, the primary cause of 
impaired autophagy in AM 
In this study, I showed that MCBs are present in the AM of patients with ILD. These 
MCBs are the hallmark evidence of dysfunctional lysosomes. It is known that MCBs 
are related to conditions with dysfunctional lysosomes such as lysosomal storage 
disorders (LSDs) [509]. Studies showed that the accumulation of lipid body like 
structures in leucocytes, such as alveolar macrophages, is relevant in infection, cancer, 
and inflammation [510, 511]. The frequent observation of MCBs in AM suggested that 
the lysosome-degradation pathway was impaired. In these AM, lysosomes had 
difficulty in processing the cellular waste that had been delivered to them. Macrophages 
from only 4 ILD patients (n=2 with fibrosis, n=2 without fibrosis) were studied for the 
presence of MCBs so it cannot be determined if the presence of MCB correlates or is 
associated specifically with fibrosis or if MCBs are not present in healthy AM.  
Macrophages express a range of factors mediating iron uptake and they play important 
roles in maintaining systemic iron homoeostasis [512]. Iron overload causes 
macrophage dysfunction, decreased cellular chemotaxis and phagocytosis [513, 514]. 
Kao and colleagues showed that the chronic iron overload increased lysosomal pH and 
caused an increased number of dysfunctional lysosomes which led to blockage of 
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autophagosome degradation with increased LC3-II and p62 expression [515]. In our 
group, we had shown increased expression of CD71 in AM from IPF patients which 
was also associated with disease progression [65]. CD71, also known as transferrin-
iron-transferrin receptor-1 (TfR-1), is widely expressed in macrophages and it is 
proposed as a major route of iron uptake in the absence of RBC by mediating diferric 
transferrin endocytosis [516]. Thus, the increased CD71 which leads to chronic iron 
overload might be an underlying mechanism for lysosome dysfunction in AM in IPF. 
The co-localisation of autophagic vacuoles and lysosomes was further evidence that the 
degradation step via lysosomes was impaired. Incomplete autophagosome degradation 
may either be the cause or the outcome of the accumulated MCBs in AM. Incomplete 
autophagosomes degradation may lead to repeated “capture-degradation” cycles which 
could lead to pathological consequences in AM (Fig 6.6-C). It is likely that the 
accumulation of autophagosomes was the outcome of dysfunctional lysosomes. The 
fusion of autophagosome and lysosome was not affected, however, this needs to be 
further studied. 
The increased accumulation of autophagosome could also cause further lysosome 
damage by being an excessive waste burden. In fibrotic lungs, the rapid assembly of 
LC3-II in contact with fibrotic ECM in the setting of dysfunctional lysosomes may 
cause further accumulation of autophagosomes. The newly formed cellular waste 
(excessive autophagosomes) may lead to a pathological “capture-degradation cycle” 
and cause further damage to lysosomes.  
As mentioned, autophagy can be activated in by many factors among which smoking 
and ageing are most relevant to IPF. In fact, as shown in Fig 6.3, there were autophagic 
positive cells in both groups. These autophagic cells after resting in tissue culture 
suggested common autophagy-inducing factors in both groups which might be smoking 
and ageing. As shown in Appendix-B (Fig A-2), there was no difference in smoking or 
age in the participants in the fibrotic and non-fibrotic groups. Thus, the increased LC3-
II expression and blocked autophagosome degradation observed in fibrotic AM were 
the results of other factors such as lysosomal dysfunction as shown in this study.  
Nevertheless, both smoking and ageing could be contributing factors that lead to the 
observation in the established lung fibrosis. 
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6.5.3 Impaired autophagy-lysosome pathway may lead to 
other functional consequences in AM 
Gaucher disease is a type of LSDs that mainly affects macrophages. It is caused by the 
systemic lack of lysosomal hydrolase β-glucocerebrosidase and with glucocerebroside 
restricted to the monocyte/macrophage lineage [509]. Gaucher macrophages (GMs) are 
shown as distinct “alternative” activated macrophages and do not express pro-
inflammatory cytokines, such as tumour necrosis factor α, IL-6, IL-1β and IL-10 in 
patients’ spleen tissues [517]. They are skewed towards the “alternative” activated 
macrophages as they expressed CCL18 and interleukin-1 receptor antagonist and 
CD163 by IHC staining [517]. Recently studies have shown that GMs are efficient in 
phagocytosis but compromised in reactive oxygen species production and have 
impaired chemotaxis [518]. Upon phagocytosis, GMs have decreased expression of 
Atg16L1 and increased expression of p62 which suggest impaired autophagy in these 
macrophages [519]. There is evidence showing different lysosome phenotypes 
modulate the function of peritoneal and bone marrow-derived macrophages from mice 
[520]. Thus the changes shown in AM in the present study could be the causes of the 
properties in AM in the fibrotic lungs.  
Impaired macrophage autophagy affects macrophage immune response and may 
promote inflammation [521]. Autophagy also affects cell death and is relevant to pre-
apoptotic signals due to the accumulation of damaged mitochondria which should be 
removed by autophagy [522]. It is known that AM from IPF patients release a variety 
of mediators and growth factors that may be pro-fibrotic [71] and impaired autophagy 
could be an underlying mechanism.  
Thus, impaired autophagy-lysosome pathway in AM from IPF patients may create an 
environment that favours fibrosis. The cause of impaired autophagy in AM needs to be 
further studied. It may be that the fibrotic environment results in blocked autophagy or, 
alternatively, impaired autophagy may be the cause of lung fibrosis. Indeed some rare 
lysosomal disorders do cause ILD [523], although none of these has been shown to 
cause usual interstitial pneumonia (UIP) which is the pathological phenotype that is 
associated with IPF.  
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6.5.4 Fibrotic ECM potentiates autophagy-lysosome 
dysregulation and assist in autophagy degradation  
As shown, contact with ECM modulates macrophage autophagy in vitro: 1) it reduces 
autophagy level (LC3-II expression) that is otherwise apparent in freshly isolated cells 
cultured on low attachment flask; 2) specifically fibrotic ECM enhances both basal 
autophagy and mTOR-dependent autophagy; and 3) fibrotic ECM does not specifically 
block autophagy but enhanced autophagy may be the mechanism for the increased 
recruitment of p62.  In this case, p62 functions as an autophagy cargo receptor (termed 
selective autophagy) and mediates the degradation of ubiquitinated cargo material such 
as aggregated proteins or intracellular infective organisms [524]. 
Lung fibrosis occurs when the synthesis and degradation of ECM are dysregulated [175]. 
Formation of ECM is also dependent on the proliferation, activation and apoptosis of 
fibroblast which is the major cell for ECM production [176]. In IPF besides the 
excessive accumulation of the ECM, the components of ECM also changed. At the later 
stage of IPF, type-I collagen is found increased and type-IV collagen is found decreased 
[204]. As described in chapter-5, I had also shown the regulation of autophagy by 
collagen-I and collagen-IV in vitro and the effect of fibrotic ECM on autophagy is 
similar to collagen-I as presented here. Furthermore, the effect of adhesion molecules 
(e.g. integrins), morphology changes during the attachment to ECM and bioactive 
peptides (generated by ECM proteolysis) have already been discussed (chapter-5). 
However, the formation of fibroblast-derived ECM is more complex and versatile. My 
studies presented here used fibroblast-derived ECM from fibrotic and normal 
fibroblasts which is a highly relevant model to study ECM [525]. The specific properties 
of the fibrotic ECM need to be further elucidated and many factors should be considered. 
The stiffness of ECM [208], the organisation and orientation (e.g. cross-linking) of 
ECM [175], post-translational modifications [175, 209] and other physical/mechanical 
changes that may be different between the fibrotic ECM and the non-fibrotic ECM. 
Therefore, these factors could contribute to the regulation of autophagy by fibrotic ECM. 
In fact, IPF fibroblast-derived ECM can change the gene expressions of the fibroblast 
itself and form a positive feedback-loop of fibrosis [155].  The exact mechanism of 
fibrotic ECM in the regulation of autophagy still needs to be further understood. 
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Fibrotic ECM does not cause the blockage of autophagy pathway in vitro but increased 
the basal autophagosome formation. The increased autophagy in AM in IPF patients is 
associated with impaired lysosomes. It is possible that the impaired autophagy observed 
in fibrotic AM is a result of lysosomal dysfunction is similar to that observed in primary 
LSDs. Although specific lysosomal-disorder genetic defects have not been identified in 
IPF, the damage to lysosomes could be secondary to 1) factors in the local micro-
environment in the fibrotic lungs (hypoxia and ER stress); 2) external factors (smoking, 
dust, inhalation of other materials or virus infection); and 3) host factors such as 
polygenetic traits and ageing [17]. More likely, all these factors may contribute to 
lysosomal dysfunction and lung fibrosis. 
The persistent active basal autophagy in the setting of excessive fibrotic ECM could 
have different roles at different stages of fibrosis: 1) in the early stages of injury, with 
intact lysosomes, activation of basal autophagy leads to reduced cellular stress and 
maintains cellular homeostasis in AM; 2) in the later stages of established lung fibrosis 
where there is lysosomal impairment, the continuous activation of autophagy leads 
paradoxically to AM dysfunction and potentially a pro-fibrotic cellular phenotype.  
To summarise, there is impaired autophagy in AM from fibrotic ILD which is caused 
by the blockage of autophagosome degradation due to dysfunctional lysosomes. ECM 
actively regulates autophagy in macrophages and contact with fibrotic ECM potentiates 
autophagy dysfunction by enhancing autophagosome formation through upregulated 
basal autophagy. Furthermore, lysosomal impairment, rather than autophagy induction 
or inhibition, may be a therapeutic target in IPF. 
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Chapter 7 Autophagy regulates exosome 




In this study, I examined the effect of altered autophagy on exosome secretion in 
macrophages and studied the profile of alveolar exosomes in IPF patients. 
There were less multi-vesicular bodies (MVBs) observed in fibrotic AM (from fibrotic 
ILD) than non-fibrotic AM (from non-fibrotic ILD) under TEM. AM released 
extracellular-vesicles (EVs) ex vivo which were confirmed by TEM and SEM. 
Furthermore, the anti-CD9 bead-based flow cytometry assay showed that alveolar EVs 
expressed the exosome marker CD63. NTA analysis showed that fibrotic AM released 
less exosomes ex vivo than non-fibrotic AM (p<0.05).  
In fresh BAL fluid, samples from fibrotic ILD showed consistent low level of exosomes 
and was 2.7 times lower than that in the samples from non-fibrotic ILD (p<0.001). 
Exosomes pelleted from the same volumes of BAL fluid showed lower concentrations 
of both total exosomal protein (p<0.05) and total exosomal RNA in fibrotic ILD 
(p<0.05). In a small cohort (n=12), the baseline level (0-month) of alveolar exosomes 
was lower in the progressed IPF patients than that in stable IPF patients (p=0.07). 
However, the changes in alveolar exosome levels between 0-month and 12-month were 
not significant (p>0.05). Human peripheral blood monocyte-derived macrophages 
(MDM) release exosomes in vitro and this was affected by the modulation of the 
autophagy pathway with rapamycin and bafilomycin A1. 
Alveolar exosomes from ILD patients did not express monocyte/macrophages surface 
markers which included CD14, CD16, HLA-DR, Mac-2 and CD206. Pelleted alveolar 
exosomes can be internalised into MDM which decreased the original exosome level in 
the culture media (p<0.001) and increased LC3-II expression in MDM.  
In summary, impaired autophagy in AM affected their exosome secretion ex vivo which 
might contribute to the low levels of alveolar exosomes in the fibrotic lungs in humans 
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that may be associated with disease progression in IPF. Autophagy and exosomes may 
be new targets for the management of IPF. 
7.2 Introduction 
 
Exosomes are small EVs (most commonly 40 nm to 100 nm in size) that are released 
when MVBs are directed to fuse with the plasma membrane [324]. They serve as 
mediators of cell-to-cell communication through their cargo proteins and RNAs. 
Exosomes are classified as a homogeneous population and they express a group of 
conserved but distinct proteins such as tetraspanin protein CD9, CD63 and CD81 [324, 
361]. Furthermore, the cellular membrane proteins could also be integrated on 
exosomes during endosome formation [331]. Exosomes can also carry and spread 
disease-relevant proteins, for example, the amyloid protein can be found on exosomes 
in Alzheimer diseases [377].  
Exosomes are produced via the endosomal pathway and they also interact with the 
autophagy-lysosome pathway [348, 349]. Identification of the amphisome, a structure 
when the autophagosome fuses with the endosome, was the first piece of evidence 
linking autophagy and the exosome pathway [350]. More recently, there is direct 
evidence showing Atg12 and Atg3 interact with Alix, an important protein of the 
endosome pathway, to promote basal autophagy and regulate the fusion of 
autophagosomes and MVBs [357].  
Normally, MVBs are either directed to the plasma membrane (released as exosomes) or 
to lysosomes (for degradation). Any changes in the autophagy-lysosome pathway could 
affect exosome secretion. Fader and colleagues showed that autophagy induction 
promoted the fusion of MVBs with autophagosomes and therefore decreased the 
secretion of exosomes in K562 cells [353]. On the other hand, blockage of 
autophagosome-lysosome fusion by bafilomycin A1 increased the secretion of 
exosomes [354-356]. Furthermore, in conditions of lysosomal dysfunction, MVBs are 
more likely to be directed away from lysosomes to the plasma membrane and eventually 
increases the exosomes secretion [327]. The release of exosomes has been proposed as 
a mechanism to compensate for the removal of toxic proteins when the lysosome 
pathway is dysfunctional. More evidence is emerging from the studies in lysosome 
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storage disorders (LSDs) and certain neurodegenerative diseases to support exosomes 
as a mechanism to alleviate cellular stress [327] 
Exosomes have been proposed as a useful tool for diagnostic and therapeutic purposes 
in kidney and liver fibrosis [318, 424]. TGF-β1, a key mediator of fibrosis, has been 
found enclosed in exosomes upon epithelial injury in a kidney model. These TGF- β1 
enclosed exosomes further increased tissue injury [425]. Exosomes are proposed as 
potential biomarkers for the diagnosis of lung cancer and other pulmonary diseases 
[317] but little is known in lung fibrosis. A small study in IPF showed that in serum 
exosomes the expression of miR-141 (anti-fibrotic) had decreased and the miR-7 level 
(fibrogenic) had increased [422]. 
In fibrotic lungs, accumulating evidence suggests that the autophagy-lysosome pathway 
which has a regulatory role in the exosome secretion is impaired [97, 297, 301]. 
Furthermore, my data showed that in fibrotic AM the autophagy-lysosome pathway is 
blocked (chapter-6). Thus, the exosome biogenesis in AM and the overall exosomal 
profile in the fibrotic lungs might both be affected and require further investigation. 
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 Impaired autophagy-lysosome pathway in AM affects their exosome secretion  
 
 Impaired autophagy in fibrotic lungs affects alveolar exosome levels 
 






 To determine the pattern of AM-released EVs from ILD patients ex vivo 
 
 To determine the level of exosomes in BAL fluid retrieved from ILD patients 
 
 To determine the association of exosome level and disease progression in IPF 
 
 To determine the effect of autophagy modulation on exosome secretion in MDM 
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7.4 Results 
In this chapter, I first demonstrated the presence of MVBs in AM along with the 
autophagosomes and MCBs (Fig 7-1). The number of MVBs may be less in fibrotic 
AM than non-fibrotic AM (Fig 7-2). Thus, the effect of the impaired autophagy-
lysosomes pathway on exosome release was further investigated.  
The secretion of EVs by AM ex vivo was confirmed under TEM and SEM (Fig 7-3). 
AM-derived EVs were captured by anti-CD9 beads and they were CD63 positive (Fig 
7-4). Fibrotic AM released less exosomes ex vivo measured by NTA analysis (Fig 7-4). 
These results led to the question of whether the total exosome level was decreased in 
the fibrotic lungs in general.  
To address this, BAL fluid exosome level was determined with fresh samples by NTA 
analysis (Fig 7-5). The level of alveolar exosomes from fibrotic ILD was consistently 
low and was 2.7 times less than that in non-fibrotic ILD (Fig 7-6). Furthermore, 
exosomes pelleted from the same volumes of BAL fluid (Fig 7-6) showed lower 
concentrations of total exosomal protein and total exosomal RNA in fibrotic ILD.  In a 
small cohort (Fig 7-7, n=12), progressed IPF showed lower baseline (0-month) alveolar 
exosome level than stable IPF. However, the changes of alveolar exosome levels 
between 0-month and 12-month were not different.  
Thereafter, the origin of BAL fluid exosomes was investigated by targeting the 
monocyte/macrophage surface markers (Fig 7-8). Results showed that they did not 
express CD14, CD16, HLA-DR, Mac-2, 25F9 or CD206 on their surface.  
Finally, in vitro experiments were designed to understand the role of autophagy on 
exosome release in MDM. Mimicking the observation in AM, MDM were treated with 
rapamycin (with or without bafilomycin A1) which showed increased MVBs under 
TEM (Fig 7-9) and increased exosomes in the culture medium (Fig 7-10). 
Finally, to study the function of alveolar exosomes, the pelleted BAL fluid exosomes 
were found internalised by MDM (Fig 7-11) and increased LC3-II expression in MDM 
was observed (Fig 7-12).    
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7.4.1 Impaired autophagy and dysfunctional lysosomes in 
AM may affect their secretion of exosomes  
 
 
Figure 7-1 Impaired autophagy and dysfunctional lysosomes in AM may affect their secretion of 
exosomes. 
The key compartments of exosome machinery (MVBs), autophagy-lysosome pathway 
(autophagosomes) and dysfunctional lysosome (MCBs) were observed besides each other in AM by 
TEM, scale bar = 100 nm. 
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Figure 7-2 AM from fibrotic ILD may have less MVBs. 
As shown in the example TEM images, fibrotic AM (B) had less MVBs than non-fibrotic AM (A), 
scale bar = 0.5 µm (A) and 200 nm (B). Representative images of patient samples who were diagnosed 
with fibrotic ILD (n=2) and non-fibrotic ILD (n=2). 
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Figure 7-3 AM-released EVs were confirmed by TEM and SEM. 
AM-released EVs were confirmed by TEM (A) and SEM (B). Scale bar = 200 nm (TEM) and 2.0 µm 
(SEM). 
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EVs (arrowed) appeared to be released from the cell surface as determined by TEM (A) 
and SEM (B).  
In the TEM image, the released vesicles had clear boundaries with the cell membrane 
which suggested that they were not any surface structures of the cell but released from 
the cell. Compared to the scale bar, the diameters of the vesicles were approximately 
100 nm, which is the size of exosomes by definition. Of note, part of the autophagosome 
(isolation membrane/ phagophore, arrowed) was also observed in the same cell. 
EVs of different sizes released by AM were observed under SEM. Compared to the 
scale bar (2.00 µm), the sizes of EVs were variable and the majority of them were 
around 200 nm (small vesicles). Larger vesicles were also observed which had reached 
around 600 nm in diameter. This suggested that the released vesicles from AM ex vivo 
were a mixture of EVs which included: exosomes (40 nm to 100 nm) and microvesicles 
(100 nm to 1,000 nm).  
The results from electron microscopy studies suggested that there might be more MVBs 
within the fibrotic AM and the release of different extracellular vesicles by the AM was 
active. The level of exosomes released by AM ex vivo was further studied using 
quantitative methods. 
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Figure 7-4 AM from fibrotic ILD released less exosomes ex vivo. 
The same number of cells (0.5×106) were seeded in a 24-well plate and cultured for 20 hours before 
replacing with fresh medium (0.5 mL) and cultured for 4 hours. After the 4-hour incubation with AM, 
culture medium was collected and the cells were lysed in 120 µL RIPA buffer and the supernatant was 
collected for protein assay. (A) CD63 was expressed on CD9-beads captured EVs released by AM; 
(A1) CD9-beads selection in control medium; (A2) CD9-beads selection in the supernatant of AM 
cultured medium. (B) Exosome levels in AM cultured medium was determined by NTA (4 
measurements of each sample) and represented as the mean of the area under curve (AUC) of vesicles 
with the sizes between 40 nm - 100 nm. *p<0.05, **p<0.01, ***p< 0.001, n.s. not significant. One 
way ANOVA, Tukey's Multiple Comparison Test. 
(  
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Anti-CD9 beads flow cytometry assay showed that these vesicles expressed the 
exosome marker CD63 (A). The number of exosomes (B) released into the culture 
medium by fibrotic AM was less than the non-fibrotic AM (62.43 ± 10.20 vs 121.50 ± 
24.62, n=6, p<0.05).  
As AM are the dominant type of cell in the alveolar space, the different pattern of 
exosome secretion of AM might affect the level of exosomes in the lungs at real time. 
To test this hypothesis, fresh BAL fluid samples were collected from patients and 
analysed with NTA or exosomes were pelleted and the total protein and RNA were 
compared in the following experiments. 
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Figure 7-5 Measurement strategy and quality control of exosome study with NTA. 
Normal distribution of BAL fluid vesicles. Each sample was measured at least 6 times and the area 
under curve of 40 nm - 100 nm was calculated to represent the exosome level and was used for analysis. 
(B) Small vesicles were the major EVs in the BAL fluid. Intensity against particle size: low level (blue 
& short), high level (red & tall).  
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7.4.6 BAL fluid from fibrotic ILD had low levels of 





Figure 7-6 BAL fluid from fibrotic ILD had low levels of exosomes, total exosomal proteins, and 
total exosomal RNAs. 
Fresh BAL fluid was retrieved from patients and kept on ice before further processing. (A) Exosome 
concentration was determined with NTA (fibrotic ILD n=12 and non-fibrotic ILD n=7). (B & C) 
Exosomes were isolated by ultracentrifugation from 6 mL of BAL fluid then re-suspended in 250 µL 
of PBS for total protein assay (B, fibrotic n=8, and non-fibrotic n=11) or the extraction of total RNA 
(C, fibrotic n=6, and non-fibrotic n=8) and the results were compared. (D) Normalised total RNA 
concentration with the total protein concentrations. * p<0.05, ***p<0.001, student t-test.  
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Results showed that the exosome concentration in alveolar space was significantly 
decreased in the fibrotic ILD compared with the non-fibrotic ILD (35.16 ± 3.54, n=12 
vs 95.44 ± 15.95, n=7, p<0.001), and the exosome in non-fibrotic ILD was 2.7 fold 
higher. 
BAL exosomes were isolated from the same volumes (6 mL) of fresh BAL fluid for 
total protein or total RNA. The protein concentration of pelleted exosomes was lower 
in fibrotic ILD than that of non-fibrotic ILD (154.10 ± 14.24 µg/ mL, n=8, vs 232.40 ± 
25.73 µg/ mL, n=11, p<0.05).  
The total RNA concentration of fibrotic ILD was lower than that of non-fibrotic ILD 
(30.00 ± 12.10 ng/ µL, n=6 vs 86.21 ± 13.05 ng/ µL, n=8, p=0.01). When normalised 
the total RNA with total protein, the results showed the same finding that in fibrotic 
ILD there was less RNA than the non-fibrotic ILD (1.70 ± 0.67, n=6 vs 3.34 ± 0.32, 
n=8, p=0.03). Given the nature of the BAL fluid and the isolation process, with 1.67 ± 
0.07 (mean ± SD, n=14) as the A260/A280 for quality control, the results were 
acceptable.  
Since the level of BAL fluid exosomes was lower in the ILD with lung fibrosis, the 
level of BAL fluid exosomes and its association with disease progression were studied 
with banked BAL fluid samples.   
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7.4.7 Low level of baseline BAL exosome may be 




Figure 7-7 Low level of baseline BAL exosome may be associated with progressed IPF. 
BAL fluid samples (stored at -80 ºC) were defrosted and the level of exosomes was measured using 
anti-CD9 beads flow cytometry assay. IPF-NP: stable IPF (non-progressor); IPF-PG: progressed IPF. 
Disease progression was defined as a ≥10% decline in FVC or death within 12 months. Open circle: 
0 months (baseline), solid circle: 12 month; Within the group paired student t-test, between stable IPF 
(n=12) and progressed IPF (n=13) unpaired student t-test. 
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The exosome level in defrosted BAL fluid was determined with anti-CD9 beads flow 
assay and represented as the fold change of CD9 fluorescence (stained against 
unstained).  
From stable IPF patients, results suggested that there were no significant changes of 
exosome levels during the 12 month period (0-month vs 12-month = 7.51 ± 1.81 vs 7.49 
± 1.84, n=12, paired t-test, p=0.99).  
With progressed IPF the changes of BAL fluid exosomes were not observed either: 0-
month vs 12-month = 4.00 ± 0.53 vs 5.14 ± 1.43, n=13, paired t-test, p=0.46.  However, 
the baseline BAL exosome level (0-month) in the progressed IPF was lower than that 
of stable IPF (p=0.07). This suggested that low baseline exosome level in BAL fluid 
might be associated with progressed IPF. However, these findings need to be better 
characterised and validated with a larger cohort. 
Besides, the concentration of exosomes, another important question to be addressed was 
the origin of these exosomes. Particularly, in a macrophage dominating lung disease, 
the contribution of macrophages to the exosome pool in IPF lungs was studied with a 
panel of specific markers that expressed on immune cells in the alveolar space including 
monocyte/macrophage markers.   
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7.4.8 BAL fluid exosomes retrieved from ILD patients did 
not express common monocyte/ macrophage surface 
proteins 
In order to study the origin of the alveolar exosomes, exosomes were coupled with anti-
CD9 beads and a panel of monocyte/ macrophage markers were investigated. CD9 
expression was used to confirm the successful isolation of exosomes (data not shown).  
 
 
Figure 7-8 BAL fluid exosomes retrieved from ILD patients did not express common monocyte/ 
macrophage surface proteins. 
Common monocyte/ macrophage surface proteins such as CD14 (F), CD16 (H), HLA-DR (J), Mac-2 
(L), 25F9 (N), CD206 (P) were not detected on alveolar exosomes. General leucocyte protein CD45 
(B) and lymphocyte marker CD3 (D) and were not detected. Different cells (PBMC, monocytes, 
MDM-ED macrophage) were used as positive controls as indicated in the figure. Representatives of 
n=6 experiments (fibrotic ILD, n=3, non-fibrotic ILD n=3). 
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So far, the impact of an impaired autophagy pathway on exosome release in the alveolar 
macrophages had been studied. Less MVBs were found in fibrotic AM and low 
concentration of exosomes were found in the culture medium in these macrophages. 
Low level of exosomes was found in BAL fluid from patients with lung fibrosis and 
may be associated with disease progression. Macrophage markers were not detected on 
exosomes. 
In the following experiments, the interaction of autophagy-exosome pathways was 
further explored with in vitro models. The effect of exosome release by the modulation 
of the autophagy pathway in MDM was studied.   
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7.4.9 Rapamycin and bafilomycin A1 treated MDM 




Figure 7-9 Rapamycin and bafilomycin A1 treated MDM contained MVBs and autophagic 
vacuoles. 
Rapamycin and bafilomycin A1 treated MDM contained MVBs (arrowed) and autophagic vacuoles 
(arrowhead). MDM were treated with 25 µM rapamycin and 50 nM bafilomycin A1 for 4 hours before 
they were fixed and processed for TEM analysis. Scale bar =2 µm (A) and 0.5 µm (B). 
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7.4.10 Modulation of autophagy-lysosome pathway 
changed the concentration of MDM-released 




Figure 7-10 Modulation of autophagy changed the concentration of MDM-released exosomes 
into the culture media. 
The concentration of exosomes was determined by (A) anti-CD9 beads flow assay and (B) NTA 
analysis of exosome levels in different conditions. Each sample was measured 4 times and a mean was 
used for statistical analysis. Control: distilled water. Monocytes were differentiated to macrophages 
(MDM) for 7 days and cells were treated as indicated conditions for 4 hours: medium: IMDM+10% 
FBS (filtered); vehicle: DMSO (as RB) diluted in culture medium; Baf A1: bafilomycin A1, 50 nM; 
Rap: rapamycin 25 µM; R+B: Baf A1 and Rap. *p<0.05, n.s. not significant, one-way ANOVA, 
Tukey's Multiple Comparison Test, n=4 (A) and n=3 (B).  
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Supernatants following treatments were coupled with anti-CD9 beads for flow 
cytometry analysis (A). Exosome levels were higher when MDM were treated with both 
rapamycin and bafilomycin comparing with bafilomycin alone (3.40 ± 0.50 vs 2.18 ± 
0.07, n=4, p<0.05), whereas no difference was observed between bafilomycin A1 
treatment and medium or vehicle control (2.18 ± 0.07 vs 2.40 ± 0.16 vs 2.53 ± 0.10, 
n=4, n.s.).  
Another set of experiments were performed and exosome levels were measured by NTA 
(B). Results showed that MDM treated with rapamycin and bafilomycin A1 for 4 hours 
had increased exosome levels in the supernatant compared with treatment of the 
medium control or vehicle control (60.71 ± 18.97 vs 15.74 ± 5.74, p<0.05 and  60.71 ± 
18.97 vs 18.94 ± 3.39, p<0.05). Although the exosome levels in the media treated only 
with bafilomycin A1 (28.04 ± 4.16) or only with rapamycin (47.24 ± 6.33) were not 
significantly changed compared with the controls.  
Together both sets of data suggested that modulation of the autophagy pathway 
regulates the exosome secretion in macrophages. Furthermore, the effect of BAL fluid 
exosome on the autophagy pathway in MDM in vitro was studied. 
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Figure 7-11 Internalisation of BAL fluid exosomes into MDM. 
(A) The number of BAL fluid exosomes were decreased after culture with MDM. Pelleted BAL fluid 
exosomes (30 µg) were incubated with MDM for 24 hours. Exosome concentration in different media 
after the experiment was determined with anti-CD9 beads based flow cytometry assay and represented 
as mean fluorescence (MFL) of CD9. **p<0.01, *** p<0.001, n.s. not significant, one way ANOVA, 
Tukey's multiple comparison tests; (B) exosomes were stained with Q-tracker (red) before the 
incubation with MDM for 24 hours. After the incubation, cells were rinsed with PBS before the image 
was taken. Exosomes (arrowed) were observed within a macrophage and near the nucleus, scale bar = 
50 µm. 
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As shown above, the mean of the exosome levels (CD9 MFL) in the culture medium 
after 24 hours culture of MDM [cells(+)/exosomes(-)] was significantly increased when 
compared to the control medium [cells(-)/exosomes(-)] (6.29 ± 0.86 vs 2.55 ± 0.18, 
p<0.01). The change was 2.46 fold which suggested that culture of MDM released a 
significant amount of exosomes into the medium. 
Exosomes were pelleted from BAL fluid and the resuspended BAL fluid exosomes 
[cells(-) / exosomes(+)] had the highest concentration among all the conditions. The 
incubation with MDM had significantly decreased the exosome level (14.13 ± 0.18 vs 
7.53 ± 0.55, p<0.001). After incubation, the exosome level dropped to a level equivalent 
to the MDM culture medium (7.53 ± 0.55 vs 6.29 ± 0.86, p>0.05). The decrease of 
exosomes in the presence of MDM indicated that exosomes were engulfed by the 
macrophages after the 24 hours of incubation.   
Stained exosomes were observed within some macrophages after the incubation with 
MDM. Exosomes were located near to the cell nucleus which was a typical location of 
internalised exosomes.  
To test whether the external exosomes had activated the autophagy pathway, cell lysates 
from the above experiment were prepared for western blot and probed for LC3 
expression. 
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Figure 7-12 BAL fluid exosomes increased LC3-II expression in MDM. 
(A) Western blotting probing for LC3-II expression. ENF: pelleted BAL fluid exosomes from non-
fibrotic ILD; EFR: pelleted BAL fluid exosomes from fibrotic ILD; positive control: bafilomycin A1 
(50 nM) treatment for 4 hours; (B) densitometry analysis of LC3-II expression. NF, non-fibrotic; FR, 
fibrotic. Student t-test, n.s. not significant. 
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7.5 Summary and Discussion 
Autophagy and exosome formation are closely related processes in the maintenance of 
cell homoeostasis. The present study has demonstrated the interaction between the 
autophagy-lysosome pathway and the exosome machinery in lung fibrosis.  
7.5.1 Low exosome levels are associated with fibrotic ILD 
ILD is an entity that covers more than 100 different diseases [146]. One strategy to 
categorise ILD is based on the degree of inflammation and fibrosis of the condition [79]. 
It is well recognised that in fibrotic lungs, particularly in UIP, there is only mild 
inflammation presented [80, 81]. Interestingly, studies have shown that inflammation 
generally increased exosome secretion. In a mouse model of hepatitis, inflammation 
increased the number of circulating exosomes [526]. In sarcoidosis, an active immune 
disease that mainly affects the lungs, a link between active inflammation and increased 
exosomes activity had been reported [391]. Thus, the finding that exosomes have 
decreased in number in the fibrotic lungs compared to non-fibrotic ILD as presented in 
this study is not unexpected.  
It is not known whether the lack of inflammation in IPF contributes to the low level of 
exosomes or less exosomes result in little inflammation in the fibrotic lungs. However, 
a loop of “low exosomes and little inflammation” may aggravate the condition in lung 
fibrosis.  
As shown in this study, low exosome levels in the BAL fluid were determined in the 
fibrotic lungs (Fig 7.6). Furthermore, low level of exosomes in IPF patients may be 
associated with disease progression (Fig 7.7). Recently, a study showed an inverse 
relationship between the exosomes level in plasma and the stage of lung cancer, i.e., the 
more advanced cancer, the lower the concentration of exosomes [423]. In lung fibrosis, 
the deficiency of alveolar exosomes and their content suggested that they might be a 
potential indicator for the status of the diseases and may be a candidate for a treatment 
strategy.  
Though there is little inflammation in IPF lungs as determined at the histological level 
at the point of diagnosis, inflammation may indeed be a critical factor in the 
development of the disease [527]. The types of cells and their status change dramatically 
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during lung inflammation and wound healing [528]. The continuous inflammation due 
to chronic lung epithelium injury may alter the exosome pool in the alveolar space 
dynamically. Thus, exosomes might serve as a good candidate of monitoring lung 
fibrosis as proposed in other lung diseases [317]. Besides the number of exosomes, their 
cargo protein and especially microRNA cargos are more likely to be distinct at different 
stages of lung fibrosis similar to other lung conditions [317]. In the later stage of 
established lung fibrosis, excessive ECM in the interstitial space provides cells with a 
unique micro-environment which might interrupt and compromise cellular 
communication. 
7.5.2 The origin of alveolar exosomes in IPF 
Besides the commonly expressed proteins, EVs may also carry membrane protein of 
their parent cells [331]. In the present study, the anti-CD9 beads based flow cytometry 
assay showed that alveolar exosomes do not express the monocyte/ macrophage lineage 
surface proteins that included monocyte markers (CD14 or CD16), alveolar macrophage 
markers (HLA-DR, Mac-2, and 25F9) or CD206 (alternatively activated macrophages). 
However, this does exclude macrophages contributing to the exosomal pool in the IPF 
lungs and in theory, they should be one of the dominant cell populations in the alveolar 
space. In fact, the exosomes released by human MDM on day-7 or human AM in tissue 
culture did not express the panel of markers tested (data not shown). The understanding 
of macrophage-derived exosomes in resting or stimulated status need to be further 
studied.  
Besides macrophages, there are more than 40 types of different cells in the lungs [529]. 
All of them may contribute to the alveolar exosome pool. Thus, I also tested the 
expression of cell surface markers of other cell types included CD45 (leucocyte), CD3 
and CD75 (lymphocyte), CD11b and CD11c (myeloid origin cells), CD42a (platelets) 
and Ep-CAM (epithelium cells) and none of these were expressed on BAL fluid 
exosomes (data not shown).  
Microvesicles reflect the surface proteins of the membrane composition of the parent 
cell more closely than exosomes [323]. A mouse model of LPS induced acute lung 
injury (ALI) suggested that the mouse AM-derived EVs (F4/80 and CD11c as markers) 
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were the major population in the early phase of ALI and contributed the most to the 
inflammatory process [401]. The NTA data showed that in ILD BAL fluid samples, the 
sizes of the majority vesicles were below 200 nm and microvesicles in ILD were in very 
small numbers. Thus, the absence of cell surface marker supported the notion that 
exosomes are the major EVs in the ILD lungs. 
Macrophage-derived exosomes have been shown to be functional vesicles [402-404]. 
Inflammation and infection can change the profile and function of macrophage-derived 
exosomes [396, 402]. In fact, different phenotypes of macrophages release specific 
exosomes with distinct properties [396]. My data showed that fibrotic AM released less 
exosomes ex vivo which suggested that the deficiency of macrophage exosomes might 
be an important mechanism that is associated with lung fibrosis. Characterisation of the 
exosomal protein and RNA profiles that are specific to unique cell types, and exosomal 
function, could offer new insights and tools for the clinical management of IPF patients 
in the future. 
7.5.3 The relationship between autophagy and exosome 
release 
Constitutive autophagy promotes cell viability and enhances homoeostasis and it is 
closely associated with the endocytic-exosome pathway [348, 349]. As shown in my 
study and by others, the modulation of autophagy can change the number of exosomes 
and also affect the cargos and surface protein components in exosomes [327].  
In this study, I showed that fibrotic AM, which have impaired autophagy (chapter 6) 
released less exosomes than non-fibrotic AM which have normal functional autophagy, 
ex vivo. Modulating autophagy by treating MDM pharmacologically for a period of 4 
hours resulted in no change in exosome secretion with bafilomycin, increased exosome 
secretion with rapamycin, and a further increase in exosome release with rapamycin and 
bafilomycin. (Fig 7.10). These data suggested a relationship between autophagy activity 
and exosome release in macrophages. Furthermore, the results of in vitro experiments 
are consistent with the clinical observation of exosomes in BAL fluid from fibrotic and 
non-fibrotic patients. Firstly, these data explained the effect of impaired autophagy on 
exosome secretion of AM as presented here (Fig 7.4). Non-fibrotic AM had functional 
autophagy, similar to MDM treated with rapamycin which correspondingly showed 
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increased exosomes ex vivo. In contrast, fibrotic AM had blocked autophagy, similar to 
MDM treated with bafilomycin, and correspondingly released less exosomes than non-
fibrotic (or rapamycin-treated) cells. Secondly, these data support the clinical data of 
fresh BAL fluid samples which showed that the exosome levels were higher in non-
fibrotic ILD (more inflammation and active autophagy) and lower in the fibrotic ILD 
(little inflammation and blocked autophagy) (Fig 7.6). Finally, the data presented here 
may suggest that the exosome machinery in AM might have been damaged during the 
development of lung fibrosis. There might be a stage when AM actively release 
exosomes when lysosomes are dysfunctional but with activated autophagy (similar to 
rapamycin and bafilomycin treatment). As the disease progresses, further damage may 
occur to the exosome machinery that leads to the final status as presented here that is 
similar to bafilomycin treated cells. 
In theory, the induction of autophagy should limit exosome secretion and the blockage 
of lysosomal function should enhance it. In K562 cells, it was shown that autophagy 
induction promoted the fusion of MVBs with autophagosomes and therefore decreased 
the secretion of exosomes [353]. On the other hand, blockage of lysosome function by 
bafilomycin A1 increased the secretion of exosomes in a couple of studies [354-356]. 
It might be possible that different cell types respond differently to autophagy 
manipulation. The precise interaction between autophagy and exosome biogenesis in 
MDM needs to be further clarified. The exact mechanism by which autophagy blockage 
may impair exosome release in AM needs to be further studied.  
7.5.4 Autophagy and exosomes as potential targets for 
intervention in lung fibrosis 
Further studies, particularly the functional nature of exosomes in lung fibrosis are 
required, but the autophagy pathway an exosome release may be an attractive target for 
therapeutic intervention. Others have speculated that in established disease, intervention 
through the autophagy pathway might not be effective in the treatment of IPF [530]. In 
this study, I have shown that the autophagy-lysosome pathway is blocked in AM. Thus, 
the treatments targeting the autophagy pathway should probably start at an earlier stage 
of the disease, in order to gain clinical benefits for the patients. 
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There are on-going efforts to further test the effectiveness of modulating autophagy as 
a target for the treatment of IPF [531]. As mentioned earlier, animal models consistently 
showed that the promotion of autophagy pathway is beneficial and disruption is harmful 
[297, 298, 301] but the precise mechanism for inducing benefit or harm is not clear. Gui 
and colleagues showed chloroquine, a blocker of lysosome function, did not rescue 
bleomycin-mediated mouse death and when rapamycin was combined with 
chloroquine, mice had a higher mortality than rapamycin alone [298]. If autophagy is 
regarded as a therapeutic target of IPF treatment, exosomes may be the downstream 
mediators that exert the biological effect. Exosome levels could be used as a tool to 
identify the fibrotic conditions and to determine and predict disease progression (e.g., 
low exosomes levels and distinct proteins or RNAs) and to determine the effectiveness 
of treatment. It would be prudent to better define the exact role and utility of exosomes 
and their relation to autophagy using for example animal model of lung fibrosis before 
other applications.  
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Chapter 8 Final discussion 
In this thesis, I investigated the autophagy pathway in AMs in interstitial lung disease 
and the effect of ECM on macrophage autophagy. Furthermore, I studied the exosome 
profile in the BAL fluid and linked this to the impaired autophagy in IPF lungs.  
8.1 ECM regulates autophagy pathway and exosome 
secretion in macrophage in IPF lung 
Macrophages orchestrate the major events in the alveolar space including having an 
essential role in normal wound healing.  
As shown in Fig. 8-1, upon epithelial injury, macrophages mediated the normal wound 
healing process and are responsible for the removal of dead cells and the resolution of 
inflammation. Newly derived type 1 epithelial cells eventually replace dead or apoptotic 
ones and bring the alveolar epithelial lining back to the normal condition. In this setting, 
if macrophage function is impaired in the first place, their ability to maintain cellular 
and tissue homoeostasis is compromised. As shown in the right panel in Fig 8-1, basal 
autophagy is upregulated under continuous cellular stress which results in increased 
number of autophagosomes in macrophages (stage-I). This consistent up-regulation of 
basal autophagy is believed to be a mechanism that leads to pathological consequences 
[532]. Aberrant wound healing may occur due to physiological, such as ageing and gene 
mutation/modification, or pathophysiological factors, such as smoking, air pollution 
and unknown reasons (stage-II of Fig 8-1). The failure of inflammation resolution 
exaggerates the response to tissue repair and leads to the proliferation and activation of 
lung fibroblasts, differentiation of myofibroblasts, excessive deposition of ECM and the 
formation of pathological structures such as fibroblastic foci (stage-III of Fig 8-1).  
Macrophage autophagy, a key mechanism for maintaining cellular homoeostasis, may 
operate at different levels through these stages. The initial internal and external cellular 
stress results in the continuous low-level autophagy which attempts to remove cellular 
waste but may not do so efficiently (stage-I of Fig 8-1). If the autophagy pathway is 
further damaged, through pathological factors (local inflammatory mediators, ageing, 
smoking, genetic mutations etc.), this results in yet further impairment to the autophagy 
pathway and, as a consequence, dysfunctional autophagosomes are accumulated in 
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macrophages (stage-II of Fig 8-1). In this thesis, I have demonstrated that the 
autophagosome degradation is blocked in AMs from patients with lung fibrosis, and 
showed the presence of dysfunctional autophagosomes accumulated in these cells. If 
autophagy is induced continuously in a setting of blocked autophagosome degradation, 
this further exacerbates cellular dysfunction. The accumulated autophagosomes are 
regarded as newly formed cellular waste which will initiate the formation of the 
isolation membrane and the formation of autophagosomes to remove the un-degraded 
waste; however, the newly formed autophagosome would not be degraded and thus a 
cycle of continuous formation of dysfunctional autophagosomes is initiated which is 
detrimental to the cell. This un-resolving situation eventually leads to the loss of normal 
homeostatic function of the alveolar macrophage and the development of disease (stage-
III of Fig 8-1).  
ECM in the lung is dramatically altered during the development of IPF. I have 
demonstrated that autophagy is more active when cells are in contact with ECM and 
fibrotic ECM induces autophagy. Thus ECM assists in the formation and degradation 
of autophagosomes. ECM is a bioactive material. Collagen-I, the most abundant 
component in the ECM in IPF, also upregulated basal autophagy in macrophages in 
vitro. When the epithelial barrier is compromised, bioactive ECM peptides and debris 
come into contact with AMs and may modulate autophagy in AMs (stage-II). As the 
condition progressed, the enhanced production of ECM caused excessive deposition 
and the feature of IPF is then established (stage-III). With the existing blockage of 
autophagosome degradation in alveolar macrophages, the accumulation of 
autophagosomes may aggravate the situation in IPF lungs. 
During the development of chronic lung fibrosis, the structures and cellular composition 
in the alveolar space are also changed. All these factors affect the profile of lung 
exosomes. In this study, I showed that in IPF, the overall exosome level was decreased. 
I have also demonstrated that AMs from the fibrotic lungs, in which the autophagosome 
degradation is blocked, released fewer exosomes to the culture media ex vivo. The 
precise mechanistic link between autophagy and exosome release needs further study. 
Other studies have shown that when normal autophagosome degradation is blocked, the 
release of exosomes is increased. The clinical studies in this thesis involved patients 
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with already established IPF and other ILDs (stage 2 or stage 3 of Fig 8-1), and mostly 
the samples were from a single time points. Thus, during the development of fibrosis, 
there may be stages where AMs actively release exosomes or when autophagosome 
degradation is still functional.  
The functional status of autophagy and the level of exosome at different stages in IPF 
need to be further investigated and to be better characterised. In this study, participants 
in the fibrotic group were mainly diagnosed with IPF which unfortunately was in the 
late stage of lung fibrosis when diagnosed. Thus, the stages of disease are unlikely to 
change the findings presented in this theses as in fact, the stages of the diseases were 
the same. However, as a group of complicated diseases, ILD including IPF, the status 
of autophagy and the level of exosomes might actively change during the development 
of the disease as discussed. In future studies, these questions need to be answered with 
the premise of the established methodology for early diagnosis and categorising the 
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8.2 The association between exosomes and 





Figure 8-2 Inflammatory ILD has increased level of exosomes and total exosomal proteins and 
RNAs compared to fibrotic ILD. 
The RNA and protein profile of fibrotic and non-fibrotic exosomes may also differ but has not been 
studied. For example, exosomes from different disease states may have different inflammatory, fibrotic 
or tissue repair properties mediated by microRNA or proteins. 
 
 
According to the pathological patterns, ILD can be generally categorised into two 
groups depending on their status of inflammation and fibrosis [79]. UIP/IPF is 
characterised by lung fibrosis but little inflammation. The disease progression if IPF is 
thought to be a consequence of abnormal wound healing. Other ILD conditions are 
characterised as inflammatory-driven with limited fibrosis because wound healing is 
not impaired.  
In my study, I showed that in IPF lungs there was significantly decreased the number 
of exosomes compared to other non-fibrotic ILD. Furthermore, the total exosomal 
protein and total RNA from the IPF lungs were significantly lower than those from non-
fibrotic ILD. Most studies associate exosomes with active inflammation and suggest 
that exosomes are mediators of the inflammatory response. This may be the case in ILD 
that in fibrotic lungs, such as UIP and chronic HP that decreased level of exosomes may 
result in the lack of inflammation. On the contrary, in inflammatory ILD, there is a 
higher concentration of exosomes and increased contents mediating intercellular 
communication that contributes to active inflammation. Therefore reduced exosomes 
may be the reason that fibrotic ILD, such as IPF/UIP, exhibits little inflammation. My 
data also suggested that in patients with progressive IPF, the baseline level of exosomes 
is lower than in patients whose disease remained relatively stable over 12 months (‘non-
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progressive’), which suggested that low exosome level in the lung may be a risk factor 
or predictor for disease progression. 
Furthermore, in a larger scope, exosomes may be served as a candidate marker for 
inflammatory lung disease. To validate the observation of lower exosome-level in 
fibrotic ILD comparing to non-fibrotic ILD, other controls should be considered in 
future studies, such as age and sex-matched healthy volunteers and other types of lung 
conditions with active lung inflammation, e.g., COPD, ALI, lung cancer and pneumonia. 
As discussed in the first section (8.1) in detail, the exosome level might be actively 
changing at different stages IPF which need to be further characterised.  
The specific protein and RNA profiles of fibrotic versus non-fibrotic exosomes have 
not been studied. For the disease-relevant proteins, it is necessary to compare the surface 
proteins that may mediate pro-inflammatory and anti-inflammatory pathways More 
interestingly, exosomal RNA in the fibrotic lungs may offer a disease marker for 
IPF/UIP and pro-fibrotic RNA may be present in these exosomes and might be 
implicated in lung fibrosis. 
An alternative function for exosomes is that they mediate tissue repair. In collaboration 
with Prof. Donna Davies and Dr. Franco Conforti, we showed that depletion of 
exosomes from the BAL fluid may delay wound repair compared with original BAL 
fluid with exosomes in an in vitro epithelial wound assay (data not shown). The aberrant 
wound healing in IPF may be due to low levels of exosomes which carry proteins and 
RNA that mediate the epithelial healing. For example, exosomes exhibit heparin-
binding epidermal growth factor-like growth factor (HB-EGF) and amphiregulin which 
are ligands for mammalian EGF receptor [533]. HB-EGF and amphiregulin can 
promote epithelial cell growth and are involved in epithelial wound healing. Thus, the 
function of BAL fluid exosomes needs to be fully explored.  
8.3 Restore normal autophagy in alveolar 
macrophages as a strategy to treat IPF 
The lysosome is the common destination for both the autophagosome and MVBs. The 
status of lysosomes is therefore critical in both pathways. IPF is associated with an aged 
population. Ageing can modulate the function of lysosomes and in aged cells, 
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lysosomes become less competent in dealing with cellular waste. As shown in my study, 
in fibrotic AMs the presence and accumulation of membranous cytoplasmic bodies 
(MCBs) suggested lysosomal dysfunction. The fusion of autophagosomes and 
lysosomes was likely not affected based on the co-localisation of autophagosomes and 
lysosomes. However, with other tools and assays dissecting the lysosome key proteins, 
enzymes, RNAs and the pH changes (acidity) may help understand this important type 
of organelles in both exosome and autophagy pathways in macrophages [534, 535]. 
Based on current evidence, restoration of the normal autophagy-lysosome pathway in 
the fibrotic AMs should be targeted at promoting the production and function of 
lysosomes [536]. Induction of lysosomal biogenesis by genetic or pharmacological 
activation of lysosomal transcription factor EB restored lysosomal levels [537]. 
Promotion of lysosome was tested in the animal model of brain diseases and effectively 
restored brain function and memory [538-540].  
My study showed that ECM increased autophagy in macrophages, but if the 
autophagosome degradation is blocked, the enhancement of autophagy by ECM will 
aggravate cellular dysfunction and lead to the further accumulation of dysfunctional 
autophagosomes. In theory, promoting functional lysosomal degradation is a strategy 
that can be used in the presence of fibrotic ECM.  
Promoting lung homeostasis by targeting the key regulatory cell, i.e. alveolar 
macrophage, could be a strategy that benefits the prognosis of IPF. At different stages 
of IPF, the induction of autophagy should be cautious but the promotion of lysosome 
function may be more beneficial. Besides the promotion of lysosomal function in 
macrophages in advanced IPF, the strategy could be aimed at early stages of fibrosis 
before the “permanent” damage to the autophagy-lysosome pathway. Targeting the 
earlier window for intervention by enhancing the cellular communication via exosomes 
is a promising way for the management of IPF than in the advanced IPF. 
8.4 Exosomes, a cell-free approach for IPF treatment 
In my study, I have shown that the level of BAL fluid exosomes was significantly 
decreased in fibrotic ILD and progressive IPF. Fibrotic AMs, in which autophagy is 
blocked, also released fewer exosomes in the culture media ex vivo. Restoring the 
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intercellular communication via normal exosomes could possibly promote normal 
wound healing in the early stages and resolution of fibrosis. 
Mesenchymal stem cell (MSCs) derived extracellular vesicles have successfully 
alleviated liver fibrosis [473], peritoneal fibrosis [541], kidney injury and fibrosis [542, 
543] and bleomycin-induced lung fibrosis [544-546]. This suggested that exosomes 
alone could be used as a strategy to manage IPF in which exosome levels were 
decreased as shown here. Furthermore, exosomes are able to travel through ECM and 
be internalised into cells in vitro. Thus, the excessive ECM may not limit the 
communication through exosomes. In established fibrosis, exosomes can be used as 
messengers that move across the ECM barrier and targeting other relevant cells in the 
lung interstitium. This would be an effective means to deal with other cells under the 
epithelial lining such as fibroblasts and myofibroblasts. Exosomes can reprogram the 
cells towards fibrosis resolution other than pro-fibrosis.  
Modulation of autophagy regulates the exosome biogenesis in vitro and restoring the 
normal autophagy pathway by the strategies described above may rescue exosome 
biogenesis. On the other hand, exosomes also affect the autophagy pathway. In this 
study, I also showed that BAL fluid exosomes can be internalised into MDMs in vitro 
and increased the LC3-II expression in macrophages. Thus, exogenous exosomes also 
modulate the autophagy pathway. This could be a physiological positive feedback loop 
that enhances cellular homeostasis and re-programmes the fibrosis process to normal 
wound healing. Restoring exosomes in fibrotic lungs with a specific population, such 
as macrophage-derived exosomes, may be beneficial for the resolution of normal tissue 
repair.  
Another strategy to enhance functional exosome secretion in the fibrotic lung, rather 
than the autophagy pathway, is to deliver exogenous exosomes to the lung. 
Administration of mesenchymal stem cell-derived exosomes can rescue fibrosis in the 
bleomycin model. The systemic administration of exosomes intravenous improved the 
functional recovery of mice in models of stroke, brain tumour and brain damage [547-
549].  
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8.5 Future work 
For the future studies, there are still many questions that need to be addressed and to be 
better understood, such as the dissection of autophagy and exosome pathways in 
macrophages at different stages of fibrosis, targeting autophagy and exosomes as means 
of IPF management and the role of ECM in the development of IPF. 
The blockage of autophagosome degradation has been identified in AMs in the fibrotic 
lungs, but the precise nature and the location of the blockage in AMs need to be defined. 
The present evidence suggests that the damage to the autophagy pathway is in the latter 
stages of the pathway, most likely dysfunctional lysosomes. The factors that contribute 
to this blockage might be many, such as ageing, genetic susceptibility, oxidative stress, 
ER stress, and smoking. It is valuable to exam the lysosome-related proteins in different 
groups of IPF such as familial and sporadic or divided by risk factors such as smoking 
history, biological age, and immunological age. The proteins and signalling mechanism 
relating to the fusion of lysosomes with autophagosomes also need to be studied. The 
ATP-dependent proton pump V-ATPase is essential for the maintenance of low pH 
within lysosomes, the subunits of V-ATPase might be impaired. There is also V-
ATPase independent mechanisms for lysosome-autophagosome fusion [490]. These 
results can help to design the proper strategy for intervention. Enhancement of 
lysosomal production and function has shown benefits in neurodegenerative diseases, 
however, pharmaceutical compounds are not yet available.  
As discussed, the role of macrophage autophagy during lung fibrosis may change at 
different stages of the process. The role of macrophage autophagy in lung fibrosis needs 
to be further studied with animal models. Firstly, a better understanding is needed of 
the changes in autophagy in lung fibrosis models, such as the bleomycin model. 
Furthermore targeting the autophagy pathway in conditional lung macrophage knockout 
mice, such as Atg knockout macrophages may reveal the function of macrophage 
autophagy in response to fibrosis stimuli.  
The dynamic changes of the lung during the initiation, progression, and resolution of 
lung fibrosis in the bleomycin model of lung fibrosis could give insights on the human 
IPF. With the modern tools, using genetically modified mice, such as the macrophage-
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specific lysosome gene knockout mice, will extend the understanding of current 
hypothesis. The course and outcome of fibrosis in the bleomycin model of these 
genetically modified mice would gain more knowledge towards the stages of 
intervention and the possibilities to reverse the progression with the promotion of 
lysosome function.  
The exosome machinery is impaired in IPF but the mechanism and exact molecules 
need to be studied. As it is a pathway closely related to the autophagy pathway, it is 
interesting to further explore the interactions between the two pathways. The precise 
mechanistic link between autophagy and exosome release in the fibrotic AM needs to 
be further defined. 
Exosomal surface proteins study did not reveal common surface markers for specific 
cells in the lung. However, specific RNA contents might give more information about 
the contribution of different cells to the exosome pool in IPF lungs. For example, it has 
been shown that M1 and M2 macrophages express exosomes with different RNA 
profiles [413]. Fully exploring the protein and in particular, the total and microRNA 
profile of fibrotic and non-fibrotic AM-derived exosomes will help understand the 
function of these exosomes. In vitro epithelial wounding models and co-culture 3D 
models of lung fibrosis would help to understand the potential pro-fibrotic or pro-
resolution properties of the AM-derived exosomes. 
ILDs are heterogeneous diseases, and the classification of the disease should be 
optimised for treatment and research. Low concentration of exosomes may be a 
candidate indicator for lung fibrosis and disease progression in fibrotic ILD. For the 
validation of low exosome concentrations as a potential indicator for lung fibrosis, it 
needs to be studied with a larger population in a separate (validation) cohort. The 
proteins and genetic cargos in exosomes also need to be further studied, in order to gain 
a better understanding of their functions. With proteomic and gene array assays, there 
is a chance to identify the disease-relevant proteins and RNAs in exosomes.  
The role of bioactive ECM should also be further investigated. Targeting the cell surface 
integrins, lysosome motility, and position, and soluble ECM may be relevant to 
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understanding the cross-talk between ECM and autophagy-lysosome pathway [215, 
291].  
In summary, both impaired macrophage autophagy and decreased exosome secretion 
may serve as targets for therapeutic purposes for IPF. Restoring functional autophagy 
and normalising the intercellular communication through exogenous exosomes may 
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Appendix A: Additional results 
Normally, autophagy can be induced with relatively low concentrations of rapamycin 
with a longer period (e.g., 24 hours) incubation. In RAW264.7 mouse macrophages, 
autophagy induced with low concentrations of rapamycin was not reproducible. The 
pattern observed on western blotting with low concentrations of rapamycin was similar 
to the pattern of the starvation-induced autophagy as presented in Figure 5-1. 
 
Figure A-1 Autophagy induction with low concentrations of rapamycin was not reproducible in 
RAW264.7 mouse macrophages. 
RAW264.7 cells (1×106) were seeded in a six-well plate the day before treatment. On the next day, 
cells were treated as indicated. (A) Succesful autophagy induction, i.e. decrease of LC3-I and increase 
of LC3-II expression, was observed with low concentrations of rapamycin with 24 hour incubation 
(n=1); (B) the autophagy induction with low concentrations of rapamycin was not reproducible, 
representative blot of experiments performed 4 times on different occasions (n=4); (C) time-course 
experiment with low concentrations of rapamycin did not show different LC3-II expression at different 
time points within 24 hours (n=1). Cells were treated as indicated before the cell lysates were prepared 
for western blotting. Positive control: Neuro 2A cell lysate; vehicle control: DMSO diluted in complete 
DMEM medium (as highest rapamycin); medium control: DMEM with 10% FBS. Representative blots 






Appendix B: Patient information 








at time of BAL 
Smoking 
 category 
1118 IPF 0 64 1 
0853 IPF 1 66 1 
0395 IPF 1 77 3 
0947 IPF 0 74 2 
1134 IIP (no fibrosis) 0 58 1 
1123 IIP (no fibrosis) 0 66 2 
0983 IIP (no fibrosis) 0 70 4 
0951 IIP (no fibrosis) 1 78 4 
0948 IIP (no fibrosis) 1 78 1 
1155 IIP (no-fibrosis) 0 56 2 
Smoking category: 1=Never; 2= Ex-smokers (Ex) <20pyr; 3=Ex 20-40pyr; 4= Ex 
>40pyr; 5=current smoker<20pyr; 6= current smoker 20-40pyr; 7= current smoker 
>40pyr. Pyr= pack year history, 1 pack year = 20 cigarettes a day for 1 year. 
 
 
















Lane-1 NF 1035 IIP 0 71 2 
Lane-2 NF 1043 IIP  1 53 4 
Lane-3 FR 0823 IPF 1 75 1 
Lane-4 FR 1044 IPF 1 74 3 
Lane-5 FR 1045 Asbestosis 1 70 3 
Lane-6 FR 0996 IPF 1 71 1 
Lane-7 NF 1035 IIP  0 71 2 
Lane-8 FR 0849 IPF 1 69 1 
Lane-9 FR 1033 IPF 0 54 3 
Lane-10 NF 1056 Sarcoidosis 0 64 1 
Lane-11 NF 1051 IIP  1 79 1 
Lane-12 NF 0564 IIP) 1 71 5 
Lane-13 FR 0579 IPF 1 78 2 
Lane-14 NF 1023 IIP  0 57 5 
Smoking category : 1=Never; 2= Ex-smokers (Ex)<20pyr; 3=Ex 20-40pyr; 4= Ex >40pyr; 
5=current smoker<20pky;  6= current smoker 20-40pky; 7= current smoker >40pky. 
Fibrotic group is highlighted in bold. Nearly half were never smokers Cat-1 (n-3), one patient 
was ex-smoker Cat-2 (n=1) and the other three patients were ex-smoker Cat-3 (n=3). Pyr= 





The level of smoking and years of age of participants between the fibrotic and non-
fibrotic groups at the time of recruitment were compared and no difference was found.  
 
Figure A-2 No difference was found in smoking or age of the participants between fibrotic and 
non-fibrotic groups in this study.  
 The smoking history and age of participants as listed in the above table were grouped and compared. 
(A) No difference was found in smoking history in the two groups, fibrotic vs non-fibrotic = 1.91 ± 
0.28 vs 2.62 ± 0.43; (B) No difference was found in age of the two groups, fibrotic vs non-fibrotic = 
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